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Epitope 'mapping studies on a highly conserved rhoptry 
antigen. from Plasmodium falciparum. 
Abstract. 
Malaria is one of the most widespread parasitic disease. It is caused by 
Plasmodium protozoa. Plasmodium falciparuni infection leads to the most virulent 
symptoms in human. Researchers have been devoted to develop a malaria vaccine for 
malaria eradication, especially against P. falciparum. Rhoptry associated protein-1 
(RAP-1) is one of the P. falciparum vaccine candidates because it protected monkeys 
in an immunization experiment and some monoclonal antibodies raised against this 
protein can inhibit parasite growth in vitro. 
This thesis describes work in which the epitopes of the inhibitory monoclonal 
antibodies were mapped by using a combination of recombinant DNA technology and 
peptide synthesis. The part of rap-1 gene, which contains epitopes of inhibitory 
monoclonal antibodies, was subcloned and expressed in Escherichia coli in a 
3-galactosidase fusion form. The use of restriction enzymes and exonuclease III to 
generate different fragments of rap-1 gene suggested that the epitopes of these 
monoclonal antibodies cluster near a proteolytic cleavage site on the protein (between 
A190 and D191). This was confirmed when the epitopes of all the inhibitory 
monoclonal antibodies were located on a TLTPLEELYP210 peptide generated as one 
of a series of overlapping decapeptides. 
The study of RAP-1 protein immunogenicity in rabbit and humans showed 
that both species are also able to recognize this inhibitory epitope'. The epitope 
mapping of another set of monoclonal antibodies raised against a recombinant RAP-1 
protein lacking its 'native', conformation was carried out. The results suggested that this 
expressed protein can stimulate immune responses against the 'inhibitory epitope' but 
two additional epitopes are also recognized by these monoclonal antibodies. 
"-ii 
Sequence analysis of the rap-] gene from a number of isolates and clones 
demonstrated that the RAY-i protein is highly conserved in P. falciparuin from several 
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Amino acid abbreviations. 
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C Cysteine 
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Names used for recombinant plasmids and clones in this thesis. 
The naming system used for each plasmids and recombinant clones in this 
thesis are explained below. The details of these plasmids and clones are described in 
Chapter 3. 
UR, MS 	bacteria clone containing pUR278 or pMS1S plasmid. 
1-1'-ES' MSES 	recombinant clone which possesses pUR278 or pMS1S 
plasmid containing EcoRI-Sall fragment. 
P1-11 ES' pMSES 	recombinant pUR278 or pMS1S plasmid which containing 
EcoRI-SalI fragment. 
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1.1.1. Classification and general characteristics. 
Malaria is caused by protozoan parasites of the genus Plasmodium, which 
is classified into the phylum Apicomplexa (Schmidt and Roberts,1989). Other genera 
containing important parasites in this phylum are Eimeria, Toxoplasma and Theileria 
(Fig.1.1). All of the protozoa in this phylum share some characteristics. The most 
common and important feature is the presence of an apical complex at some stage of 
their life cycle. The apical complex typically includes a polar ring, micronemes and 
rhoptries. The polar ring is an electron-dense structure under the cell membrane, which 
encircles the anterior tip. The rhoptries are electron dense pear shaped organelles. Two 
to several rhoptries, depending on the species, share a common duct toward the cell 
membrane inside the polar ring structure. Micronemes are smaller but more abundant, 
elongate organelles, which are also seen as electron-dense structures under the electron 
microscope. The rhopiries and the micronemes are thought to play a crucial role in 
host cell invasion through secretion of their contents into the host cell during invasion 
(Bannister and Mitchell, 1989). 
The specific characteristics of the genus Plasmodium amongst the 
apicomplexa are (i) its complex life cycle in which it undergoes asexual reproduction in 
both vertebrates and invertebrates and sexual reproduction in invertebrates; (ii) the 
female macrogametes and male microgametes develop independently; (iii) cilia and 



















Figure 1.1. Classification of Plasmodium falciparum and related genera (Schmidt and 
Roberts, 1989). 
2 
1.1.2. Human malaria parasite. 
There are many species of Plasmodium but only four of them can cause the 
malaria disease in humans. Those species are Plasmodium falciparum, Plasmodium 
,nalariae, Plasmodium ovale and Plasmodium vivax. Each species can be 
distinguished by its morphology and pathology. Plasmodiumfalciparum is responsible 
for the most virulent form of malaria, known as malignant tertian. It is responsible for 
most of the malaria deaths. 
1.1.3. Life cycle of Plasmodium spp. 
The life cycle of Plasmodium spp. is outlined in Fig. 1.2. For a clear 
description, the malaria life cycle is divided into two stages; the asexual stage in human 
and the sexual stage in the mosquito. 
1.1.3.1. Asexual stage. 
1.1.3.1.1. Exoerythrocytic stage. 
The malaria parasites are transmitted by female mosquitoes of the genus 
Anopheles. Infection is caused by injection of the sporozoite form of the parasite into 
the bloodstream along with mosquito saliva during blood meal ingestion. The 
sporozoites enter parenchyma cells in the liver shortly after injection. After invasion, 
the parasite develops into an irregular shaped exoerythrocytic schizont which grows 
asexually and develops into merozoites within the cell. In P. falciparum the mature 
schizont ruptures after about 5.5 days, releasing up to 30,000 exoerythrocytic 
merozoites into the bloodstream (Schmidt and Roberts, 1989) which are capable of 
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Figure. 1.2. The life cycle of Plasmodium falciparuin malaria parasite (see text for 
detail). 
1.1.3.1.2. Erythrocytic stage. 
After release from the liver, the exoerythrocytic merozoite binds and enters 
a red blood cell. Once in the red blood cell, the parasite, surrounded by the 
parasitophorous vacuole membrane, develops through three different stages, ring, 
trophozoite and schizont, which can be distinguished under a light microscope 
(Schmidt and Roberts, 1989). The infected red blood cell and parasitophorous vacuole 
membrane are modified during these developments. During the ring stage, the 
merozoite structure begins to dedifferentiate as the merozoite-specific organelles 
disappear (Aikawa, 1971). Although, ribosomes are not seen until the trophozoite 
stage the protein synthesis actually starts in the ring stage of the parasite (Brown et al, 
1982). The parasite obtains amino acids from digestion products of haemoglobin, 
which is endocytosed, from the plasma and from de novo synthesis from carbon 
sources (Sherman, 1979). At the schizont stage, the parasite undergoes nuclear 
division and certain cytoplasmic organelles are developed. At the end of schizogony, 
mature erythrocytic merozoites can be seen in the infected red blood cell. Each 
schizont produces 8-24 merozoites in P. falciparum, 12-24 merozoites in P. viva, 
6-12 merozoites in P. malariae and P. ovale (Kreier and Baker,1987). The mature 
merozoites are released into the blood stream and invade other red blood cells to 
continue the erythrocytic cycle. The time required for each cycle of development 
varies between species, 72 hours in P. ,nalariae, 48 hours in P. falciparum, P. viva, 
P. ovale (Kreier and Baker,1987). This period also coincides with the appearance of 
fever, the clinical symptom of malaria. It has been suggested that this may be caused 
by soluble exo-antigens released by which subsequently induce tumour necrosis factor, 
TNF (review in Playfair eta!, 1990). 
It was previously thought that the preerythrocytic merozoites can reinvade 
hepatocytes and cause the relapse of malaria in P. viva and P. ovale. Now, evidence 
5 
suggests that relapses may be caused by a dormant form of the liver schizont (Krotoski 
et al, 1982). 
1.1.3.1.3. Gametogony. 
During the erythrocytic cycle, some merozoites develop into male 
microgametocytes or female macrogametocytes after entering a red blood cell. The 
mechanism, which 'switches on this process, is still unknown. In P. falciparum 
gametogony takes about ten days during which time mature gametocytes develop in 
the blood spaces of the spleen and bone marrow and later, appear in the blood stream 
(Schmidt and Roberts, 1989). The shape and size of gametocytes within the infected 
cells are specific for each species. The gametocytes remain in the red blood cell until 
they die, are destroyed by the host immune system, or are taken up by a mosquito. 
1.1.3.2. Sexual stage in the mosquito. 
1.1.3.2.1. Sexual stage. 
When the gametocytes are ingested by the Anopheles mosquito, both 
microgametocytes and macrogametocytes are released from the red blood cell 
membrane and develop into microgametes and macrogametes respectively. There is no 
significant difference in the characteristics of macrogametocytes and macrogametes. 
The microgametocyte, however, rapidly divides its nucleus to form six to eight nuclei. 
Each nucleus migrates into a flagellum, which buds from the microgametocyte. The 
exflagellation process is completed when the flagella immediately break free into the 
plasma of the blood meal. 
Fertilization occurs when the microgamete penetrates through the 
macrogamete membrane and both nuclei fuse to form a diploid zygote. The zygote 
quickly undergoes meiotic division and develops into a motile ookinete. The ookinete 
then penetrates through the epithelial cell layer of the intestinal wall of the mosquito. 
At the basement membrane, the parasite transforms into an oocyst and is covered by 
an electron-dense capsule. The size of the oocyst becomes larger projecting into the 
body cavity as the parasite grows rapidly inside. 
1.1.3.2.2. Sporogony. 
Mitotic division and differentiation within the oocyst generates thousands 
of sporozoites, the infective form of the parasite. Two weeks after the mosquito was 
infected, the oocyst bursts to release mature sporozoites. The released sporozoites 
move toward the salivary glands of the mosquito where the parasites can be 
transferred into the vertebrate hosts during blood meal ingestion. 
1.1.4. Erythrocytic invasion process. 
Because the protein under investigation in this project may relate to the 
erythrocyte invasion process, this process will be explained in more detail. However, 
it should be noted that the invasion process of the sporozoite shares common features 
with the phenomenon of the merozoite because of the presence of the apical complex 
structures in both cells. Though the sporozoite and the merozoite forms of parasite 
have a different target cell and also contain rhoptry proteins specific to each stage, the 
entry of parasite in both forms occurs only after the apical complex is attach to the 
host cell surface. 
During the malaria life cycle, merozoites originate from two different cells, 
from .hepatocytes -so called exoerythrocytic merozoites, and from red blood cells -so 
called erythrocytic merozoites. From an avian malaria parasite study, Aikawa noticed 
some characteristics different between these two merozoites (Aikawa, 1971). 
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However, for the purposes of this discussion, it has been assumed that the invasion 
process in both kinds of merozoite are the same. Here, the invasion process of 
erythrocytic merozoite is described as a model of erythrocyte invasion by the malaria 
parasite. 
The merozoite initiates invasion of the erythrocyte through the recognition 
by a parasite surface protein(s) of receptor molecules on the red blood cell membrane. 
The major receptors on the red blood cell membrane are believed to be the major red 
cell sialoglycoproteins, glycophorins A, B and possibly C (Cox, 1983) in P. falciparum 
and the Duffy blood group in P. vivax and P. knowlesi (Miller et al, 1977). Following 
successful attachment, the parasite reorientates until its apical end contacts the red 
blood cell membrane (Dvorak a al, 1975). Initially, the erythrocyte membrane is 
slightly raised and then invagination occurs at the junction, which thickens, increasing 
to about 15 nm (Aikawa a al, 1978). 
As the parasite enters the red blood cell, the parasitophorous vacuole is 
formed. The mechanism of parasite interiorization into the red blood cell is still 
unclear. However, the ability of Cytochalasin B, a glucose transport inhibitor and 
microtubule disruptive agent, to inhibit entry movement, but not parasitophorus 
vacuole formation (Aikawa a at, 1981), reveals that the mechanisms of these two 
processes are different. Electron microscope studies suggest that the invagination of 
the red blood cell membrane is generated by rhoptries and micronemes (Bannister and 
Mitchell, 1989). Many electron micrographs show an electron-opaque projection 
which connects the opening duct of the rhoptries to the rhesus erythrocyte membrane 
during invasion by P. knowlesi (Aikawa et al, 1978, Bannister and Mitchell, 1989). 
Moreover, the study of parasitophorus vacuole origin suggested that the 
parasitophorus vacuole membrane is derived wholly or partly from the merozoite 
(Dluzewski a al, 1992). These facts together with the appearance of lamellar 
membranous material associated with rhoptries, and its secretion into the 
parasitophorous vacuole during invasion, lead to the conclusion that the rhoptries may 
1!]
[3] 
have an important role in invasion (Bannister et al, 1986). Several rhoptry proteins 
have been identified and roles for them in the invasion process have been proposed. 
These proteins will be described later (see section 3.3.2.4.). 
During the entry process, the surface coat of the parasite is lost. In 
P. berghei yoeli the surface coat accumulates on the surface of the merozoite which 
still remains outside the red blood cell (Ladda et al, 1969). Invasion is complete when 
the parasite is totally internalized and the erythrocytic membrane fuses behind it in an 
iris diaphragm-like manner (Aikawa et at, 1978). The whole invasion process may last 
only 20 seconds (Wilson, 1982). 
1.2. Global Malaria Situation. 
1.2.1. Spreading of malaria disease. 
Human malaria is spreading in a vast area between latitudes 64 degrees 
North and 31 degrees South (Fig. 1.3.). However, it is not found in some areas, for 
example and and very high altitude areas where conditions are unsuitable for the 
vectors or the parasites. The fact that transmission of malaria requires an average 
temperature above 15 degrees centigrade for at least one month in a year (Knell, 
1991), raises the possibility of the malaria spreading at the higher latitudes if the global 
temperature increases because of the greenhouse effect. 
Malaria, like some other blood diseases, can be transmitted by blood 
transfusion, blood cross contamination among drug addicts, congenital infection etc.. 
In America, the average annual rate of malaria transmission by blood transfusion was 
0.25 cases per million units of blood collected during 1972 to 1988 (Nablen et al, 
1991). Seventeen cases of congenital infection were also recently reported in the 
Southern province in Zambia during the rainy season (Larkin and Thuma, 1991). These 
Es 
Figure. 13. World map diagram shows approximate distribution of malarious regions 
and some estimated data (adapted from UNDPJWORLD BANKJWHO Special 
Programme for Research and Training in Tropical Disease-WHO Division of Control 
of Tropical Diseases, 1990. 
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incidences, even at very low number, may help the malaria disease to spread into a 
malaria-free area. 
Improvements in transportation can also play an important role in the 
spreading of malaria. In Britain, imported malaria cases have been reported for many 
years. The number of cases have increased from 101 in 1970 to 2,212 in 1985. Most 
of these are travellers from endemic areas in Asia and Africa (Knell, 1991). Imported 
malaria may have a significant impact in the 'anophelism without malaria areas, i.e. 
areas contain Anopheles mosquitoes which are capable of transmitting the malaria but 
are uninfected with malaria parasite. 
The outbreak of malaria in South America is an example of the human 
contribution to the increasing spread of malaria in some developing countries. 
Deforestation in malaria endemic areas puts workers at risk of malaria infection and 
enlarges the human reservoirs of the malaria parasite. 
The World Health Organization estimated that there are one hundred million 
cases of malaria annually. Among those patients, approximately 1 to 2 million people 
will the each year, mostly from P. falciparum infection (Knell, 1991). These figures do 
not reflect the total impact of malaria on global health. In 1991, Brinkmann reported 
that malaria accounted for 20%-50% of all admissions in African health services, 
although these are only 8%-25% of total malaria cases (Brinkmann and 
Brinlcmann,1991). He also documented the rapidly increasing incidence of malaria in 
Gambia (7.3%), Togo (10.4%) and Rwanda (21.0%). 
1.2.2. Effect of Malaria disease. 
Economically, the main impact of the malaria disease may be visualized in 
the terms of financial loss and labour loss. However, in the real situation, the malaria 
disease also has a more subtle impact on human by affecting the human gene pool. It is 
known that malaria can play an important role as a selective pressure on some genetic 
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blood disorders, such as sickle-cell anaemia and thalassaemia, in some parts of the 
world (Knell, 1991). This selective pressure increases the survival chance of the 
disorder gene carriers compared to the rest of the population and so the variant genes 
are more likely to be carried over to the next generation. 
Malaria also has an indirect effect on medical services. Not only does it 
weaken the immune system in the case of chronic infection, but it also affects other 
aspects such as the blood banking industry. In America, travellers who have had 
malaria or taken antiinalaria chemoprophylaxis are excluded for three years from blood 
donation (Nahlen et al, 1991). 
1.2.3. Malaria control and the problems. 
The life cycle of the malaria parasite is complex. The parasite is transferred 
between human and the Anopheles mosquito. This complexity increases the difficulty 
of malaria control programmes. On the other hand, the host and vector specificity raise 
hopes for malaria eradication. Here, some of the methods used in control programmes 
and their problems are discussed 
1.2.3.1. Vector eradication. 
The human malaria parasite has to spend a part of its life cycle in the 
Anopheles mosquito. The eradication of this mosquito will decrease the incidence and 
spread of the malaria disease. Many methods are used to eliminate the mosquito, for 
example, the use of insecticides, environmental control and biological control. 
Insecticides have been used as a tool for fighting malaria for many years. 
The most well known synthetic insecticide is DDT (Dichioro-diphenyl-
trichloroethane). Many other insecticides have also been developed to improve the 
insecticidal effect and to reduce undesirable impacts on the environment. After 
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prolonged use of these insecticides, some problems frequently occur: (i) to effectively 
control the vector, vast areas have to be treated indefinitely; (ii) a huge amount of 
money is required; (iii) damage to the environment and/or the accumulation of 
insecticides in the food chain may occur; (iv) development of resistance to the 
insecticides among the Anopheles mosquito population. 
Control of the malaria insect vector by destroying its breeding site is used 
in some endemic areas. The use and effectiveness of environmental control methods is 
limited by geographic conditions and lack of trained personal to plan, carry out and 
monitor the process. 
Up to now, the biological control of the mosquito is only used in a small 
scale (Knell, 1991). The mosquito is either eliminated by a natural predator or a 
pathogen. For example, guppy fish are considered to be a suitable predator for the 
mosquito larvae in enclosed collections of water, though its use is restricted by 
appropriate habitat requirements. Bacterial pathogens such as Bacillus thuringiensis 
and Bacillus sphaericus are under investigation by several researchers. They are 
known to produce a toxin after being eaten by mosquito larvae (Knell, 1991), therefore 
they are considered as control agent. However, the use of these bacteria in nature may 
have an adverse impact on the environment and more study is required. 
1.2.3.2. Human protection. 
In principal, the ultimate aim of much malaria related research is to protect 
man from malaria infection. Human protection from the malaria parasite can be 
achieved by a combination of physical and biological methods. These protection 
methods need the individual responsibility of people for taking appropriate 
precautions, so the most important factor is to ensure that people in endemic areas 
have been educated about malaria infection. 
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Utilization of a bednet and a mosquito screen are among the oldest and most 
effective physical protection methods. Because the mosquito feeds through the late 
evening to early in the morning, sleeping under the cover of the bednet or the mosquito 
screen seem to be the best solution. The protectivity of bednets, which may fail to 
protect if it is damaged or improperly used, can improve upon impregnation with 
insecticides. In Gambia, bednets treated with permethrin, an insecticide, were shown 
to protect people from Anopheles gambiae bloodfeeding. At 500 mg of the perrnethrin 
per square metre the blood feeding rate is reduced by 91% compared with untreated 
bednet (Linsay et al, 1991). For outdoor protection, the use of an insect repellent and 
sensible clothing are the most convenient methods. 
Biological methods of protection include propylaxis treatment and drug 
cure. Amongst the oldest anti-malaria drug known to man is an extract obtained from 
the bark of the Cinchona tree. It has been used since the seventeenth century. The 
active alkaloid in the extract, quinine, was identified and is still among the best 
antimalarial compounds in used today. Many anti-malarial drugs have been discovered 
over the years from chemically synthesized drugs to herb extracts; for example, 
chloroquine, proguanil, mefloquine, pyrimethamine, sulphonamides, primaquine, 
halofantrine, atovaquone, artemisinine (active ingredient in Artemesia annua, Linn. or 
Qinghao) and its derivatives. The activities of these drugs are directed against different 
molecular targets of the malaria parasite (see Table 1.1). However, it was found that 
some malaria parasite strains have developed resistance to the well established 
anti-malarial drugs. In 1961, the first report of two patients who had 
chloroquine-resistant P. falciparurn from Columbia was published (Moore and Lanier, 
1961). The discovery of this chloroquine-resistant strain alerted all the malaria endemic 
countries. In 1963, a case of multidrug-resistant P. falciparum strain was reported in 
Thailand (Young et al, 1963). Thirteen years later, the chloroquine-resistant 
P. falciparum was found in Africa and is now spreading at a very high rate (Peters, 
1985). Recently, resistance strains of halofantrine, a new malaria drug which 
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Class Drug(s) Proposed activity 
Cinchona Alkaloid Quinine Inhibits haem polymerase enzyme activity (Slater and Cerami, 1992). 
Aminoquinolines Chloroquine Inhibit DNA synthesis (Polet and Barr, 1968). 
Binds to DNA. RNA ( Howells et al, 1970). 
Retains lytic capacity of ferriprotoporphyrin lx (Howells, 1985).  
Inhibits haem polymerase enzyme activity ( Slater and Cerami, 1992). 
Aminoquinolines Mefloquine Unknown probably by: 
Inhibits host cell digestion (Ginsburg, 1991). 
Retains lytic capacity of ferriprotoporphyrin IX (Howells, 1985). 
Interacts with phospholipids (Howells, 1985). 
Inhibits haem polymerase enzyme activity ( Slater and Cerami, 1992). 
Aminoquinolines Primaquine Disrupting respiratory chain of the parasite (Gutteridge, 1991).  
Inhibits _dihydroorotate_dehydrogenase_( Howells, _1985). 
Biguanide Pyroquanil Inhibits dihydrofolate reductase (Walter, 1991). 
Cycloguanil 
Hydroxynaphtho- Atovaquone Disrupting respiratory chain of the parasite (Howells, 1985). 
guinone (566c80) 
Phenanthrenemetha Halofantrine Unknown probably the same as mefloquine (Peters, 1985). 
not  
Pyrimidine Pyrimethamine Inhibits dihydrofolate reductase (Walter, 1991). 
Sesquiterpene Artemisinin Unknown probably by: 
lactone Inhibits of protein synthesis (Howells, 1985). 
Causes membrane degeneration ( Klayman, 1985). 
Sulfonamides and DDS (4.4' - Inhibits dihydropteroate synthase (Walter, 1991). 
Sulfones diaminodiphenyl 
sulfone)  
Table 1.1. shows summary of antimalaria drugs in current uses and their possible modes of action. 
15 
is not yet commercially available in Thailand, were identified by a group of Thai 
researchers (Wongsrichanalai, 1992). 
Failure of vector eradication and human protection, as described previously, 
forces scientists to find alternative ways for malaria eradication. Vaccination probably 
is the best long term solution if an effective vaccine can be developed. The success of 
the WHO smallpox vaccination programme gives encouragement to this approach. 
1.3. Malaria vaccine. 
Here, some basic principles related to human immune response and some 
vaccine candidates are described. 
1.3.1. Antibody stimulation in human. 
Human immunity can be functionally divided into two types, an innate 
(natural) immunity and an adaptive (acquired) immunity (Roitt et al, 1985). Innate 
immunity is non-specific and is mediated by phagocytes and natural killer (NK) cells. 
It acts as a first bather against all foreign antigens. Adaptive immunity is a specific 
immunological reaction, which involves other types of leukocytes (white blood cells), 
called lymphocytes. Adaptive immunity can be artificially stimulated by an 
appropriate part of an antigen using vaccination. This discussion will only concentrate 
on the adaptive immunity. 
Stimulation of the adaptive immune response can be divided into two steps, 
a T cell activation and a B cell activation. T cells and B cells are two main types of 
lymphocytes which carry specific receptors on their surface. To ensure the specificity 
of immune response, each T cell and B cell can bind only one antigenic determinant in 
an antigen molecule (epitope). 
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After foreign antigens enter a human body, they are taken up 
non-specifically by antigen presenting cells (APC) such as macrophages, monocytes, 
etc. The antigens are partially degraded into small peptides (Riley et al, 1991 and 
Harlow and Lane, 1988) and some peptides are presented on the cell surface in 
complex with a major histocompatibility complex (MHC) class II protein. Antigen 
presenting cells carry the processed antigens to the secondary lymphoid organs, such 
as spleen and lymph nodes, where the antigens are presented to the lymphocytes. The 
T cell activation process occurs when a T cell subpopulation called T helper cells, with 
a matched antigen receptor, bind to an antigen peptide-MHC class II complex on the 
surface of an APC leading to proliferation and differentiation. 
For a B cell, the antigenic determinant region, a B cell epitope, on a foreign 
antigen is bound specifically to the B cell antigen receptor, an immunoglobulin. Similar 
to the APC, the antigen is taken up in the B cell and is processed into smaller peptides. 
Again, the processed peptides are also presented at the B cell surface in the 
antigen-MHC class II protein complex. This complex has to contain at least one T cell 
receptor binding site to create a strong immune response for T-cell-dependent antigen. 
Binding of a T helper cell to the antigen-MHC class II protein complex stimulates the 
B cell to undergo division and differentiation. The dividing B cell may differentiate into 
two types of cells, plasma cells and memory B cells. This B cell activation process 
also results in the class of secreted antibody shifting from 1gM to IgG and higher 
affinity antibodies. 
Plasma cells have an expanded cytoplasm and high rate of protein synthesis. 
They are the main sources of antibody production. Plasma cells are short lived cells, 
mostly seen in the lymphoid organs. To retain a specific immunological memory, some 
dividing B cells differentiate into memory cells. Memory B cells are long-lived cells 
which are ready to respond to the primary activated antigen. The secondary response 
causes by memory cells is therefore faster and more potent. 
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Some antigens can directly stimulate B cells to proliferate and secrete 
antibodies without a signal from T helper cells. These antigens are called 
T-cell-independent antigens. Most of these antigens are large polymeric molecules 
with repeated antigenic determinants and are resistant to degradation. Because the 
response by-passes the T helper cell interaction, there is no differentiation of B cells 
into memory B cells and so no secondary response in this case. 
1.3.2. Immunity to malaria. 
In endemic areas, human protective immune response against the malaria 
parasite has been naturally stimulated by prolonged infection since childhood (review 
by Ravetch et al, 1985). A baby, born to an immune mother, is protected from lethal 
malaria infection until the age of three months probably by transplacenta transfer of 
protective antibodies, para-amino benzoic acid deficiency in its milk diet and the 
nonpermissive environment of fetal erythrocytes compared with normal erythrocytes 
(Wyler, 1990). From this protective stage Up to two years old, the child is at its most 
susceptible stage to lethal malaria infection. Through several infections, the protective 
immunity will build up gradually as the severity of clinical symptoms decreases. It 
should be noted, however, that natural stimulation rarely produces sterile immunity 
and that the immunity generated is species specific. People in endemic areas usually 
have low parasitaemias without showing any symptoms. Protective immunity is also 
vulnerable to the immunological and physiological changes in an individual. For 
example, immune people who stay outside endemic areas for a period of time and 
pregnant women in endemic areas once again become susceptible to lethal malaria 
infection. 
In 
1.3.3. Evasive factors in human. 
The malaria parasite, like many other parasites, has to adapt in order to 
survive in the host and escape from the host immune system. Several evasive factors of 
the Plasmodium parasites play an important role for this purpose. Mainly, the parasites 
evade attack by the host immune response by (i) avoidance of the immune system (ii) 
antigen polymorphism (iii) alteration of the host immune response. 
In both exoerythrocytic and erythrocytic stages, all of the parasites of the 
genus Plasmodium develop within the vertebrate host cells. Parasites come into close 
contact with the immune system for only a short period of time during invasion of 
new cells. Moreover, P. falciparum infected red blood cells are sequestered in the 
capillaries of internal organs. This mechanism is speculated to prevent infected cells 
from clearance and destruction (Ravetch et al, 1985). 
During its complex life cycle, the malaria parasite expresses many proteins 
in each stage of development. Many proteins in each stage are immunologically 
distinct. Thus, an individual who has immunity against the exoerythrocytic stage may 
become infected if the erythrocytic stage of parasite is injected into his blood stream 
and vice versa. Two other mechanisms, which are believed to help the parasite to 
avoid immune recognition, are antigenic polymorphism and antigenic variation. The 
antigenic polymorphisms were identified among individual isolates of P. falciparum 
from the same and different geological sources using panels of monoclonal antibodies 
(McBride et al, 1982, McBride et al, 1985 and Schofield et al, 1982). Data from 
sequence analysis of the MSA-1 gene from different isolates and clones of 
P. falciparum suggested that this polymorphism may result from the recombination of 
a limited number of alleles (Tanabe et al, 1987, review by Day and Marsh, 1991). 
Antigenic variation is a mechanism by which a parasite clone 'switches' its ahtigen(s) 
by an undetermined mechanism to a new variant in order to avoid immune recognition 
when put under immune pressure (Miller et al, 1986). The only possibly example of 
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antigenic variation in P. faiciparuin is the existence of different forms of PfEMP-1 in 
prolonged culture of a genetically identical parasite clone (Leech, 1991). The 
possibility of antigenic variation in other malarial proteins has led to a postulation that 
repeated infections are needed to stimulate the immune response against a wide range 
of parasite variants before natural immunity against malaria infection is achieved 
(review by Mendis, 1991). 
The malaria parasite is able to alter its host immune system in two ways. 
First, by unknown mechanism, the infected host immune system is suppressed (Hyde, 
1990). This not only directly helps the parasite to survive in the host but also 
increases the susceptibility of the host to other pathogens. Second, it is thought that 
the malaria parasite is capable of creating a smoke-screen effect by producing highly 
immunogenic surface antigens with tandem repeats, which are shed after invasion into 
host cells, to distract the immune response from potentially protective antigens 
(Schofield, 1990). It is also believed the tandem repeat character of some parasite 
antigens causes polyclonal B-cell activation in a T-cell-independent manner. This 
prevents the host immune response from developing immunity against important 
targets which may induce protective immunity (Miller et al, 1986, Hyde, 1990). 
1.3.3.1. Malaria vaccine strategies. 
In 1961, Cohen and his colleagues shown that malaria immunity in children 
can be achieved by passive transfer of gamma-globulin from immune adults (Cohen 
et al, 1961). A similar experiment was also carried out in Thailand (Sabchareon et al, 
1991). The latter experiment revealed that all Thai patients showed stage-specific but 
non-sterilizing immunity against P. falciparuin and P. vivax after passive transfer of 
IgO from African adullts in malaria endemic areas. This suggested that immunity to the 
malaria parasite can be achieved if an appropriate antigen(s) is found. However, the 
complexity of the malaria life cycle and the changes of antigen expression during 
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different stages of the life cycle make the identification and selection of such antigen(s) 
a major problem for malaria vaccine research. 
The source of malaria antigens used in several malarial vaccine studies 
originally came from parasite cultures. Different stages of the P. falciparum can be 
sucessfully cultured in vitro and in vivo i.e. exoerythrocytic stage (Sacci et al, 1992, 
Mazier, 1984, Millet et al, 1991), erythrocytic stage (Tragger and Jensen, 1977) and 
gametocyte (Ifediba and Vanderberg, 1981). However, these antigens may be 
contaminated with some infectious agents or toxic components during culture or 
purification process and so can not be considered as human malaria vaccines. For this 
reason, it is important to identify protective antigens which can form the basis of 
recombinant protein vaccines. 
Many proteins have been proposed to be vaccine candidates. These antigens 
mainly were identified by using either monoclonal antibodies or immune polyclonal 
human sera. The results of extensive screening has shown that these vaccine candidates 
may be divided into two broad groups; (i) surface antigens and (ii) other organelle 
proteins whose functions are important for parasite survival. Several surface antigens 
in different stages of the malaria parasite have been considered as vaccine candidates, 
for example, antigens on the surface of sporozoite, infected erythrocyte, gamete or 
gametocyte and merozoite. Many proteins in the latter group were also identified but 
their functions remain unclear. However, postulated functions of these proteins relate 
to host cell binding, invasion, sequestration, fertilization and other aspects of parasite 
development. Some of the vaccine candidates will be discussed in detail later. 
For successful vaccination, some criteria are important to malarial vaccine 
design. These criteria are; (i) it must protect all or most immunized individuals i.e. it 
should not be genetically restricted (ii) it should contain both T and B cell epitopes for 
a maximized and prolonged immune response (iii) there should be no antigenic 
variation and little antigenic polymorphism in the gene which encodes for the 
protein(s) (iv) it must be safe, e.g. must not raise autoimmunity or cause 
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immunosuppression in immunized persons (v) ideally, it should stimulate the immune 
response equally well in both native and denatured forms so that the vaccine may be 
easily obtained using recombinant technology. 
1.3.3.2. Malaria vaccine candidate. 
Theoretically, immunity could be generated against several distinct stages of 
the parasite life cycle. Thus, many researchers attempt to find vaccine candidates in 
different stages of the parasite depending on their area of interest. Vaccines derived 
from different stages have their own advantages and disadvantages. A vaccine against 
the malaria sporozoite will protect an immunized individual from malaria infection but 
to achieve total protection, a high titer of antibody is probably needed because if a 
small number of sporozoites escape from the immune system, they may still lead to 
malaria infection. On the other hand, an erythrocytic stage vaccine may be able to 
stimulate a high titer of antibody due to the boosting effect of repeated infection of 
erythrocytes. Though a blood stage vaccine can not protect people from infection, the 
parasite may be cleared from the blood stream, or if only partial protection is achieved, 
the symptoms may be minimized. A transmission blocking vaccine which would be 
derived from gamete or gametocyte antigens acts differently to both the vaccines 
mentioned above. It does not benefit the vaccinated individual but would help to 
prevent the spreading of malaria disease. 
1.3.3.2.1. Vaccine candidate against the sexual stage. 
The aim of the sexual stage vaccines is to block malaria transmission and 
may be particularly valuable in low level transmission areas. The target stage for 
transmission blocking vaccines are the male and female gametes, the zygote and its 
motile product, the ookinete which develops in the mosquito midgut in 5-30 mins, 
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30-120 mins and 20-24 hours, respectively after mosquito feeding (Sinden, 1984). 
Candidate antigens in P. fa1ciparun include a 230 kDa antigen and a 48/45 kDa 
doublet which are found on the macrogamete surface (Vermuelen, 1985). They contain 
immunodominant epitopes but only the 48/45 kDa protein can raise antibodies which 
interfere with the fertilization process of the macrogamete. However, the immune 
response to 48/45 kDa protein is MHC class II restricted (Good et at, 1988). Another 
vaccine candidate is a 25 kDa protein which is localized on the surface of zygote and 
ookinete. It contains an epidermal growth factor-like domains (Kaslow a al, 1988) 
and appears to conserved (Kaslow et at, 1989). This protein considered to be a good 
vaccine candidate because the immune response to this protein does not appear to be 
MHC class II restricted (Kaslow, 1989 and Good et al, 1988). 
1.3.3.2.2. Vaccine candidate against the exoerythrocytic stage. 
The potential for a vaccine against the exoerythrocytic stage of the malaria 
parasite was indicated when Mulligan and his colleagues found that immunization 
with ultraviolet irradiated sporozoites of the avian malaria can protect birds against 
sporozoite challenge (reviewed by Nussenzweig and Nussenzweig, 1985). In 1967, 
Nussenzweig also shown that irradiated sporozoites of P. berghei can protect mice 
from malaria infection (Nussenzweig a al, 1967). 
Similar experiments have been carried out in humans. In one study 
immunization of human volunteers with sporozoites-infected mosquitoes which had 
been irradiated showed that the protection was induced after 6-8 immunizations by 
mosquitoes bites. The immunity, which is species and stage, but not strain, specific 
persisted only a few months. No boosting effect to the immunity was shown after the 
challenge (for reviewed see Clyde, 1990 and Rieckman, 1990). In a more recent study, 
human volunteers were also immunized with irradiated sporozoite-infected 
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mosquitoes. Protection was induced after 19 sessions of immunization, consistent with 
the results of the former experiments (Herrington et al, 1991). 
Monoclonal antibodies raised against the sporozoite stage can protect mice 
against malaria infection after passive transfer. These monoclonal antibodies identified 
an antigen on the sporozoite surface, the circumsporozoite protein,CS protein (see 
review by Nussenzweig, 1990). In 1984, the gene encoding the circumsporozoite 
protein of P. falciparum was cloned and sequenced (Dame et al, 1984). The sequence 
revealed that the middle of the gene contains an immunodominant domain of 37-41 
tandem repeats of four amino acids, NANP and two to four repeats of a variant 
sequence, NVDP. The number of repeats varies among different isolates (reviewed by 
Nussenzweig, 1990). 
As an immunodominant region of this potential vaccine candidate, the 
tandem repeats have been used as the basis of 4 P. falciparum vaccine trials in human. 
There is only a vaccine trial of which the protection against malaria infection was 
investigated while the other reports examined the possibility of immune response 
stimulation. A synthetic peptide, Acetyl-Cys-(NANP)3, was used in an 
immunization. Only some immunized person responded to this vaccine but they 
produced a low titer of antibody to sporozoites, lower than those of people in the 
endemic areas. No strong boosting effect was shown (Edinger et al, 1987). 
Recombinant protein containing the tandem repeats was also investigated. The protein 
used was a fusion protein of MDP('4ANP)15NVDP(NANP)15NVDP and 32 amino 
acids from tetracycline resistance gene read out of frame. This protein fail to stimulate 
immune responses to the repeat region of the CS protein as high as those individuals in 
the endemic areas (Ballou et a!, 1987). Recently, another clinical trial used 
recombinant protein of (NANP)16 fused with hepatitis B virus surface antigen as a 
vaccine in a phase I trial. This vaccine can stimulate antibodies production in all 
volunteers and the antibodies persisted in most cases over ten months. However, the 
protection against malaria infection still has to be evaluated (Vreden et al, 1991). A 
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protection evaluation experiment has been carried out. The peptide (NANP)3 
conjugated to tetanus toxoid using aluminium hydroxide as an adjuvant was tested. 
The majority of vaccinees developed low titers of antibodies to the synthetic peptide 
(NANP)50. Seven vaccinees who had high titers of antibodies were challenged with 
sporozoites by infected mosquitoes. One of these volunteers was protected and some 
of the other vaccinees showed a delay in their prepatent period (Herrington et al, 1987 
and Herrington et al, 1990). All the vaccines tested were stated to be safe for human 
used, with no obvious side effects. 
The failure of the tandem repeat peptides to induce protective immunity 
may due to the lack of an appropriate T cell epitope in the peptides used in vaccine 
trials (Sinigaglia and Pink, 1990, Egan et al, 1987). Moreover, the studies of animals 
immunized with irradiated sporozoites revealed that the protective immunity does not 
depend only on the antibodies, but also on the levels of 'Y-interferon and CD8+ cells 
(Schofield et al, 1987). A study in inbred congenial mice led to the conclusion that the 
T-cell immune response to the synthetic peptide vaccines and CS protein is genetically 
controlled through the major histocompatibility complex (Good et al, 1987). Recently, 
a nonpolymorphic T-cell epitope of CS protein which can be recognized by most 
mouse and human individual has been identified and may be included in a future 
malaria vaccine (Sinigaglia et al, 1988). 
The CS protein is found to be a major component of the sporozoite surface. 
Its sizes vary from 30-60 kDa among different species (Nussenzweig and 
Nussenzweig, 1985). It accounts for 10-15% of the proteins synthesized by a mature 
sporozoite. The CS protein also found on the hepatocyte plasma membrane, 
parasitophorus vacuole membrane and flocculent material in the peripheral vacuole of 
infected hepatocytes (Millet et al, 1991). 
It was suggested that the CS protein may play a crucial role in immune 
evasion and is not a target for protective immunity (Schofield, 1990). This was 
supported by the lack of correlation between the level of protection observed in an 
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immunization experiment, WA titer(using glutaraldehyde-fixed P. falciparum 
sporozoite) and ELISA based on serum activity against the repeat region (Herrington 
et al, 1991). Recently, it was found that the CS protein of P. yoelii and P. berghei 
sporozoite bind specifically to sulfated glycoconjugates and the binding activities were 
inhibited by fucoidan and heparin ( Pancake et al, 1992). The results of another 
experiment suggested that region II of the CS protein at the C terminal-domain has 
some homology to proteins bound specifically to sulfated glycoconjugates responsible 
for the binding to sulfatides [Gal(3-SO4)[31-Cer] and cholesterol-3-sulfate (Cerami 
et al, 1992) which may be present on the hepatocyte surface. However, it should be 
noted that this experiment is based on the binding ability of the CS protein to a 
hepatocyte and not the invasion of the sporozoite. The results of this finding is very 
interesting but remain unclear because proteins which bind specifically to sulfated 
glycoconjugates are involved in widely diverse biological process (Holt, 1989). 
It has also been suggested that the NI region (flanking region at the 
N-terminus of the repeat in the CS protein) is responsible for the invasion of 
sporozoites into the human hepatoma cell line, HepCi2-A16. Cross-linking studies 
show that the Ni region may bind to 55 and 35 kDa receptors on HepG2-A16 cells. 
These receptors are not found in primary human hepatocytes. The cross-linking 
studies between sporozoites and primary human hepatocytes revealed that 55 kDa 
(serologically distinct from that in HepG2-A16) and 20 kDa receptors interact with a 
16 kDa non-CS protein, sporozoite hepatocytic binding antigen, termed SHEBA 
(Hollingdale, 1990) 
Many researcher are trying to find a new vaccine candidate against the malaria 
sporozoite. Other sporozoite proteins are thought to be promising vaccine candidates. 
Khusmith and her colleagues have identified another surface sporozoite protein of 
P. yoelii, sporozoite surface protein 2 (SSP2). The SSP2 is a 140 kDa protein 
localized at the sporozoite surface. It is encoded by a gene distinct from CS protein but 
also contains six amino acids tandem repeats, NPNEPS, and some homology to the 
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region II of CS protein at the C-terminus. Mice immunized with a mixture of 
mastocytoma cells, which are transfected with the CS gene and a fragment of the SSP2 
gene, are completely protected from malaria infection (Khusmith et al, 1991). By 
sequence comparison, it is now believed that the homologue of this protein in 
P. falciparum is thrombospondin related anonymous protein or TRAP (Rogers, et at, 
1992). Other P. falciparum sporozoite vaccine candidates have been identified, such as 
CSP-2, a protein recognized by monoclonal antibody E12, namely LSA-1 (Hollingdale 
et al, 1990). The CSP-2 was identified as a protein which may responsible for the 
induction of protective immunity in mice against P. berghei. Unlike CSP-2, LSA-1, 
recognized by monoclonal antibody E12, is a conserved protein in several species of 
Plasnwdium, Toxoplasma and Eimeria. It also cross-reacts at the apical end of 
blood stage merozoites of P. falciparum, P. yoelii and the P. berghei exoerythrocytic 
stage merozoite. LSA-1 is also a sporozoite protein which cross-reacts with an antigen 
associated with parasitophorus vacuole. A similar antigen was also previously 
identified by Hope and his colleagues (Hope et at, 1984b). 
1.3.3.2.3. Vaccine candidate against the erythrocytic stage. 
This stage of malaria parasite is a possible target for a malaria vaccine. It 
was shown that Aotus monkeys were protected from lethal malaria infection after they 
had been immunized with mixture of merozoites and immature schizonts from culture 
using Freunds complete adjuvant (Siddiqui et at, 1977) 
The target of immune sera was revealed by the study of the effect of 
irnrnuneAotus serum (Chulay et al, 1981a). The serum of an Aotus monkey which was 
immunized with P. falciparuni-infected Aotus monkey erythrocytes, aggregated the 
merozoites in vitro but there was no visible effect on intracellular parasites. From 
further study, the in vitro growth inhibition activity was shown to be serum 
dose-dependent and was associated with the IgG fraction from immune serum (Chulay 
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et a!, 1981b). Human immune sera also caused aggregation of merozoites and the 
inhibitory effect appeared to be species specific (Vernes et al, 1984). 
The protein(s) target responsible for the stimulation of this type of 
protective immunity has been seriously investigated. Several proteins have been 
identified and proposed as vaccine candidates. However, it is difficult to definitely 
state the best vaccine candidate because so little is known about the function of these 
proteins. The primate models allow an empirical study of the ability of interesting 
proteins to elicit protective immunity. Many proteins have been investigated in the 
primate trials. Some of these vaccine candidates will be described (see below). 
Merozoite surface protein-1 (MSP-l) which is also known by several other 
names e.g., MSA-1 (merozoite surface antigen-1), PMMSA (precursor to the major 
merozoite surface antigen), Pf 195 and p190 is a glycoprotein on the merozoite surface 
(see review in Hyde, 1990). It is initially synthesized as a 190-195 kDa protein and 
processed into smaller fragments during late schizogony. These processed 
polypeptides are thought to form a multi-subunit complex at the merozoite surface and 
most of them are shed during the invasion process (Blackman and Holder, 1992 and 
Blackman et a!, 1991). Purified MSP-1 when immunized with Freunds complete 
adjuvant can elicit protective immunity in Aotus monkey (Siddiqui a al, 1987) and in 
Saimiri monkey (Hall a a!, 1984). A synthetic peptide, covering the N-terminal of this 
protein coupled with tetanus toxoid, also gave partial protection in Sairniri monkeys 
(Cheung a al, 1986). Although, a study in different isolates of parasite showed that 
this protein is polymorphic (McBride a a!, 1982), a more recent study suggested that 
this polymorphism is based on dimorphic genotypes (Tanabe a al, 1987). This 
suggested the MSP- 1 may still be used as a vaccine candidate. 
Another merozoite surface antigen has also been identified. Merozoite 
surface antigen-2 (MSA-2) is a surface protein which has a molecular weight about 
45-51 kDa. This protein is recognized by a group of monoclonal antibodies (Epping 
et al. 1988). This protein, however, also shows antigenic polymorphism in different 
isolates (Fenton, 1991). 
The ring-infected erythrocyte surface antigen (RESA, Pf155) is a 155 kDa 
protein which is found associated with the dense granules of the developing 
merozoites (Brown et al, 1985). It is transferred from the merozoite to the host cell 
during the invasion and is found associated with the cytoskeleton at the surface of the 
infected red blood cells. The IgG fraction of some human immune sera which inhibit 
parasite invasion in vitro, mostly contain antibodies directed against this protein 
(Wãhlin et al, 1984). Rabbits immunized with the C-terminal octapeptide repeats 
induced antibodies which can react with the native protein (Berzins et al, 1986). The 
purified antibodies from these rabbits have an inhibitory effect in merozoite invasion 
assays. A significant result from this experiment was the finding of octapeptide-
specific IgG in human immune sera and the discovery that these affinity purified IgGs 
also inhibit the parasite invasion in vitro. Protective immunity was elicited in Aotus 
monkey immunized with a fusion protein containing a fragment of the N-terminus 
repetitive sequence but not the C-terminus repeat sequence (Collins et al, 1986 and 
Collins et al, 1988). 
A glycoprotein binding protein-130 (GBP-130) is also considered as a 
vaccine candidate. It was thought to act as a surface merozoite receptor of the 
glycophorins on the erythrocyte surface because of its ability to bind to an aerylamide 
matrix coupled with glycophorin (Perkins, 1984). Although, recent work revealed that 
this binding may be a non-specific reaction (Van Schravendijk et a!, 1987), this protein 
may still be used as a vaccine based on the fact that it was able to stimulate the 
protective immune response in Saimiri monkeys (Dubois et al, 1984). However, an 
immunization study in Aotus monkeys using recombinant protein which contained a 
fragment of GBP-130 showed no protective immune response among the immunized 
animals (Aronson eta!, 1991). 
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The most extensive studies on a malaria synthetic vaccine have been 
performed by Patarroyo and his colleagues (Moreno and Patarroyo, 1989, Patarroyo 
et cii, 1988, Patarroyo et al, 1987). Purified proteins of different sizes from cultured 
parasite extracts, 155 kDa, 115 kDa, 105 kDa, 90 kDa, 83 kDa, 60 kDa, 55 kDa, 
50 kDa, 40 kDa, 35 kDa, 30 kDa and 23 kDa, were used to immunize Aotus monkeys. 
After challenge of the immunized animals with P. falciparum, most of immunized 
monkeys showed no protection, except monkeys immunized with 35 kDa and 83 kDa 
proteins. The 155 kDa and 55 kDa also elicited partial protection. Sequencing the 
N-terminus sequences of these protective antigens revealed that the 83 kDa is a 
processed fragment of MSA-1 and the 155 kDa protein is the RESA protein. To 
identify the protective epitope of these antigens, several peptides were synthesized to 
cover the N-terminal regions of the 155 kDa, 83 kDa, 55 kDa and 35 kDa proteins. An 
immunization experiment, using these synthesized peptides, showed that Aotus 
monkeys immunized with peptides derived from 83 kDa, 55 kDa and 35 kDa were 
partially protected from P. falciparum challenge. Another experiment was carried out 
using a combination of these synthetic peptides. The result showed that 4 of 8 Aotus 
monkeys immunized with peptides which contain the N terminal sequence of 55 kDa 
and 35 kDa proteins self-cured after developing moderate parasitemia. These two 
peptides together with another peptide which has sequence corresponding to the 
43rd-53rd amino acid of MSP-1 elicited protective immunity in 20 of 24 immunized 
monkeys. 
Based on these experiment, two synthetic malaria vaccines were designed. 
One synthetic vaccine, SPf66, is composed of the N terminal sequence of 55 kDa and 
35 kDa, 43rd-53rd amino acid of MSP-1 and 2 repetitive sequences of the CS protein. 
Another vaccine, SPf 105, contains the 5' region repeat of RESA, the 277th-287th 
amino acid of MSP-1, a repetitive sequence of the CS protein and a T-cell epitope of 
CS protein. These two synthetic proteins were separately polymerized to form large 
synthetic protein molecules and used to immunized volunteers. The SPf 105 only 
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elicited immune response which limited the infection for a short period in two of four 
immunized individuals. However, the SPf66 showed complete protection in some 
immunized individuals. There was no correlation between protection and antibody 
titer against the synthetic vaccine or stimulation index of peripheral blood 
mononuclear cells. A lack of correlation between the protection and the immunological 
parameter was also observed in a pilot-scale human immunization trial with SPf66 
(Salcedo et al, 1991). Sera from 185 immunized individual exhibited in vitro growth 
inhibition activity but this did not correlate with antibody titer. 
Recently, the analysis of the human sera immunized with the SPf66 
revealed that the protection of malaria infection may correlate with antibodies 
recognizing a KEK-containing peptide (Molano et al, 1992). Polyclonal antibodies 
appear to bind to the amino terminal lysine (K) and glutamic acid (E). This KEK 
motif is also found in other malaria proteins involved in invasion process and is 
proposed to interact with the erythrocyte. This epitope may be responsible for the 
stimulation of malaria immunity in immunized volunteers. 
An attempt to repeat the original monkey immunization experiment using 
SPf66 and a combination of those three synthetic peptides in another laboratory failed 
to achieve the same level of protection as originally observed by Patarroyo 
(Ruebush II, 1990). The reason of the difference in experiment results is not clear. The 
efficacy of the SPf66 vaccine is now being tested in a number of field trials. 
1.3.3.2.4. Rhoptry antigens. 
Because of the fact that the rhoptry contents may be crucial for the 
invasion process, a group of rhoptry antigens are also considered as vaccine candidates 
for an asexual stage vaccine. An early immunization experiment showed that a 
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235 kDa rhoptry protein from P. yoelii can protect mice from infection (Holder and 
Freeman, 1981 and Oka et al, .1984). 
Several rhoptry antigens have been identified. Some of these antigens are 
found as non-covalent complexes of two or more proteins which are 
co-immunoprecipitated by certain monoclonal antibodies. In some cases, proteins are 
processed into smaller fragments during parasite growth. 
lthoptry proteins so far identified are a 80/65/42 kDa complex called RAP 
(rhoptry associated protein) complex (Ridley et al, 1991), a high molecular weight 
240 kDa protein (Roger et al, 1988), a 150/135/105 kDa protein complex called the 
Rhopfl complex (Lustigman et a!, 1988) and a 55 kDa protein (Smythe et a!, 1988). 
The first of these complexes is the major subject in this theses and will be discussed 
later in section 3.3.2.5. 
The 240 kDa protein was identified by a monoclonal antibody. The 
protein is synthesized in the schizont stage of the parasite and is processed into a 
225 kDa protein. The 150/135/105 kDa protein components of another complex are 
named as RhopHl/RhopH2IRhOpH3 respectively. They were also reported existing 
as a 140/130/105 kDa protein complex (Cooper et al, 1988). Many groups of 
researchers also identified similar protein complexes which are probably identical 
(Sam-Yellowe and Perkins, 1990, Campbell et a!, 1984, Siddiqui et al, 1987 and 
Etzion et al, 1991). These complex components are synthesized in mid to late-
trophozoite, prior to formation of the rhoptry and the complex is formed soon after 
their synthesis (Lustigman et al, 1988, Sam-Yelloweet a!, 1988, Cooper et a!, 1988). 
The protein complex is shown to be recognized by immune sera from humans in 
endemic areas (Coppel et a!, 1987). During the invasion, the protein complex transfers 
to the newly invaded erythrocyte where the RhopH3 is modified by an unclear 
mechanism. Some evidences suggested that this modification is not due to the 
glycosylation or phosphorylation (Lustigman et a!, 1988). From immuno-gold electron 
microscopic study, Sam-Yellowe and her colleagues showed that the 110 kDa protein 
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is secreted into the parasitophorus vacuole during parasite invasion (Sam-Yellowe 
et al, 1988). The present evidence from both DNA and protein studies supports the 
existence and conservation of the RhopH3 gene in different isolates (Brown and 
Coppel, 1991). A DNA fragment encoding RhopH3 was cloned and expressed in 
Escherichia coli by Coppel and his colleagues (Coppel et al, 1987). The whole gene 
sequence was recently reported and revealed that the RhopH3 gene contains no 
repetitive sequence (Brown and Coppel, 1991).Although the function of this protein 
complex still unclear, it was suggested to act as an alternative ligand for binding with 
erythrocyte ( Sam-Yellowe and Perkins, 1990). An immunization experiment in Aotus 
monkeys using a 143/132/102 kDa rhoptry complex gave partial protection (Siddiqui 
et al, 1987). 
A low molecular weight rhoptry antigen was found as a 55 kDa protein 
(Smythe et al, 1988). Very little is known about the 55 kDa protein. It is thought to be 
achored in a membrane via a glycosylphosphatidylinositOl moiety because it was 
biosynthetically labelled with [ 3H]glucosamine and L3Nmyristic acid. 
Another identified protein is a 80 kDa protein, called apical complex 
antigen-1 or AMA-1 (Peterson et al, 1989). It is localized at apical complex, possibly 
in rhoptries, and on the surface of the merozoite after erythrocyte rupture. There is no 
evidence of the presence of this protein in a newly invaded ring. The AMA-1 is first 
synthesized in the trophozoite stage and is rapidly processed to a 62 kDa peptide 
(Crewther et al, 1990). Like all known rhoptry protein encoded genes, the ama-i gene 
contains no repetitive repeat and is conserved among different isolate of P. falciparum 
(Thomas et al, 1990). 
1.3.3.2.5. Rhoptry associated protein-1 (RAP-1). 
The RAP complex is able to be immunoprecipitated by many monoclonal 
antibodies, which recognized 80 kDa peptide, as 80/65/42/40 kDa major peptides and 
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77/70 kDa minor bands (Ridley et al, 1990a). The 77/70 kDa bands are suggested to 
be degradative products of the RAP-1 protein during preparation. Similar molecular 
weight proteins were also identified by other researchers (Campbell et al, 1984, 
Howard et al, 1984, Schofield et al, 1986, Clark et al, 1987, Bushell et al, 1988 and 
Howard, 1990). Western blot study of the RAP complex suggested that the RAP 
complex is composed of, at least, two gene products, a 80 kDa protein which was 
processed to a 65 kDa protein after translation, so called RAP-i(Ridley et al, 1990a) 
and a 42 kDa protein, called RAP-2 (Saul et al, 1992). As it forms the major interest 
of this thesis, the RAP-1 protein will be discussed in more detail. 
The rhoptry associated protein-1 was localized in the rhoptry organelle of 
the P. falciparuni by using immunofluorescence assay (IFA) and electron microscopy. 
The WA gave an punctate pattern which corresponds to the rhoptry organelle of the 
parasite. The localization of this protein also confirmed by immuno-gold labelling 
technique. Most of the RAP-1 protein was detected in the body of the rhoptry 
organelle and less dense at the neck of this organelle (Bannister, unpublished results). 
The RAP-1 is first synthesized as a 84 kDa protein precursor at 
mid-trophozoite stage before it is processed into a 80 kDa peptide (Bushell et al, 
1988). This processing may be required for its complex formation with the RAP-2, 
which is synthesized at the same time from a different gene (Ridley et al, 1991 and 
Saul et al, 1992). After complex formation, the 80 kDa protein is further processed 
into a 65 kDa (or 66 kDa) peptide at around the time of schizont rupture (Schofield 
et al, 1986, Clark et al, 1987, Ridley et al, 1990a). 
Of the monoclonal antibodies against RAP-1 protein so far described, most 
of them bind to conserved epitopes among different isolates and some have shown 
inhibitory effects on parasite growth in vitro (Schofield et al, 1986, Clark et al, 1987 
and Hope, 1984a). The inhibitory effect was proposed to be the result of merozoite 
invasion blocking. It was suggested that rhoptry proteins may be externally accessible 
during release and reinvasion (Sam-Yellowe and Perkins, 1990). The RAP-1 protein is 
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not only found in rhoptries (puntate pattern by IFA and immuno-labelling electron 
microscope) but also found associated with membrane-like material protruding from 
rhoptries (Bushell et al, 1988). After invasion, only the 80 kDa protein can be 
detected in the newly infected red blood cell but not the 65 kDa protein (Clark et al, 
1987, Howard and Reese, 1984). This evidence suggests that the RAP-1 protein may 
be functionally important for merozoite release and/or the reinvasion of erythrocytes 
and may responsible for the induction of protective immunity. 
Indeed, an immunization experiment in Saimiri monkeys showed that the 
RAP complex can stimulate protective immunity in immunized animals (Ridley et as!, 
1990b). Importantly, the serum from protected monkeys only recognized the RAP 
complex in the total parasite extract on a western blot. This immunization experiment 
proved that the RAP complex alone can ellicit protective immune responses against 
malaria infection and that the RAP complex is a good malaria vaccine candidate. 
The gene encoding RAP-1 protein was first studied in detail by Ridley and 
his colleagues (Ridley et al, 1990a). A sequencing study revealed a single reading 
frame of 2349 base pairs encoding 813 amino acids. The RAP-1 protein contains no 
repetitive sequence but has a serine-rich region with KSSSPS motifs at the N-terminus 
half of the peptide. A sequence at the end of N-terminus was also proposed as a signal 
peptide. All of the cysteine residues, some of which are known to take part in 
disulfide bridge formations, are located at the C-terminal half of the molecule. These 
cysteine amino acids are flanked by amino acid sequences which have potential for 
amphiphilic helix formation, a structure found in many membrane interacting proteins. 
A cleavage site for processing of 83 kDa into 65 kDa has also been located between 
A190 and D191 (Ridley et al, 1991). 
The sequence comparison of this gene in Honduras IJCDC isolate (Howard 
et al, 1992) and K1 isolate (Ridley et al, 1990a) revealed that RAM gene is highly 
conserved in these two isolates. Up till now, the data about the RAP-1 protein has led 
to the conclusion that this protein is a good P. faiciparum vaccine candidate. 
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However, more studies are needed to gain a better understanding of both the 
immunology and function of the RAP-I protein. 
1.4. Scope of the thesis. 
The importance of the RAP-1 protein as a malaria vaccine candidate has 
been progressively solidified in the past few years. Like many other malaria vaccine 
candidates, the function and immunological aspects of the RAP-1 protein are still 
unclear. Obviously, these informations are crucial for vaccine design and development. 
Evaluation of inhibitory experiments shows that several monoclonal 
antibodies which directly recognized the RAP-1 protein can inhibit parasite growth 
in vitro. This suggested that the binding of these monoclonal antibodies at specific 
sites may affect the function of the RAM protein and lead to the growth inhibition of 
the parasite. Thus, it is of great interest to identify those antibody binding sites on the 
RAP-i protein. 
The aim of this thesis is to map the epitopes of the inhibitory monoclonal 
antibodies in order to identify functional and immunologically significant regions of the 
RAP-1 protein for future malaria vaccine development and to determine possible 
inhibition mechanisms (Chapter 1-5). Another part of the thesis is devoted to epitope 
mapping of the monoclonal antibodies generated by a recombinant RAM protein to 
compare immunogenicity different between the recombinant protein and the native 
RAP-1 protein (Chapter 6). To emphasize the degree of conservation in the rap-1 gene, 
sequences of the rap-i gene from different isolates of the P. falciparum were 
determined and compared (Chapter 7). 
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Chapter 2 
Materials and methods 
2.1. Materials. 
2.1.1. Bacterial strain and recombinant bacteriophage. 
The important genotypes and phenotypes of a E. coli strain, recombinant 
bacteriophage and expression plasmids used in this study are described below. 
2.1.1.1. Bacterial strain. 
F. coli strain Genotypes and reference 
NM522 supE, thi, tx(lac-proAB), Lxhsd5(r—, in—), [F, proAB, 
lacIqZAM151. 
(Gough and Murray, 1983) 
This strain of F. coli grows well in LB medium or minimal medium (see 
section 2.1.7.2.) supplemented with thiamine (vitamin BI) because it cannot 
synthesize thiamine (thi). The supE genotype allows suppression of an amber (UAG) 
mutation during translation of mRNA. Because the a-glutamyl phosphate reductase 
(proA) and the a-glutamyl kinase (proB) encoded genes on the genomic DNA were 
deletedm, the bacteria has to maintain its F episome which carries both genes if it is 
grown on the minimal medium supplement with thiamine. The Ahsd5 (r, m) genotype 
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of this strain will prevent the cleavage of DNA by endogenous restriction endonuclease 
and also modification process by methylation. 
2.1.1.2. Recombinant bacteriophage. 
The RAP-1 gene insert was originally obtained from the Xrapi.1 (Ridley et al, 
1990a). The Arapi. 1 is the recombinant Xgtl 1 which contains a part of rap-1 gene 
from nucleotide 182 to 1953 (amino acid D62 to H651) The rap-] gene insert is 
flanked by an EcoRI linker at both ends (see detail in chapter 3) 
2.1.2. Plasmids used in this experiment. 
Expression plasmids References 
pUR278 Ruther and Muller-Hill, 1983 
pMS1S Scherf et al,1990 
The pUR278 and pMS1S are expression plasmids derived from pBR322. Both 
plasmids carry 3-lactamase genes which lead to the ampicillin resistance phenotype in 
the transformant cell. The interested gene or fragment may be subcloned into the linker 
region at the C-terminus of the 3-galactosidase gene which is regulated by lac 
promoter (see more detail in chapter 3). 
2.1.3. Genomic DNA of the P.falciparum. 
Genomic DNAs from different strains of the P. falciparuni were used in the 
PCR experiment (see chapter 7). The genomic DNAs of the strain GF881, K29, T9/94, 
T9/96 were kindly provided by Dr. Jana McBride. The HE3 and 3D7 genomic DNAs 
92 
were gratefully received from Dr. Shiu-wan Chan. The Ki genomic DNA was kindly 
prepared by Dr. Robert Ridley. The MAD20 genomic DNA was prepared by mini-
preparation method as described in the method section (see method 2.2.2.3.). 
2.1.4. Enzymes and buffers. 
Most enzymes were purchased from commercially available sources for DNA 
manipulation. The buffers for these enzyme reactions were usually provided by the 
manufacturer but some buffers were prepared in the laboratory. The table below shows 
the sources from where the enzymes and the buffers were ordered. It also includes the 
components of the buffers used which were prepared in the lab from sterile reagents. 
Enzymes and buffers Sources or components 
All restriction endonuclease enzymes and 
their buffers  
Boehringer Mannhein 
T4 DNA ligase Pharmacia 
Kienow fragment of DNA polymerase Northumbria Biological Limited 
Thermalase IBI 
lOxOne-phor-All buffer Phamacia 
10xligase buffer 200 mM Iris-Cl (pH 7.6) 
50 mM MgC12 
50 mM_dithiothreitol 
lOxmermalase buffer ml 
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2.1.5. Commercial kits. 
In this study, several commercially available kits were used. Their 
manufacturer sources of the kits are listed here. 
Kits and their sources Manufacturers 
PRIME ITTm RANDOM PRIMER KIT Stratagene 
Erase-a-Base system Promega 
Gene clean II kit BIO 101 Inc. 
Qiagen plasmid preparation kit Hybaid 
Nick column Pharmacia 
Protoblot System Promega 
Pepscan kit Cambridge Research Chemicals 
2.1.6. Antibodies. 
Antibodies and monoclonal antibodies were used for localization of their 
epitopes in this study. The characters of each monoclonal antibodies and polyclonal 
antibodies will be described in Table 3.1 (see chapter 3) and Table 6.1 (see chapter 6). 
Other antibodies were also used as second antibody for antigen detection in western 
blot analysis and the Pepscan system, an overlapping peptide synthesis kit. The 
antibodies used on the western blot are alkaline phosphate conjugated but the 
antibodies used in the Pepscan system are horseradish peroxidase conjugated. Both 
types of the antibodies are listed below with the commercial sources. 
EEO 
Second antibodies Sources 
Goat 	anti-rabbit 	IgG 	alkaline 	phosphatase 
conjugated 
Promega 
Anti-mouse IgG alkaline phosphatase conjugated Promega 
Anti-human IgG alkaline phosphatase conjugated Promega 
Swine and-rabbit IgG peroxidase conjugated Cambridge Research Chemicals 
Rabbit anti-mouse IgG peroxidase conjugated Cambridge Research Chemicals 
Goat anti-human IgG peroxidase conjugated Cambridge Research Chemicals 
2.1.7. Important reagents and chemicals. 
Most chemicals used in this study were analytical grade chemicals which are 
commercially available. In Pepscan peptide synthesis experiment, high grade chemicals 
are required for reliability of the peptide synthesis. These high grade chemicals can be 
obtained only from special suppliers. The lists below show the suppliers and the high 
grade chemicals used for this study. 
2.1.7.1. Chemicals for Pepscan experiment 
Suppliers Chemicals Grades 




Suppliers Chemicals Grades 
BDH Methanol AnalaR 
Dichioromethane Ana1aR 
Sodium lauryl sulfate Ana1aR 
2-mercaptoethanol AnalaR 
Sodium dihydrogen orthophosphate Ana1aR 
Citric acid AnalaR 
Sodium hydroxide AnalaR 
Hydrogen peroxide(60% hydrogen) AnalaR 
Triethylamine AnalaR 
Phenol AnalaR 
Acetic anhydride AnalaR 
Sigma Trifluoroacetic acid protein sequencing grade 
Bovine serum albumin IgG free 
Ovalbumin grade II 
Tween20 	(polyoxyethylene 	sorbitan 
monolaurate) 
Rathburn NN-Dimethyllormamide protein synthesis grade 
2.1.7.2. Media and reagents. 
The reagents and their components used in this study are listed below. All 





LB medium. per liter; 
Bacto-tryptone 10 g 
Bacto-yeast extract 5 g 
NaC1 10  
adjusted pH to 7.0 with 5 N NaOH 
LB Agar. as LB broth; 
Bacto agar 15 g 
SxSpizizen salts. per liter; 
(NH4)2SO4 2 g 
K2HP043H20 18.3 g 
6 g 
Trisodium citrate'2H20 1 g 
MgS047H0 0.2 g 
7.2 
Minimal medium. per 400 ml; 
20% Glucose 4 ml 
Spitizizen salts 80 ml 
Thiamine HC1 (100 mg/ml) 200 R1 
Ampidillin (100 mg/ml) 200 tl 
Bacto agar 6 g 
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-Competent cell preparation reagents. 
Reagents Compositions 
STE buffer. 0.1 M 	NaCl 
10mM Tris-Ci, pH 8.0 
1 mM 	EDTA 
TSB buffer 10% 	PEG 
5% 	DMSO 
10 mM M902 
10mM MgSO4. 
in LB broth 
-Bacteriophage DNA preparation reagents. 
Buffers Compositions 
SM buffer per liter 
NaCl 	 5.8 g 
MgS047H20 	 2 g 
1 M Tris-Cl, pH 7.5 	50 ml 
2% gelatin solution 	 5 ml 
Adsorption buffer. 10 mM M902 
10mM 	CaC17 
ME 
-DNA preparation reagents. 
Reagents Compositions 
Solution 1 50 	m 	glucose 
25 mM 	Tris-Cl, pH 8.0 
1 	m EDTA,pH8.0 
Lysozyme solution. 10 mg/ml Lysozyme 
10 	m 	Tris-CI, pH 8.0 
Solution 2. 0.2 N 	NaOH 
1% 	SDS 
Solution 3. 5 M Potassium acetate 	60 ml 
Glacial acetic acid 	11.5 ml 
Sterile distilled water 	28.5 ml 
Solution 4. 1.6 M 	NaCl 
13% w/v PEG 8,000. 
Phenol:chloroform. 50% 	Phenol 
48% 	Chloroform 
2% 	Isoamyl alcohol 
1OxTE 100 	m Tris-Ci, pH 8.0 
10 	m 	EDTA, pH 8.0 
bufferl 	for 	genomic 	DNA 	mini- 150 mM NaCl 




lOxKlenow buffer 0.5 M 	Tris-Ci, pH 7.6 
0.1 M 	M907 
dNTP mix 0.125mM dATP 
0.125mM dflP 
0.125 mM dGTP 
0.125 mM dCTP 
loxBacteriophage 	T4 	polynucleotide 0.5 M 	Tris-Ci, pH 7.6 
kinase 0.1 M 	MgCl 
50 mM 	Dithiothreitol 
1 mM 	Spermidine HC1 
1 mM 	EDTA, pH 8.0 
lOxSl nuclease buffer 2 M 	NaCl 
0.5 M 	Sodium acetate (pH 4.5) 




Loading buffer 0.25% 	Bromophenol blue 





1OxTBE 890 mM Tris-borate 
20mM 	EDTA 
1OxTAE 0.4 M 	Tris-acetate 
0.O1M 	EDTA 
-Nick column reagents. 
Reagent Compositions 
Buffer solution 10 mM 	Tris-Cl, pH7.5 
1 mM 	EDTA 
-Hybridization reagents. 
Reagents Compositions 
Denaturing solution 1.5 M NaCl 
0.5 M NaOH 
Neutralization solution 1.5 M NaCl 
0.5 M Tris-Cl, pH 7.2 
0.001 M EDTA, pH 8.0 
Prehybridization solution 6xSSC 
0.4mM EDTA, pH 8.0 
0.1% Tetrasodium pyrophosphate 
0.2% SDS 
50 mg/L Heparin 
47 
Reagents Compositions 
20xSSC 3 M 	NaC1 
0.3 M 	Trisodium citrate 
adjust to pH 7.0 with 10 N NaOH 
Washing solution (for probe removal) 0.1xSSC 
0.1% 	SDS 
0.2 M 	Tths-Cl, pH 7.5 
-Exonucleaselll digestion reagents. 
Reagents Compositions 
Si nuclease mix 7.4X Si buffer 27 p1 
(supplied with the kit) 
Si nuclease 60 units 
Distilled water 172 p1 
Kienow mix lOx Kienow buffer 30 p1 
Kienow DNA polymerase 3 units 
dNTP mix 0.125mM dATP 
0.125mM dYFP 
0.125 mM dGTP 
0.125 mM dCTP 
Ligase mix lOx Ligase buffer 100 p1 
50% PEG 100111 
lOOmMDfl 10 p1 
T4 DNA ligase 5 units 
Distilled water 790 p1 
-Sequencing reagents. 
Reagents Compositions 
1OxTM buffer 70 	m Tris-Ci, pH 7.5 
70 mM MgC1 
300 	m NaCl 
100 mM Dithiothreitol 
1 mm EDTA 
T0.1E 10 	m Tris-Cl, pH 7.5 
0.1 mM EDTA 
chase mix 0.5 mM dATP 
0.5mM dCTP 
0.5mM dflP 
0.5 mM dGTP 
Fixing solution 10% Methanol 
10% Acetic acid 
Formamide dye mix 98% Formamide 
0.025% Xylene cyanol FF 
0.025% Bromophenol blue 
iO mM EDTA,pH 8.0 
Ez 
For ddNTP solutions were prepared as follow: 
Stock solution A(iil) C(W) G(W) T(jil) 
0.5 mM dCTP 500 25 500 500 
0.5 mM dGTP 500 500 25 500 
0.5 mM dflP 500 500 500 25 
10mMddATP 1 - - 
10mMddCTP - 8 - - 
10mMddGTP - - 16 - 
lOmMddflP - - - 50 
T0. 1E buffer 500 1000 1000 1000 
-SDS-PAGE gel electrophoresis reagents. 
Reagents Compositions 
30% Acrylamide solution 29.2% Acrylamide 
0.2% N, NTmethylenebisacry1amide 




0.05% Bromophenol blue 





Stain solution 0.125% 	Coomassie blue R-250 
50% 	Methanol 
10% 	Acetic acid 
Destaining solution 50% 	Methanol 
10% 	Acetic acid 
-Western blot reagents. 
Reagents Compositions 
PBS 0.9% NaCl 
10 	m Tris-Cl, pH 7.4 
Blocking solution 5% Pat-free milk powder in PBS 
Transfer buffer 25 mM Tris base 
192 mM Glycine 
20% Methanol 
0.1% SDS 
Alkaline phosphatase buffer 100 mM Tris-HC1, pH 9.5 
100 	m NaCl 




Acetylation solution DMF 	 5 parts 
Acetic anhydride 	 2 parts 
Triethylamine 	 1 part 
Cleavage solution 95% 	Trifluoroacetic acid 
(for deprotection) 2.5% 	Phenol (w/v) 
2.5% 	Ethànedithiol 
Disruption buffer 1% 	Sodium dodecyl sulphate 
0.1 M 	Sodium dihydrogen 
orthophosphate 
adjust pH to 7.2 with 50% NaOH 
Supercocktail 1% 	OvaThumin 
1% 	Bovine serum albumin 
0.1% 	Tween2OinPBS 
10xPBS per liter; 
NaCl 	 85 g 
Disodium hydrogen orthophosphate 10.7 g 
Sodium dihydrogen orthophosphate 	3.9 g 
lOxPBSITween 20 as 1OxPBS 
Tween 20 	 5 ml 
ABTS buffer per 2 liter; 
1 M disodium hydrogen 
orthophosphate 	 200 ml 
1 M citric acid 	 160 ml 
adjust pH to 4.0 with citric acid or NaOH 
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Reagents Compositions 
Substrate solution per 100 ml of ABTS buffer; 
azino-di-3-ethyl- 
benzthiazodinsulphonate 	50 mg 
60% hydrogen peroxide 	60 jil 
2.1.8. Computer analysis software. 
In the Pepscan experiment, the peptide synthesis schedules were produced 
by a software provided with the Pepscan kit. Although, the software is also capable of 
analysis the data directly from the ELISA plate reader, the software was not used for 
data analysis because the ELISA plate reader used in this study has not been connected 
to the IBM-compatible computer. Instead, the data was manually typed into the 
mainframe computer, the Castle, at the Edinburgh University and histogram graphs 
were produced by a programme called Easygraph (as shown in chapter 6 and 7). 
The pictures of gel electrophoresis, autoradiograph and western blot 
detection illustrated in this thesis were reproduced by a scanner (256 greyscales from 
Logitech) and fototouch programme (window version) supplied with the scanner. The 
scanned pictures were rescaled to fit A4 pages without further alteration. 
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2.2. Methods. 
2.2.1. Microbiological techniques. 
2.2.1.1. Bacterial culture. 
Three techniques were used for bacterial culture in this study, namely streak 
plate, spread plate and liquid culture. The purpose of streak plate technique was to 
purify a single colony from liquid culture or a mixed colony. To receive bacteria 
colonies from liquid culture, the spread plate technique must be applied. The liquid 
culture technique is used to multiply a large amount of bacteria and for fusion protein 
production. To obtain exponential phase culture, the overnight grown culture had to be 
diluted with prewarmed medium in a ratio 1:10 and was further grown for 1 hour. 
2.2.1.2. Bacterial storage. 
Bacteria can be stored on an agar plate for short term storage or as a stab 
for long term storage. The short term storage is stored as single colonies which are 
ready for further manipulation. The long term storage, nevertheless, must be 
re-streaked before single colony can be obtained. 
-Short term storage. 
The aim for the short term storage of the bacteria is to maintain the clone 
stock during the study. The E. coli is usually streaked on solid medium and allowed to 
grow overnight in 37°C before the plate is stored at 4°C up to 1-2 month. However, 
different clones of F. coli need different media during storage. The F. coli strain 
NM522 can be stored on the minimum medium. The E. coil clones with recombinant 
plasmids which carry the j3-lactamase gene have to be stored on the minimum medium 
supplement with ampiciliin to sustain their plasmids. 
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-Long term storag± 
A well separated colony was picked by a flame sterile inoculating needle. 
The needle was stabbed through the LB agar in a small glass vial. The cap of the vial 
was tightened and the vial was stored in the dark at room temperature. 
2.2.1.3. Competent cell preparation. 
For convenience, the competent cells were prepared on a large scale by a 
rapid method modified from a method described by Chung and Miller (Chung and 
Miller, 1988). A single colony of NM522 was grown in 250 ml flask containing 100 ml 
LB broth overnight. 10 ml of the culture was diluted with 90 ml of pre-warmed LB 
broth and was grown further for 1 hour to achieve early log phase growth. The cells 
were collected by centrifugation (2,000 rpm for 15 mins). The cell pellet was 
resuspended in 10 ml of ice-cold TSB buffer and incubated on ice for approximately 
10 mins. The treated cells were either used immediately or they could be frozen with 
liquid nitrogen and stored at -70°C as 0.1 ml aliquots in microfuge tubes. 
2.2.1.4. Induction effusion proteins. 
To obtain recombinant fusion proteins from a recombinant clone, a single 
colony of bacteria was grown in 5 ml bottle containing 1 nil LB broth and 50 j.tg/ml of 
ampidilhin overnight at 37°C with 200 rpm shaking. The culture was diluted 1:10 in 1 
ml pre-warmed LB broth and grown for 2 hours at the same condition. 2 mM of IPTU 
was then added before the culture was grown further for 90 mins. In one experiment, 
the culture was induced overnight after the dilution of the bacterial culture. 
4 
2.2.2. DNA manipulation techniques. 
Many molecular biology techniques related to DNA were used in this study. 
These DNA manipulation techniques are described below. 
2.2.2.1. Phage DNA preparation. 
The phage miniprep was modified from the method described by 
Grossberger (Grossberger, 1987). The original plate of Xrapl. 1 was kindly prepared by 
Dr. Rob Ridley. A single plaque was transferred into a 0.3 ml adsorption buffer (see 
2.1.7.2.) in 20 ml glass tube with a sterile 200 tl Eppendorf pipette tip. To the tube 
was added 0.2 ml of an exponential culture of bacteria which was previously grown in 
LB broth containing 0.4% maltose (see 2.2.1.1.). The culture was incubated at 37°C 
for 10 mins to allow adsorption of the phage before 10 ml of LB broth supplement 
with 10 mM M902 and 0.1% glucose was added. The tube was then incubated at 
37°C overnight. The bacterial debris was separated by centrifugation (3,000 rpm for 
10 mins). DNase free RNase was added to digest contaminating RNA. The supernatant 
was centrifuged at 26,000 rpm for 2 hours to collect the phage particle. The pellet was 
resuspended in 200 p1 of SM buffer, and freshly made 200 41 of SM buffer containing 
1 mg/ml proteinase K was added before the mixture was incubated for 2 hours at 37 °C. 
The mixture was extracted once with phenol:chloroform to extract the 
phage particles. To precipitate the phage DNA, 100 0 of 7.5 M ammonium acetate 
and 1 ml 100% ethanol were added. The DNA precipitate was centrifuged (12,000g 
for 15 mins) and washed with 0.5 ml 100% ethanol, air dried and dissolved in 50 p1 of 
TE. 
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2.2.2.2. Plasmid DNA preparation. 
-Medium scale plasmid preparation by PEG. 
A single colony of bacteria was grown in LB broth in the presence of 50 9 
g/ml ampicillin overnight (see 2.2.1.1.). The cells were collected by centrifugation 
(2000g for 15 mins) at 4°C. The pellet was washed once in 100 ml ice-cold STE and 
was resuspended in 18 ml of ice-cold Solutionl (see 2.1.7.2.). The bacteria suspension 
was mixed with 2 ml of lysozyme solution (see 2.1.7.2.). The cells were lysed with 40 
ml freshly, prepared Solution 2 (see 2.1.7.2.). The mixture was inverted 2-3 times and 
incubated on ice for 10 mins. After adding 20 ml of ice-cold Solution 3 (see 2.1.7.2.), 
the mixture was shaken and further incubated for 10 mins. The bacterial genomic DNA 
and other cell debris were pelleted by centrifugation at 16,000g for 15 mins at 4°C 
without a break. 0.6 volume of isopropanol was added to the supernatant, mixed and 
incubated at room temperature for 10 mins to allow the precipitation of plasmid DNA. 
The centrifugation (4000g for 15 mins at room temperature) brought down the plasrnid 
precipitate from the solution. The pellet was washed with 70% ethanol. The plasmid 
pellet was resuspended in 6 ml of TE. After adding 6 ml of ice-cold 5 M LiC1, the high 
molecular weight RNA can be separated from the plasmid mixture by centrifugation 
(12,000g for 10 mins at 4°C). The plasmid was then precipitated from the solution by 
adding an equal volume of isopropanol and leaving on ice for 5 mins before it was 
pelleted by 12,000g centrifugation at room temperature for 10 mins. The pellet was 
again washed with 70% ethanol. 
To purify the plasmid DNA, the PEG precipitation technique was used. The 
plasmid resuspended in 500 j.il TE with 20 .tg/ml DNase-free RNase and incubated at 
room temperature for 30 mins. 500 p1 of Solution4 (see 2.1.7.2.) was added. The 
mixture was centrifuged 12,000g for 5 mins at room temperature. The obtained pellet 
was washed with 70% ethanol and dried. The pellet then was dissolved in 400 p1 of TE 
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before being extracted with equal parts of phenol, phenol: choloroform and 
chloroform. 
-Ethanol precipitation of DNA. 
The purified plasmid was precipitated by adding 3 M sodium acetate about 1 
in 10 volume of the DNA solution and 2 volumes of ethanol and leaving at room 
temperature for 10 mins. The tube was centrifuged 12,000g for 5 mins. The pellet was 
washed with 200 p1 of 70% ethanol. 
-DNA storage. 
The pellet of plasmid was dissolved in 500 p1  of TB and dispensed in 50 p1 
aliquots into microfuge tubes. One tube of plasmid DNA was stored at -20°C for 
future use and the others stored at -70°C as stock plasmid. 
-Qiagen column method. 
The use of a Qiagen column allows the DNA preparation to be achieved by 
simple step operation. The quality of plasmid DNA is high enough for double stranded 
sequencing. The method described below is recommended by the manufacturer. 
A single bacterial colony was grown overnight in 100 ml LB broth 
supplement with 50 pg/ml ampicillin (see 2.2.1.1.). The cells were pelleted and 
resuspended in 4 ml of buffer P1 (see 2.1.5.). 4 ml of buffer P2 (see 2.1.5.) was added, 
mixed and incubated at room temperature for 5 mins. Then 4 ml of buffer P3 (see 
2.1.5.) was added. The mixture was centrifuged 20,000 rpm at 4°C for 30 mins. The 
supernatant was again centrifuged for 10 mins to obtain a clear lysate. The solution 
was passed through qiagen-tiplOO which had been equilibrated with 3 ml of buffer 
QBT (see 2.1.5.). The column was washed with 10 ml of buffer QC (see 2.1.5.) before 
the column was eluted with 5 ml of buffer QF (see 2.1.5.). The plasmid was 
precipitated with 0.7 volume of isopropanol and centrifuged. The pellet was washed 
with 70% ethanol and was dissolved in 100 41 of TE. 
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-Quantitation of DNA concentration. 
The amount of DNA can be measured by spectrophotometer. The DNA 
solution was diluted between 1/100 and 1/ 1000 with TB and the optical density of the 
solution was read at a wavelength of 260 run. The concentration of DNA can be 
calculated from the standard: 
At approximately 50 .tg/m1 of double-stranded DNA; 	0D260 = 1 
2.2.2.3. Parasite DNA mini-preparation. 
The mini-preparation for the genomic DNA of the P. falciparuin used in this 
study was developed by Dr. Shiu-wan Chan (Chan, 1991). The genomic DNA 
obtained from this method provided genomic DNA suitable as a template for the PCR 
reaction. The P. falciparum strain MAD20-infected human red blood cells were 
received from the parasite culture which has been maintained in the laboratory. 
A 100 il aliquot of P. falciparum-infected red blood cells were washed 
three times with 0.5 ml of bufferl (see 2.1.7.2.). The parasitized red blood cells were 
resuspended in 0.4 ml of the same buffer with 50 .ig of proteinase K, and 5 j.tl of 
10% SDS was added. The mixture was incubated overnight at 37°C. The lysed 
infected red blood cell was extracted with phenol once. The genomic DNA was 
obtained after the ethanol precipitation (see 2.2.2.2.). The DNA was resuspended in 
5 R'  of TB. 
2.2.2.4. Digestion of DNA by restriction enzymes. 
DNA was digested by mixing the desired amount of DNA with 1 R'  (or more) 
of diluted restriction enzyme (allow at least 1 unit per 1 g  of DNA) and 1 jil of 
lOxOne-phor-All buffer or another appropriate restriction enzyme buffer. The reaction 
was made up to 10 p1 with sterile distilled water and incubated at 37°C from 1 hour to 
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overnight. In case of a double enzyme digestion, the total volume of the reaction was 
increased to 20 iii and the same amount of another restriction enzyme and buffer was 
added at the same time. After the digestion was completed, the restriction enzyme was 
inactivated at 65°C. 
For partial digestion, 0.5 units of restriction enzyme per 1 j.tg of DNA were 
used. The reaction was incubated only 1 hour at 37°C before the enzyme was 
inactivated by heat as described above. 
2.2.2.5. End-filled reaction by Klenow fragment of DNA polymerase. 
DNA with sticky-end was mixed with 1 j.tl of Kienow fragment (2 units/41), 1 
R1 of dNTP mix (see 2.1.7.2.) and 1 p1 of l0xKlenow buffer (see 2.1.7.2.). The 
reaction mixture was made up to 10 p1 with sterile distilled water and incubated at 
37°C for 30 mins. The mixture was removed from the 37°C incubator and the enzyme 
was inactivated at 65°C for 20 mm. 
2.2.2.6. Digestion of the sticky-end of DNA by Si nuclease. 
DNA with sticky-end was digested by mixing a desired amount of DNA with 
1 p1 of Si nuclease enzyme (1 unitlj.il) and 1 j.il of lOxSi nuclease buffer. The mixture 
was made up to 10 p1 with sterile distilled water and incubated at 37°C for 30 mins. 
The enzyme was then denatured by incubation at 65°C for 20 mins. 
2.2.2.7. Ligation of DNA. 
Linearized plasmid DNA was mixed in total of 10 R1  with a DNA fragment 
with compatible ends to the plasmid, 1 j.il of lOxT4 DNA ligase buffer and 1 p1 of T4 
DNA ligase(l unitlkl) The mixture was incubated at 15°C overnight. The enzyme was 
inactivated at 65°C for 20 mins. 
The ligation mixture must contain equal or higher concentration of DNA 
fragment molecules than the plasmid to optimize the ligation reaction. 
2.2.2.8. Transformation. 
An aliquot (0.1 p1) of the competent cells (see 2.2.1.3.) was mixed with 100 
pg of plasmid DNA in an ice-cold microfuge tube. The tube was incubated on ice for 
30 mins and 0.9 ml of LB broth containing 20 mM glucose was added. The microfuge 
tube was rotated slowly at 37°C for 1 hour. The culture was spreaded onto LB agar 
plate supplement with 50 g/ml ampicillin (see 2.2.1.1.) for selection of transformants. 
2.2.2.9. Agarose gel electrophoresis. 
Agarose gel electrophoresis is a technique for identification of DNA 
fragments, for example, following the digestion of DNA fragment by restriction 
enzymes and for their separation. Large 'maxi gels were used for purification of a 
digested DNA fragment. 
-Sample preparation. 
The DNA sample for gel electrophoresis was mixed with l0xloading buffer 
approximately 1 in 10 of the sample total volume. The volume of the sample was made 
up to multiple of 10 p1. 
-Mini gel electrophoresis. 
To prepare a minigel, 0.8 g of agarose was melted in 100 ml of 0.5xTBE 
buffer( prepared as 1OxTBE, see 2.1.7.2.). The gel was cast on a plastic base (about 
5 cmx 10 cm in size) and a comb was used to form sample wells. The gel was 
submerged in 0.5xTBE buffer before samples were loaded into each of the wells. The 
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gel was run at 100 volts for 1.30 hours or until DNA bands could be individually 
distinguished. 
-Maid gel electrophoresis. 
Mat gel was prepared as 0.8% of agarose in 1xTAE buffer (prepared as 
1OxTAE, see 2.1.7.2.) . Ethidium bromide was added to agarose gel and buffer. Both 
ends of the gel were placed on buffer tanks. Wick paper was used to draw buffer from 
the tanks into the gel. The agarose gel was covered with cling film to prevent 
evaporation . A salt bridge linked between the tanks to circulate buffer in both tanks. 
The gel was run at 80 volts overnight with 1xTAE buffer. The electrophoresis time 
was extended until the DNA bands were well separated. 
-Agarose gel staining. 
The gel was removed from the casting base and soaked in 0.5 j.ig/ml 
ethidium bromide with slow shaking. The gel was left in the solution for at least 
15 mins. The DNA bands were detected with a UV transilluminator which transmits 
ultraviolet light at 302 nm. The double strand DNA was visible as red-orange bands 
when the intercalating ethidium bromide emitted energy as visible light at 590 min. 
2.2.2.10. DNA fragment purification from agarose gel. 
DNA fragments separated by Mat gel electrophoresis can be purified from 
agarose by one of the two methods described below. 
-Electroelution of DNA fragment from Maid gel electrophoresis. 
A narrow block of agarose gel was removed in front of the desired DNA 
band to form a square well which was about 2-3 cm. wider than the DNA band on both 
size. A dialysis membrane was placed at the far side wall of the well to prevent the 
DNA from moving out of the well during electroelution. The well was filled with 
1xTAIE buffer and 0.5 p.g/ml ethidium bromide. The eletrophoresis was continued at 
300 volts until the DNA attached to the membrane (the DNA was located by UV 
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transiluminator, see 2.2.2.9.). The current direction was then reversed for 30 sec 
causing the DNA to move back into the well. The buffer in the well was collected and 
the ethidium bromide was extracted 3-4 times with an equal volume of 1xTAE-
equilibrated butanol. The solution was extracted once with phenol:chloroform and 
once with chloroform. The DNA was precipitated by ethanol precipitation (see 
2.2.2.2.). 
-GENECLEAN II Kit. 
A band of DNA as detected by ethidium bromide was cut from agarose gel 
run in 1xTAE and transferred to a microfuge tube. The piece of agarose was melted at 
55°C after approximately 3 volume of NaT stock solution (supplied with the kit) had 
been added. If TBE had been used for agarose preparation, 1/2 volume of TBE 
modifier (see 2.1.5.) and 4.5 volumes of NaT must be used instead of the NaT alone. 
When the agarose was completely melted, GLASSMILK suspension was added. At 
least 5 il of (LASSMILK was needed for a sample containing 5 jig of DNA. The 
microfuge tube was centrifuged at 12,000g for 5 seconds to pellet the 
GLASSMILKIDNA complex. The supernatant was removed and the pellet was 
washed 3 times with NEW WASH (supplied with the kit). The DNA was eluted with 
10 p1 of 1xTE buffer. 
2.2.2.11. Radioactive labelling of DNA. 
To detect a specific sequence in a DNA fragment, a radioactively labelled 
probe was used. The probe was obtained from the labelling of an oligonucleotide or a 
DNA fragment having a complementary sequence 
-End labelling. 
The end labelling method was used for labelling a short synthesized 
oligonucleotide. Bacteriophage T4 polynucleotide kinase in the reaction catalysed the 
transfer of a 7- 32P of ATP to the 5' terminus of unphosphorylated oligonucleotide 
(forward reaction). The reaction was set up in a total volume of 20 jfl. The reaction 
mixture includes 1 41 of oligonucleotide (3 ng/pI), 2 41 of lOxpolynucleotide kinase 
buffer, 2 p1 of [y- 32P]dATP (10 4G/pd), 2 p1 of bacteriophage T4 polynucleotide 
kinase (4 units4tl) and 13 jil of sterile distilled water. The reaction was incubated at 
37°C for 1 hour. The labelled oligonucleotide can be used without further purification. 
-Random-primed labelling. 
A new technique had been developed using 17 DNA polymerase enzyme to 
synthesize a radioactive probe complementary to a DNA template. A labelling kit 
(Stratagene) based on this technique was used in this study. The target DNA fragment 
was denatured in a microfuge tube by mixing 25 ng of target DNA and 10 R'  of 
random oligonucleotide primers. The mixture was made up to 34 p1 with sterile 
distilled water. 
The DNA was incubated in a boiling bath for 5 mins to separate double 
strand target DNA. The tube was centrifuged briefly at room temperature to collect the 
mixture at the side of the tube. The following components were added to the denatured 
DNA; 10 p1 of SxPrimer buffer, 5 p1 of [(X- 32P]dATP (10 pCi/pd) and 1 p1 of 17 DNA 
polymerase.The reaction was incubated at 37°C for 10 mins to allow the 
complementary strand probe to be synthesized. 2 p1 of stop mix was added to end the 
reaction. The probe was further purified on a Nick column. 
-Nick column. 
The nick column is a ready prepared Sephadex G-50 column for the 
separation of DNA fragments from unincorporated 32P-labelled nucleotides. 
The column was equilibrated with 3 ml of buffer solution (see 2.1.7.2.) 
before the mixture of labelled DNA probe was added. The column was then washed 
with 400 p1 of buffer solution. The purified DNA probe was eluted from the column by 
adding 400 p1 of buffer solution into the column. 
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2.2.2.12. Hybridization. 
The presence of a target sequence in a DNA fragment can be confirmed by 
the use of the hybridization technique. This technique required the transferring of DNA 
molecule onto a Nylon membrane (Southern blotting). The target sequence was then 
identified using a radioactive labelled probe. Hybridization was also used for detection 
of recombinant clones after transformation of recombinant plasmid (Colonies 
screening). Both methods are described below. 
-Southern blotting. 
After agarose gel electrophoresis (see 2.2.2.9.), the gel was submerged in 
denaturing solution (see 2.1.7.2.) for 15 mins with slow rotation in order to denature 
double strand DNA into single strand DNA. This step was repeated for a further 
30 mins. To neutralize the pH of the gel, the denaturing solution was replaced with 
neutralizing solution (see 2.1.7.2.) with slow rotation for 30 mins. The neutralization 
step was repeated twice. The gel was placed on a bridge link between two reservoirs 
filled with 20xSSC (see 2.1.7.2.); A pre-wet gel size Nylon membrane (Hybond-N 
membrane from Amersham) was carefully placed on the top of the gel so that no air 
was trapped. Three sheets of pre-wet gel size blotting paper were then laid over the 
Nylon membrane. To create a capillary effect, many gel size absorbent papers were 
stacked ontop of the blotting papers and the top of the absorbent paper stack was 
compressed by a glass plate and a 1 kg weight. The DNA transfer was continued for 
one night. After blotting, the membrane was washed with 2xSSC to remove adhering 
gel and allowed to air dry at 37°C. The transferred DNA was fixed onto the Nylon 
membrane by exposing the membrane, DNA side down, on a UV transilluminator for 5 
mins. The membrane was then prehybridized and hybridized as described below. 
-Colony screening. 
Grids were drawn on a sheet of Nylon membrane which had been cut to fit 
an agar plate. The grid membrane was placed in a plate on a LB medium supplement 
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with 50 jig/ml of ampicillin. In a plate, about one hundred colonies of transformants 
obtained from method 2.2.2.8. were patched on each grid. The replicas of the same 
colonies were also maintained on a LB plate containing 50 .tg/ml ampidihin for use as a 
master plate. Both plates were incubated up side down at 37°C overnight. The 
membrane was then removed and laid colony side up on a sheet of absorbent paper 
previously soaked in denaturing solution (see 2.1.7.2.) for 9 mins. The denatured 
membrane was again placed colony side up on a sheet of absorbent paper which was 
previously soaked with neutralizing solution (see 2.1.7.2.) for 4 mins twice. The 
membrane was washed with 2xSSC.and air dried with the colony side up. The bacterial 
DNA was bound to the membrane by UV irradiation for 5 mins. To detect target 
sequence, the membrane was prehybridized and hybridized as the method described 
below. 
-Hybridization. 
The membrane containing denatured DNA was prehybridized in 10 ml of 
prehybridization solution (see 2.1.7.2.) for at least 1 hour using the Hybridization oven 
(Hybridizer HB-1, Techne). Radio-labelled probe (see 2.2.2.11.) was added into the 
prehybridization solution and the membrane was hybridized overnight. The 
hybridization solution was then removed and the membrane was washed and 
autoradiographed (see 2.2.2.14.). The condition of the hybridization and washing 
varied depending on the experiment. 
-Removal of probe from a Nylon membrane. 
The radioactive Nylon membrane was incubated in 0.4 M NaOH at 45°C for 
30 mins and transferred to washing solution (see 2.1.7.2.) at 45°C for 30 mins. It was 
then allowed to air dry. 
2.2.2.13. Erase-a-Base system for generating nested deletion constructs. 
-Exonucleaselll digestion. 
Linearized plasmid was progressively digested by using Erase-a-Base system 
(Promega Corporation). The procedure and conditions of digestion were similar to that 
described in the manual supplied together with the system. In short, 5 .tg of 
PEG-preparation plasmid DNA was linearized with a restriction enzyme. The digested 
plasmid was then phenol-extracted and precipitated with ethanol. The plasmid was 
dissolved in the 60 p1 of one time exonuclease III buffer (see 2.1.5.). The mixture was 
incubated at 25°C for 2 rains before 500 units of the exonuclease III was added. The 
plasmid-exonuclease ifi mixture was incubated for .30 second for lag period and 
further 2 mins to allow the digestion to proceed near to the region of interest (the SspI 
site of the rap-1 gene). Aliquots of 2.5 41 of the reaction mixture were taken every 
20 seconds intervals and added into ice-cold 7.5 p1 Si nuclease mix (see 2.1.7.2.). The 
digested plasmid in the Si nuclease mix was kept on ice until 10 samples were taken. 
All the ice-cold samples were then incubated at room temperature for 30 mins before 
the 1 p1 of Si stop buffer (see 2.1.5.) was added. The reactions were heated up to 
70°C to inactivate the Si nuclease. The samples were prewarmed at 37°C prior to 1 p1 
of the Kienow mix (see 2.1.7.2.) being added in all samples. The samples were 
incubated for another 3 minutes and 1 p1 of the dNTP mix (see 2.1.7.2.) was added. 
After 5 minutes incubation, the reaction was completed. 
-Ligation and transformation. 
The linear DNA samples obtained after Kienow DNA polymerase treatment 
were circularized by the T4 DNA ligase. A 40 p1 of ligase mix (see .2.1.7.2.) was added 
to each samples. The reactions were incubated at room temperature for 1 hour. 
Aliquots of 10 p1 per samples were used in the transformation (see method 2.2.2.8.) 
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2.2.2.14. Polymerase chain reation. 
To amplify genomic DNA from P. falciparum, the following components 
were mixed up in a 0.5 ml microfuge tube; 10 R1  of loxmermalase buffer, 16 jil of the 
mixture of dNTP (1.25 mM each), 10 p1 of 5' end oligonucleotide (7.5 ng/l), 10 p1 of 
Tend oligonucleotide (7.5 ng/l), 1 41 of parasite genomic DNA (140 nglj.tl), 0.5 p1 of 
Thermalase (IBI) and 53 p1 of sterile distilled water. 
The surface of the aqueous phase was laid with 50 p.1 of light mineral oil to 
prevent vaporization. After the lid was pierced, the tube was fitted in thermo-block of 
the Thermocycler [PHC-2 Dri-Block,Techne (Cambridge) Ltd.]. The temperature of 
the reaction was controlled as follow: 
Cycles Denature Anneal Polymerization 
1 5 mins 95°C 1 mins 40°C 2 mins 70°C 
2 3 mins 93°C 1 mins 40°C 2 mins 72°C 
3 1 mins 93°C 1 mins 40°C 2 mins 72°C 
4-31 30 secs 93°C 30 secs 40°C 2 mins 72°C 
32  5mins70°C 
Ramp rate =4 
The amplified product was extracted twice with 100 p.' of chloroform. The 
amplified DNA fragment was then purified from aqueous phase of the extracted 
mixture by GENECLEAN II kit. (see 2.2.2.10.). 
2.2.2.15. Double strand DNA sequencing. 
The method of double-stranded sequencing used in this experiment was 
modified from the chain-terminating method (Sanger et al, 1977). 
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-DNA denaturation. 
For 2 sequencing reaction, 5 jig of polyethylene glycol purified, or Qiagen 
purified DNA was dissolved in total volume of 20 41 TE. 5 p1 of 1 N NaOH, 1 mM 
EDTA was added for DNA denaturation. The mixture was left at room temperature 
for 5 mins. The denatured DNA was purified by the spin-dialysis procedure (see 
below). 
-Spin-dialysis. 
Sepharose-6CBL was equilibrated with T0.1E (see 2.1.7.2.). A 0.5 ml 
microfuge was pierced through the bottom with the tip of a small syringe needle. The 
tube was then placed inside a 1.5 microfuge tube. About 20 p1 of acid-washed glass 
beads, 212-300 microns(Sigma) in T0.1E, was added to the 0.5 ml microfuge tube to 
act as a supporter and 0.3 ml of Sepharose slurry was added at the top of the glass 
bead layer. The tubes were placed in a centrifuge tube and were spun at 200g with a 
swing-out rotor until all liquid was removed. A new 1.5 ml microfuge tube was 
replaced. A denatured DNA sample was carefully pipetted onto the top of the 
Sepharose surface. The tube was again centrifuged at the same speed. The purified 
denatured DNA solution obtained from the column was collected for subsequent use. 
-Sequencing. 
The purified single stranded DNA was used as a sequencing template. For 
one primer, the spin-dialysate was mixed with 8.5 p1 of spin-dialysate, 1 p.1 of 1OxTM 
buffçr (see 2.1.7.2.) and 141 of primer (10 j.ig/ml). The mixture was incubated at 37°C 
for 15 mins to allow the primer to prime to the DNA template. Immidiately, 2.5 p.1 of 
the primed DNA was dispensed into 4 tubes each of which contains 2 p1 of one of 
dATP, dflP, dGTP, dCTP mix. The tubes were incubated at 42°C and 2 p1 of the 
following mixture was added into each tube; 1 p.1 of 1OxTM, 67 p1 of sterile distilled 
water, 0.5 p.1 of Kienow fragment (5 units/p1) and 1 j.il of [a- 35 S]dATP (10 mCi/mI). 
The reaction was incubated at 42°C for 10 mins and then 2 p1 of chase-mix was added 
into each tube. The reaction was further incubated for 5 mins before 4 p1 of formamide 
dye mix was added to stop the reaction in each tube. The reaction was boiled for 
2 mins to denature double strand DNA immediately before the sample was loaded. 
-Polyacrylamide gel electrophoresis. 
To prepare a polyacrylamide gel for sequencing analysis, the following 
components were mixed; 28.8 g of urea, 0.18 g of N, N'-methylenebisacrylamide, 3.6 g 
of acrylamide, 6 g of 1OxTBE buffer and 28 ml of sterile distilled water. The mixture 
was stirred for 30 mins and filtered with No 1 Whatman paper. Adding with 360 R1  of 
10% ammonium persulfate and 50 .il of N, N, N', N'-tetraxnethylethylenediamine 
(TEMED), the solution was poured in between two glass plate to form a 0.5 mm thick 
6% polyacrylamide gel. The gel were left for at least 1 hour to allow polymerization of 
the acrylamide. 2 R1 of sample from each tube was loaded on 6% polyacrylamide gel 
and the gel was run at 40 watts in 1xTBE buffer. 
-Fixing and drying of sequencing gel. 
After running, the gel was submerged in fixing solution (see 2.1.7.2.) for 
15-20 mins. The gel was laid on a chromatography paper and covered with a piece of 
Syran wrap (Dow Chemical Company). The edge of the chromatography paper was 
cut out to the gel-size. The gel was dried in vacuum at 80°C for at least 1 hour (Slab 
gel dryer SF1160, Hoefer Scientific Instruments) and subjected to autoradiography 
(see 2.2.2.14.). 
2.2.2.16. Autoradiography. 
Autoradiography of the hybridized membrane was carried out by placing the 
membrane on a preflashed X-Ray film(Du Pont) which was laid on an intensifying 
screen in an autoradiograph cassette. The film was exposed at -70°C for overnight and 
was developed with Automatic X-Ray film developer(X1,X-OGRAPH). 
For a sequencing gel, the cling film was removed from the dry gel and the 
gel was exposed to a X-Ray film(Du Pont) without preflashing. The exposure was 
'a 
carried out at room temperature for overnight before being developed with Automatic 
X-Ray film developer(X1,X-OGRAPH). 
2.3. Protein techniques. 
2.3.1. SDS-poiyacrylamide gel electrophoresis (SDS.PAGE). 
SDS-polyacrylamide gel electrophoresis is the protein separation method. 
The method used in this study was modified from the method described by Laemmli 
(Laemmli, 1970). Most samples used in this study were bacterial cell extracts 
expressing recombinant protein. 
-Sample preparation. 
The induced cells were pelleted in a microfuge tube by centrifugation 
(12,000g for 1 mins) and washed once with 1 ml ice-cold STE solution. The cells were 
resuspended in 0.1 ml of sterile distilled water. To obtain a SDS-PAGE sample, the 
cell solution was mixed with 0.1 ml of 2 times loading buffer. The mixture was boiled 
for 5 mins in a boiling bath. After centrifugation (12,000g for 5 mins), the sample was 
kept on ice until it was used or stored at -20°C. 
-51)5-PAGE gel electrophoresis. 
The SDS-PAGE gel apparatus used in this experiment is an SDS-PAGE gel 
electrophoresis Unit (SE250 Mighty Small II Slab Gel Elctrophoresis Unit, Hoefer 
Scientific Instruments). The gel casting method used in this experiment was followed 
according to the manufacture instruction. Ten 0.75 thick gels were cast at a time to 
ensure homogeneity of the gels. The gels were made up by using discontinuous buffer 
system which is composed of stacking gel and resolving gel. The stacking gel forms 
wells for sample loading and improves the gel resolution. The resolving gel is 
responsible for protein band separation. For this study, the resolving gel was cast as a 
7.5% polyacrylamide gel. The components of these gel are as follow: 
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resolving gel stacking gel 
30% acrylamide 15 ml 4.02 ml 
TrisCi (pH 8.8) 15 ml - 
TrisCi (pH 6.8) - 7.5 ml 
10% SDS 600 p1 300 p1 
Sterile distilled water 30 ml 18 ml 
Prior to pouring of the gel, ammonium persulfate and N, N, N', N'-
tetramethylethylenediamine (TEMED) were added as the following: 
resolving gel stacking gel 
10% Ammonium persulfate 300 p1 150 41 
TEMED 30 p1 1241 
The acrylamide solution for the resolving gel was poured into a casting 
chamber. The gels were left for polymerization at least 1 hour before the stacking gel 
was poured. Plastic combs were inserted into the stacking gel to form sample wells and 
the gels were polymerized for 1 hour. Two gels were assembled to the upper buffer 
chamber pod. Tank buffer (see 2.1.7.2.) was filled into the upper buffer and lower 
buffer chambers. 10 p1 of the boiled samples were loaded into wells and the gels were 
run at 40 mA for about 1 hour or until the dye front reached about 0.5 cm from the 
end of the gel. During electrophoresis the gels were cooled with tap water. The gels 
were removed from the gel plate and either stained using coomassie blue or used for 
western blot analysis. 
-Staining and drying of a polyacrylamide gel. 
After electrophoresis, the protein bands can be stained with coomassie blue 
dye. The gel was submerged into stain solution (see 2.1.7.2.) and incubated at 37°C for 
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at least 3 hours or until the gel was dark blue. The background dye can be washed off 
by incubating the gel in destaining solution at 37°C. The destaining process was 
repeated several times until the background dye was removed. Only 1 .ig of protein in 
a band can be detected by this method. 
The gel can be stored dry at room temperature for unlimited period. The 
drying method similar to that described in section 2.2.2.13. 
-Protein molecular weight markers. 
Protein markers for molecular weight determination used in this study were 
Prestained SDS molecular weight markers (Sigma) and Rainbow 4 protein molecular 
weight markers (Amersham). 
2.3.2. Antigen detection. 
Several methods were developed for the presence of an antigen which can 
be detected by the use of related antibody. In this study, two methods of antigen 
detection were used in different situations. Western blotting was a technique for the 
detection an antigen in electrophorized samples. Another technique was used for 
identification of a clone which expresses the antigen of interest for colony screening 
purposes. 
2.3.2.1. Western blotting. 
-Blotting procedure. 
To allow localization an antigen which was run on SDS-PAGE gel, the 
electrophorized sample must be electrically transferred onto a solid support so that the 
sample can be easily manipulated. The solid support used in this study was Hybond-C 
(Amersham). 
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A western blotting apparatus(Trans-B1otTM CELL, Bio-Rad) was used for 
transferring electrophorized samples. For efficient transferring, all filter papers and 
Hybond-C were cut into gel-size and were pre-wetted with transfer buffer before use. 
A pre-wet sponge pad was laid fiat on one side of a transferred cassette. Three sheets 
of filter paper were placed on the sponge pad. A SDS-PAGE gel was put on the filter 
paper and a Hybond-C membrane was carefully laid on the gel. Mother three sheets of 
filter paper were put on the top of the Hybond-C membrane. Each time the filter 
papers, gel and Hybond-C membrane were laid, precaution must be taken to avoid 
trapping air bubbles. Up to 4 SDS-PAGE mini-gels can be fitted in one cassette. 
Mother pre-wet sponge pad was placed on the top before two sides of the cassette 
were then assembled. The cassette was submerged in transfer tank containing transfer 
buffer. The gel was put at the cathode side and the Hybond-C membrane at the anode 
•
side of the transfer apparatus. The transferring was operated at 30 volts overnight with 
tap water cooling. After the transfer, the Hybond-C membrane was ready for antigen 
detection. The completion of the transfer can be checked by the transfer of the 
prestained or rainbow markers which were loaded into the same gel. 
-Antigen detection. 
The blotted membrane was immediately submerged in blocking buffer for 
1 hour at room temperature on a Rocking Table (LUCKHAM). The blocking buffer 
helps to prevent non-specific binding of antibody to the Hybond-C. The antibody 
raised against the antigen of interest was added. The final dilution of the antibody 
depends on the origin of the antibody (see table below). 
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Sources of antibody Final dilution 
Mouse ascites fluid 1:1000 
Mouse cell culture supernatant 1:2 
Rabbit serum 1:1000 
Human serum 1:2 
The membrane was incubated in antibody solution for 1 hour at the same 
condition as described above. The membrane was then washed with 10 ml of washing 
solution as follow: 
Washing solution Time lengths 
Tris-saline 10 mins 
Tris-saline with 0.05% NP40 2x10 mins 
Tris-saline 10 mins 
The washing solution was removed before appropriate secondary antibody 
conjugated with alkaline phosphatase (1/7500) was added and incubated for 1 hour. 
The membrane was again washed as above. The antigen band can be visualized by 
submerging the membrane in alkaline phosphatase buffer containing 330 jig/ml of NBT 
and 165 jig/ml of BCIP as substrate of alkaline phosphatase. The membrane was 
washed with distilled water several times to prevent developing of the background. 
The membrane was then air-dried before it was stored. 
2.3.2.2. Colony screening. 
In order to facilitate screening of expression clones containing 
Exonucleaseffi digested plasmid a colony screening method was used. Bacterial 
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colonies obtained from transformation after Exonuclease Ill digestion were streaked by 
sterile toothpicks on a grid Hybond-C membrane which was laid on LB broth agar 
supplement with 50 jig/ml ampicillin. The plate was incubated upside down at 37°C 
overnight. The membrane was then removed and laid, colony side up, on another LB 
plate containing 50 jig/ml ampicilhin which had been previously spread with 100 jil of 
8 mg/mi IPTG (isopropyithio-13-D-galactOside). The plate was incubated for 2 hours at 
37°C upside down. To lyse the bacterial colonies on the membrane, a Whatman 3MM 
paper was soaked with 1% SDS and placed in a lid covered plastic box. The box was 
incubated in 70°C incubator at least 20 mins. The membrane containing bacteria was 
laid on the soaked 3MM paper. The lid was tightly closed and the box was immediately 
returned to 70°C. The membrane was incubated at 70°C for 30 mins. The membrane 
was then washed several times with Tris-saline and the antigen of interest was detected 
as described in western blot procedure (see 2.3.2.1). 
2.3.3. Pepsean kit. 
The peptide synthesis in this study was performed using Pepscan kit 
purchased from Chembridge Research Chemicals. The method used based on method 
described by Cieysen and his colleagues (Geysen et al, 1987). The synthesis procedure 
composes of two steps, Fmoc-group deblocking and addition of Fmoc-amino acid 
active esters to pins which are assemble to a plastic block. After the synthesis, the 
synthesized peptides were then acetylated to remove the unnatural charge at the 
N-terminus. Finally, protecting groups were removed. All the reactions can be easily 
operated in polypropylene sandwich boxes. Because of the hazardous nature of the 
chemicals used for peptide synthesis, the reaction must be done in fume hood. The 
peptides which contain epitopes of antibody of interest were detected by an ELISA 
based technique. To reprobe the synthesized peptide, bound antibody can be removed 
by sonication described below. 
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-Fmoc-group deblocking and washing. 
The Fmoc-group can be easily removed by piperidine in DMP. Pins 
assembled to a plastic block were submerged at half their height into 20% (v/v) 
piperidine in DMF for 30 mins at room temperature. The block was removed and 
shaked off to remove the excess liquid. The pins were washed in solution as follow: 
Solution Times x treated times (mins) 
DMF 1x5 
methanol. 4 x 2 
The block was air-dried for at least 10 mins and again washed with fresh 
DMF for 5 mins. The block was removed and the excess liquid was blotted with clean 
tissue. 
-Addition of Fmoc-amino add active esters. 
The synthesis schedule was created by a software (DOS version) supplied 
with the kit. Fmoc-amino acid active esters and 1-hydroxybenzotriazole were dissolved 
in DMF according to the schedule. 100 p1 of each solution was carefully dispensed in 
each wells of reaction tray supplied with the kit. The deblocked pins were submerged 
into wells of the reaction tray as designed by the schedule. The pins were incubated in 
the amino acid ester solution for 18 hours at 30°C in a black plastic box. After the 
synthesis was completed, the block of pins was removed and washed with: 
Solutions Times x treated times (mins) 
DMF 1 x 2 
Methanol 4 x 2 
DMF 1 x 2 
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The Frnoc-group of coupled amino acid was then deblocked, washing as 
described before. The coupling procedure was again repeated until the target size 
peptides were accomplished. After the final deblocking and washing, the pins were 
processed as below. 
-Acetylation of terminal amino groups. 
100 R1 of acetylation solution (see 2.1.7.2.) was pipetted in to each well of 
fresh reaction tray. The synthesized pins were lowered into the wells. The pins were 
incubated for 90 mins at room temperature in a plastic bag. The pins were then washed 
with: 
Solutions Times x treated times (mins) 
DMF 1 x 2 
Methanol 4 x 2 
The pins were allowed to air-dry at least 10 nilns before the next step was 
operated. 
-Deprotection and neutralization. 
The side chains of synthesized peptides were removed by deprotection and 
neutralization step. The pins were incubated in cleavage solution (2.1.7.2.) for 4 hours 
at room temperature. The pins were then finally washed as follow: 
in 
Solutions and treatment Times x treated times (mins) 
dicliloromethane 2 x 2 
5% 	diisopropylethylamine 
in dichioromethane  
2 x 5 
dichioromethane 1 x 5 
air-dry at least 10 mins 
water 1 x 2 
methanol 1 x 18 (hours) 
The block of pins then was dried in vacuum in the presence of silica gel for 
18 hours and could be stored in this condition. The pins can be used for epitope 
mapping after disruption process described below. 
-Pin disruption. 
Disruption buffer (see 2.1.7.2.) was prewarmed to 60°C and poured into a 
sonication bath. The block of pins was submerged into the disruption buffer. The 
sonication was operated for 30 mins. The block was removed and submerged into 
prewarmed water (60 0C). This step was repeated 3 times with fresh prewarmed water. 
The block was finally immersed in boiling methanol for 2 mins and then air dried. The 
pins then ready to be reprobed with an antibody or stored for further used. 
-epitope detection. 
A 200 jfl of supercocktail blocking solution (see 2.1.7.2.) was dispensed 
into each well of a U-bottom MicrotestlllTM Assay Plate ( Becton Dickinson 
Labware). The pins were submerged into supercocktail solution in order to block 
non-specific binding of antibody to the pins. The pins were incubated for 1 hour at 
room temperature. After the blocking process was completed, the pins were incubated 
in a microtitre plate which contained 175 l.LI of supercocktail diluted antibody in each 
VA 
well using the dilutions described (see 2.3.2.1.). The plate was left at 4°C overnight. 
To remove non-specific binding antibody, pins were washed 4 times in PBSITween 20 
at room temperature for 10 mins each with agitation. The antibody bound peptides 
were detected by appropriate second antibody conjugated with horseradish peroxidase 
(1/2000) in the same condition as first antibody. Again, the pins were throughly 
washed as above. The epitope of first antibody was revealed after each pins were 
incubated in 150 p1 of substrate solution in a sterile flat-bottom multi-well plate (Flow 
Laboratories, Inc.) at room temperature in the dark with agitation for approximately 
40 mins or until sufficient color! was developed. The block of pins was then removed 
and the color product was monitored by a plate reader at 410 nm. The pins were finally 
cleaned by sonication and stored for re-use. 
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Chapter 3 
Expression of RAP-1 recombinant proteins 
3.1. Introduction. 
3.1.1. Expressed protein as studied material. 
One technical problem for the study of P. falciparuin protein is the 
availablility of the purified protein which was difficult to prepare. The purified protein 
also tends to be contaminated by other components. To avoid such a problem, the 
epitope mapping of the inhibitory monoclonal antibodies in this study was achieved by 
using fusion proteins between the RAP-1 protein and 3-galactosidase. The fusion 
protein was generated by recombinant techniques. 
The development of recombinant DNA techniques allows the subcloning of 
a defined DNA fragment from an organism into a prokaryotic cell, Escherichia coil, by 
the use of plasmids or bacteriophages. Hence, a gene or a part of a gene can be 
subcloned in frame with the host bacterial gene, for example lacZ gene, in a plasmid or 
bacteriophage and expressed as a hybrid product under the control of the host gene 
operating system. Large amounts of a fusion protein can be produced by induction of 
the host bacterial gene. Many foreign proteins have been successfully expressed in 
E. coli e.g., the expressed capsid proteins of foot and mouth disease virus which can 
elicit neutralizing antibodies (Kleid et al, 1981). 
This introduction will be divided into two parts, the first part will outline the 
expression system used in this experiment and the second part will describe 
monoclonal antibodies used in this study and their inhibitory effect on parasite growth 
in vitro. 
I 
3.1.2. Expression system used in this experiment. 
Several plasmids have been engineered for expression work in E. coli cell 
utilizing the lac operon. Among those are the pUR series plasmids (Ruther and 
Muller-Hill, 1983) and pMS series plasmids (Scherf et al, 1990). Both sets of plasmids 
contain an ampicillin resistance gene as shown in Fig. 3.1. Thus, the E. coli clone 
which possesses one of these plasmids may be selected and maintained on medium 
supplemented with ampicilhin. Each plasmid series was designed to allow a foreign 
DNA fragment to be subcloned into an appropriate restriction site at the C-terminus of 
the (3-galactosidase encoded gene (lacZ gene) in three different reading frames. The 
insert fragment in frame with the lacZ gene will be translated as a 0-galactosidase 
fusion protein. The advantage of pMS plasmids over the pUR plasmids is that the 
f3-galactosidase fusion protein from this plasmid can be cleaved with a protease, blood 
coagulation factor Xa, at a specific site between the j3-galactosidase protein and the 
insert encoded protein. This allows the insert encoded protein to be seperated and 
purified from the fusion protein. 
The fusion proteins from both plasmids are under the control of the 
promoter and operator of the f3-galactosidase gene. To suppress the expression of the 
fusion protein in normal conditions, the recombinant plasmid is transformed into a 
specific E. coli strain, such as NM522 (Gough and Murray, 1983). This strain of 
E. coli possesses an episome which overexpresses a repressor of the lac operon from a 
mutant repressor gene, the laclq gene as shown in Fig. 3.2a.. The expression of the 
fusion protein can be induced by adding an inducer, isopropyl (3-D-thiogalactoside, into 
the medium in order to inhibit the activity of the repressor (Fig. 3.2b). 
Because plasmid is considered to be a metabolic burden to the bacteria cell, 
a cell which loses its plasmid will grow rapidly and finally become the dominant 
population in the culture. The stability of the plasmids and the recombinant plasmids is 
increased by maintaining the transformants on a medium supplemented with ampidillin 
E*I 
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Figure 3. 1. The schematic drawing of the pMS (A) and pUR (B) series plasmids. The 
restriction sites used in this experiment are also shown (not to scale). An insert 
fragment can be subcloned into the restriction sites in the appropriate frame by using a 
suitable plasmid in each series. However, the pMS series plasmids can only be 
subcloned into three different frames at the EcoRI site. 
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Figure. 12. The Schematic diagrams show the induction phenomenon of the lacZ 
gene. At normal circumstance (a), a repressor gene on an episome produces repressor 
monomers which formed into tetramer molecules. A tetramer repressor is then able to 
bind to operator region of the lacZ gene. As a result, the lacZ gene is suppressed. In 
the presence of IPTG (b), the repressor is inactivated and dissociated from the 
operator so the lacZ gene can be transcribed to mRNA. 
to inhibit the growth of those cells which lose their plasmids. The same principle also 
applies to the episome in a host cell such as E. coli NM522. The episome in this strain 
carries a pro AB gene, a gene needed for the synthesis of proline, which is absent from 
the genomic DNA of the E. coil NM522. This strain of F. coil needs to be maintained 
in minimal medium which lacks the amino acid in order to stabilize the episome in the 
cell. 
It should be noted that expression of foreign proteins in F. coii is not 
always successful. In highly expressed prokaryotic genes, the codon usage exhibits a 
preference for the abundant tRNA species in the cell (Scaife, 1988). Expression of a 
foreign gene which contains a different codon bias may result in early termination of 
translation. This particular problem should be especially considered in the expression 
of P. falciparuin proteins in E. coii because the parasite has a different codon usage 
from those in F. coil. The AT-rich nature of the P. faiciparurn gene may also cause 
difficulties in transcription process. 
Other problems related to the expression of foreign proteins in F. coil are 
degradation of expression protein, the lack of a post-translational modification system 
and non-native protein folding. Nevertheless fragments of several P. faiciparum genes 
have been successfully subcloned and expressed in F. coli as non-native forms, for 
example the CS protein (Dame et al, 1984), blood stage antigens (Kemp, et al, 1983), 
the MSP-1 protein (Hall et al, 1984) and Ag5.1 protein (Hope et al, 1985). 
3.1.3. Analysis of inhibitory monoclonal antibodies which recognized the RAP-1 
protein. 
Previous works on production of monoclonal antibodies against whole 
P. faiciparum cells had identified seven monoclonal actibodies which can 
immunoprecipitate the RAP complex from total cell parasite extracts (Hall et al, 1983, 
Clark et al, 1987 and Ridley et al, 1990a). Five of these monoclonal antibodies, 2.13, 
2.15, 2.29, 7.12, 8.1, were shown to recognize nonconformational or continuous 
epitopes on the RAP-1 protein while other monoclonal antibodies, 11.4 and 2.22 were 
thought to recognized conformational or discontinuous epitopes in the RAP protein 
complex. 
In vitro inhibition assay data of these monoclonal antibodies were produced 
by Dr. Jana McBride (McBride, personal comm.). The IgGs of mAbs 2.15, 2.22, 2.29, 
7.12 and 11.4 were purified and their inhibition effects were evaluated. The analysis of 
these data showed that all of these monoclonal antibodies have a similar level of 
inhibition on the parasite growth in vitro as shown in Fig. 3.3. This result raises several 
questions about the immunogenicity and the function of the RAP-1 protein; (i) what is 
the inhibitory mechanism? (ii) where are the epitopes of these monoclonal antibodies in 
the RAP-i molecule? (iii) Do these monoclonal antibodies bind to the regions of 
functional significance in RAP-I? It is obvious that most of these questions may be 
answered after the epitopes of these inhibitory monoclonal antibodies have been 
mapped. 
This chapter describes an attempt to express fragments of rap-1 gene which 
encode for the epitopes of inhibitory monoclonal antibodies as a fusion protein forms 
in E. coil for a subsequent study of the epitope mapping. The monoclonal antibodies 
investigated in this study are listed in Table 3.1. 
3.2. Results. 
In order to express fragments of the rap-1 gene which contain the epitopes 
of inhibitory monoclonal antibodies in E. coli, the EcoRI-Sall fragment rap-1 gene 
was initially subcloned from the Xrapl. 1 (Ridley et al, 1990a, see Fig. 3.4.) into the 
pUR278 and pMS1S. This Xgtil clone contains a middle part of the rap-1 gene 
flanked by an EcoRI linker on both ends. The rap-1 fragment was inserted in frame 
















& 	5 mAb 2.29 
,oO 20o 300 400 500 
Mb 7.12 













100 200 300 4DO 	
g 100 2W 3W 400 50  
nAb con:enral10n1 (pg/mi) 
.m'.1 
ma concentration (ig/mt) 
Figure. 3.3. Graphs show the in vitro growth inhibitory effects of the monoclonal 
antibodies against the RAP-1 protein (Harnyuttanakom et al, 1992). The graph shows 
similar degree of P. falciparum growth inhibition. 
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mAb 2.13 IgG 1 103 
 82/65* 
mAb 2.15 IgG 1 104 + 82/65 
mAb 2.29 IgGj 105 + 82/65 
mAb 7.12 IgG 1 io + 82/65 
mAb 8.1 1gM 102 . 82/65 
mAb 11.4 IgG 1 io + - 
RpAb anti-3-galactosidase nd nd nd nd 
RpAb anti-purified RAP-i 
protein 
rid 105 nd 82/65 
Table. 3.1. Table shows the antibodies and monoclonal antibodies used in this thesis. The data and the 
monoclonal antibodies were kindly provided by Dr. Jana McBride (McBride, personal comm.). rid = not 
determined, - = negative result, * data from Ridley eat al, 1990, ** data from Hope, 1984. 
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Figure 3.4. The diagram showed the fragment of rap-] gene which was subcloned into the Xgtll. Some unique restriction sites in the rap-] gene 
are also shown. The oligonucleotide B205 used in the screening procedure is shown as a thick line (not to scale). 
[3?] 
known to be recognized by mAbs 2.13 and 7.12 (Ridley et at, 1990a). By expressing 
different fragments of the rap-1 gene generated by restriction enzymes present in the 
rap-1 gene sequence, the epitopes then can be mapped relatively to the restriction 
sites of the rap-1 gene. 
3.2.1. Subeloning and expression of the rap-] insert in E. coli. 
/ 
DNA from the 7 bact&iophage clone Xrapl.1 and pUR278 plasmid were 
purified as described in the method sections 2.2.2.1. and 2.2.2.2. respectively. The 
EcoRI-Sall fragment of the rap-] gene from the Xrapl. 1 was subcloned into the 
EcoRI-Sall restriction site of the pUR278 plasmid at the C-terminus of the 
f3-galactosidase gene in the correct frame. The EcoRI-Sall fragment encodes for 
546 amino acid residues from amino acid 62 to 608 of the RAP-1 protein. The 
subcloning strategy is shown in the Fig. 3.5. The purified recombinant lambda DNA 
and the pUR278 plasmid were digested with Sail and partial digested with EcoRI (see 
method 2.2.2.4.). The digested lambda DNA and plasmid were ligated using the 
enzyme T4 DNA ligase as described in method section 2.2.2.7. The ligated DNA was 
then transformed into competent cells of the K coli NM522 (see method 2.2.2.8.). 
Bacterial colonies were screened with radiolabelled internal oligonucleotide B205, as 
shown in Fig. 3.4., (see method 2.2.2.12). A transformant which contained an EcoRI-
Sail fragment of the rap-1 gene was detected. To ensure the purity of the clone 
obtained, the positive clone was purified by re-streaking to give a single colony (see 
method 2.2.1.1.) and rescreened by using the same method. The double screening 
method was also used for subsequent subcloning procedures. 
Eight positive clones -from the second screening were obtained. The 
recombinant clones were tested for the ability to produce the 3-galactosidase-RAP- 1 
fusion protein. The total cell extracts of uninduced and induced sample from the 
recombinant clones were subjected to SDS-PAGE gel electrophoresis (see method 
Htfldfl1 
EcoRI - Sail fragment 
pUR278 	 from Xrapl.l 
EcoRI - EcoRlI fragment 
Figure. 3.5. Diagram shows the subcloning strategies used for generating the PMSES 
and PURES from expression plasmid pMS1S and pUR278 respectively. The pUR278 
plasmid was digested with Sail and partial digested with EcoRI before the subcloning. 
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2.2.1.4. and 2.3. 1.). The result is shown in Fig. 3.6. Only one clone, UIRES, expresses 
a few high molecular weight protein bands which were strongly recognized by the 
rabbit polyclonal antibodies (RpAb) against the RAP-1 protein (Fig. 3.7.). Some low 
molecular weight proteins were also detected as minor components. The molecular 
weight of the highest expression protein band is about 180 kDa which corresponds to 
the size of the fusion protein expected. The transformant extract in lane 4 also gave 
positive bands in similar pattern to the URES extract but with noticeably weaker 
signal. Other total parasite extracts in lane 2, 6 and 7 were weakly recognized by the 
anti-RAP-1 RpAb. However, detected protein bands in these samples have lower 
molecular weight than the size of the fusion protein expected. It is still unclear how 
these proteins were generated. 
The fusion protein from the URES  clone was also recognized by the 
inhibitory monoclonal antibody 2.13 and RpAb against f3-galactosidase protein 
(Fig. 3.8.) as three major protein bands all of which are bigger than the size of the 
3-galactosidase protein (116 kDa marker). For subsequent studies, only the URES 
clone was used. 
To investigate whether the three major bands were the result of degradation 
or premature termination, URES  cells were collected at different time intervals after 
induction. The total cell extracts were run on the SDS-PAGE gel and were analyzed by 
western blot. The results are shown in Fig. 3.9. Three major bands were detected in all 
samples after 30 minutes of induction with some minor bands after 120 mins of 
induction. There was no evidence of time dependent protein degradation. This 
suggested that those three major bands may be generated by early termination of the 
transcription or translation process (see discussion below). 
The success of the subcloning process was also confirmed by double-strand 
sequencing (see method 2.2.2.15). The flanking regions of the rap- 1 gene insert of the 
PURES were sequenced. The sequences showed that the rap- 1 insert had been cloned 
in frame with the lacZ gene and the restriction site Sail at the 3' end is also maintained. 
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Figure 3.6. The eight total cell extracts of the transformants which positive with the 
radiolabelled nucleotide probe were run on the SDS-PAGE gel and were stained with 
coomasie blue (only three clones were shown here, UES, 1 and 2). Only the UES clone 
showed extra bands (star dots) in the induced sample (I) which were not present in 
uninduced sample (U). The negative control (-ye) are the total extracts of E. coli 
NM522 which carries pUR278 plasmid. The molecular weight markers are shown in 
KDa. 
1 2 3 4 UES 6 	7 8 9 
- 37+27 
Figure 3.7. The total cell extracts of the eight transformants from induced culture were 
examined for fusion proteins by western blot analysis (lane 1-8). Lane 9 was a negative 
control. The anti-RAP-1 RpAb was used as a probe. The UES clone (lane 5) produces 
the fusion protein which were strongly recognized by the anti-RAP-i RpAh used. 
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Figure 3.8. The Western blot of the UES clone total cell extract was probed with 
mAb2.13 and anti-13-galactosidase RpAb. For comparison, the total cell extract of 
E. coli NM522 which contains pUR278 also blot onto the same membrane (-ye). 
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Figure 3.9. The western blot of the total cell extract from MES clone after 30, 60, 90 
and 120 mins induction compared with overnight induction. The degradative products 
were detected after 120 mins of induction. The total cell extract of UES clone also 
give the same result. 
3.2.2. Subcloning and expression of the other restriction fragments from the 
rap-] gene. 
To facilitate the subsequent subcloning, pMS1S as well as the pUR278 were 
used. The rap-i insert from the PT31-ES  was cut with EcoRI and was subcloned into 
pMS iS at the 3' end of the lacZ gene. After the subcloning, the rap-1 insert will stay in 
frame with the lacZ gene without further manipulation. The BamHI and HindIll 
restriction site on the pMS1S plasmid were used for further subcloning. The 
subcloning strategy is described below. 
The fragment of the rap-1 gene in the recombinant plasmid from URES, 
PURES, was cut with EcoRI and purified. The purified fragment was subcloned into 
the EcoRI restriction site of a pMS plasmid at the C-terminus of the j3-galactosidase 
gene. The recombinant plasmid was transformed into E. colt NM522 and was screened 
with the same radiolabelled internal oligonucleotide as the one used in the screening of 
URES clone. Seventeen positive clones were obtained and analyzed by western blot 
(data not shown). 
Detection of the fusion protein by western blot analysis using mAb 2.13 
revealed that only seven clones produced fusion proteins. Again, the fusion protein was 
detected as three major bands at a higher molecular weight than wild type 
3-galactosidase, similar to that shown in Fig. 3.8. The highest band of the fusion 
protein migrated as 180 kDa protein. The presence of the 3 major bands at different 
time point after induction was also similar to that described in Fig. 3.9. (data not 
shown). 
An expressing clone, MSES, was selected for further study and subcloning. 
The sequences at the flanking regions of the insert were also determined. The result 
confirmed that the insert was in frame with the lacZ gene. 
Other constructs also obtained by using the available restriction sites on the 







Figure. 3.10. Diagram shows the subcloning strategies used for generating the pMSEB 
and pMSHB from the recombinant plasmid PMSES. 
Hin dill 
Figure. 3.11. Diagram shows the subcloning strategies used for generating the P-EH 
from the recombinant plasmid PUIRES. 
Be 
FactCrXa 
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Figure. 3.12. Diagram shows the subcloning strategies used for generating the PMSE5 
using the purified EcoRI-SspI fragment from recombinant plasmid PMSEB. 
M. 
construct was generated by digesting the PMSES with the BarnHI restriction enzyme 
(Fig. 3-10). The bigger DNA fragment product, which is composed of the pMS iS 
vector and EcoRI-BarnHI fragment of the rap-i gene, was purified and religated. The 
recombinant plasmid was transformed into the E. coli NM522. Using similar strategy 
pMSpi (contains the HindHl-BainHI fragment of the rap-] insert) and PUREH 
(contains the EcoRI-HindllI fragment of the rap-1 insert) were generated from 
PMSEB and PURES respectively (Fig. 3.10 and 3.11 respectively). The 5' overhang 
generated by HindIII digestion of the PMSEB was digested with Si nuclease to 
correct the translational frame before religation to produce pMS}j. 
Another construct, pMSE5 (contains the EcoRI-SspI fragment of the rap-1 
insert), was generated by different strategy (Fig. 3.12). The pMSEB was digested with 
EcoRI and BanzHI restriction enzyme. The EcoRI-BamHI fragment of the rap-1 insert 
was purified (see method 2.2.2.10.) and digested with SspI. The bigger fragment, 
which contains the EcoRI-SspI fragment, was purified and ligated to the pMS1S 
digested with EcoRI and BamHi. The uncomplementary end between SspI and BamHI 
was blunt ended by the use of DNA polymerase (see method 2.2.2.5). The linear DNA 
was then circularized by a second ligation reaction. 
All the recombinant plasmids were screened using an internal 
oligonucleotide as described above. Western blot analysis of the fusion proteins 
showed a major fusion protein band at expected sizes for all of the constructs. These 
proteins were recognized by both RpAb against the RAP-1 protein and RpAb against 
-galactosidase, except the fusion protein from UREH  which is not recognized by 
RpAb against the RAP-1 protein (data not shown). The plasmids were also subjected 
to sequencing (see method 2.2.2.15) at the flanking regions between insert fragments 
and the vectors to confirm the accuracy of the subcloning (data not shown). 
Fusion proteins generated by the recombinant clones, which contain 
different part of the rap-1 gene, were then used for epitope mapping of inhibitory 
monoclonal antibodies. 
3.2.3. The epitope mapping of the inhibitory monoclonal antibodies using the 
fusion proteins. 
The successful expression of the several restriction fragments of the rap-1 
inserts allowed the epitopes of the inhibitory monoclonal antibodies to be mapped. 
Only fusion proteins which contain the epitope of a monoclonal antibody will be 
recognized by the monoclonal antibody tested. By comparing the sequences of the 
rap-i inserts in the positive clones, the epitope can be mapped correspondingly to the 
restriction site. 
The total cell extracts of induced culture of all the constructs was run on 
SDS-PAGE gels and the proteins were transferred on to nitrocellulose membranes. 
Western blots of the fusion proteins were probed with mAbs 2.13, 2.15, 2.29, 7.12, 8.1 
and 11.4. All the monoclonal antibodies gave identical results. A western blot is shown 
in Fig. 3.13. The results showed that the epitopes of all monoclonal antibodies were 
encoded by the HindIII-SspI fragment of the rap-1 gene. 
3.3. Discussion 
Restriction fragments of the rap-i gene have been successfully expressed in 
fusion protein forms. The fusion proteins are under the control of the lacZ promoter 
and operator. This expression system was proved to be very effective by western blot 
analysis as the fusion proteins were detected only after the induction with IPTG. 
The reason for the appearance of the fusion protein as the three major bands 
as detected by mAb 2.13 is still unclear. In E. coli cell, a fusion protein may be 
digested by a scavenger protease (random degradation process) or a specific protease 
(cleavage at a specified amino acid sequence). The early co-appearance of the three 





Figure. 3.13. Epitope mapping of the inhibitory monoclonal antibodies using fusion 
protein generated from different fragments of restriction enzymes digested rap-] gene. 
All the monoclonal antibodies gave the same result. Here, only a western blot of the 
total cell extract of the recombinant clones is shown. The blot was probed with mAb 
2.29. 1) MS, 2) MSj, 3) UREH,  4) MSE5 , 5) MSEB, 6) MSES. 
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after 120 mins of induction suggested that a random degradation process is unlikely to 
be the cause of triplet pattern. 
Though the induction effect on fusion protein expression is different from 
the fusion protein which was shown to be specifically cleaved by membrane protease 
OmpT (Hellebust et al, 1989), the specific cleavage of the RAP-1 fusion protein 
cannot be ruled out. All the fusion proteins may be quickly cleaved by specific protease 
into lower molecular weight peptides at the beginning of the induction. As more of the 
fusion proteins were produced, some of the full length fusion proteins can be detected 
because the specific protease which only generated in a limit amount in a bacterial cell 
cannot digest all of the fusion protein. Other possible explanation is that they may be 
caused by the early transcription or translation process which causes shortening of 
rnRNA and the fusion protein. 
The previous work suggested that mAb 2.13, 2.15, 2.29, 7.12 and 8.1 
recognized linear epitope protein on the RAP-1 (Clark et al, 1987 and Ridley et al, 
1990a). The results from this experiment lead to the same conclusion. However, the 
mAb 11.4 which was previously reported to recognize a non-linear epitope (Clark 
et al, 1987) was able to detect 0-galactosidase-RAP-1 fusion protein on the western 
blot. It should be noted that the SDS extracted RAP-1 antigen (2% SDS) was 
imrnunoprecipitated by the mAb 11.4 in the same report but not by another mAb, mAb 
2.22, which recognized a non-linear epitope of the RAP-1 protein. This suggested that 
the epitope of mAb 11.4 may be partly formed by the primary structure of the RAP-i 
protein. 
The western blot analysis of the fusion protein from different constructs 
suggested that the epitope of all monoclonal antibodies tested locate between HindIll 
and SspI restriction sites in the rap-1 gene as shown in Fig. 3.14. These mAbs were 
reported to recognize the 80 kDa protein of the RAP-1 protein and its processing 
product, 65 kDa polypeptide (Clark et al, 1987 and Ridley et al, 1990a). The 
N-terminus of the a 65 kDa polypeptide was recently sequenced and the cleavage site 
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Figure. 3.14. The summary of the epitope mapping using fusion protein from different constructs which had been generated by restriction enzymes. 
The diagram shows the rap-] gene fragment in each clone compared with the restriction site and schematic representation of the RAP-I protein. 
103 
was located between Ai90 and D191 amino acid residues (Ridley et al, 1991). These 
data indicated that the epitopes of all niAb tested are probably located between amino 
acid residue D 19 1 and K219. 
To confirm and further localize the epitopes of these inhibitory monoclonal 
antibodies, exonuclease ifi was used to produced nested deletion of the recombinant 
protein. This work is described in Chapter 4. 
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Chapter 4 
Epitope mapping of the RAM protein using exonucleaselll 
4.1. Introduction. 
4.1.1. The importance of an inhibitory epitope. 
An antibody-antigen binding reaction involves the recognition of a small 
region on a given antigen by amino acid residues in the antigenic binding site of the 
antibody molecules. The antibody-binding region of an antigen is called an epitope. 
The epitope may be composed of continuous amino acid residues on the primary 
struture of a protein or amino acid residues which are brought together as the result of 
protein folding. The former epitope is called a continuous epitope, the latter, is called a 
discontinuous epitope. 
Binding of an antibody, such as an inhibitory monoclonal antibody, to an 
epitope on a protein may have a significant effect on the protein structure and/or the 
protein function. Hence, it is believed that the determination of such an epitopes on a 
protein (epitope mapping) may contribute to an understanding of both the 
immunological and functional nature of the protein studied. 
4.1.2. Epitope mapping techniques. 
In the past few years, several approaches have been developed to identify 
the epitopes which are recognized by monoclonal antibodies. X-ray crystallographic 
techniques have provided the most detailed information. Theoretically, this technique 
can identify both continuous and discontinuous epitopes. However, the process is very 
expensive and time-consuming. Up until now, only a few antigen-antibody complex 
had been studied by this method (Padlan et al, 1989 and Amit et al, 1986). 
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Continuous epitopes are the major interest for epitope mapping studies 
because they are more easy to identify than discontinuous epitopes. Several groups of 
researchers have applied a variety of approaches for continuous epitope mapping. For 
example, non-defined epitope mapping of some monoclonal antibodies against the 
MSP- 1 protein of the P. falciparum was carried out by the determination of naturally 
processing and chemical cleavage sites of this protein (Cooper et al, 1992). The more 
accurate mapping of eptiopes may be performed by identification of fragments 
following limited proteolysis of the antigen-antibody complex using NMR (Suckau 
et al, 1990). In the past few years, several groups of scientists have mapped epitopes 
by the method described by Geysen and his colleagues in which overlapped peptides 
are synthesized on solid supports (Geysen et al, 1987, Neurath et al, 1990 and Ohlin 
et al, 1989). Alternatively, site-direct mutagenesis has been used (Smith et al, 1991 
and Smith and Benjamin 1991). Recently, a new technique has been developed for 
epitope mapping by the use of filamentous phage expression library of random 
oligonucleotides (Stephen and Lane, 1992). 
Recombinant proteins can also be used for the preliminary mapping of 
epitopes because they provide abundant material for study and are easy to manipulate. 
Small fragments of gene can be subcloned and expressed in a bacterial cell. Expressed 
proteins which are recognized by monoclonal antibody should carry the epitope of the 
monoclonal antibody probe. By comparing the sequences of expressed proteins, it is 
possible to map the epitope into a given region. There are several methods used to 
generate small fragment for this purpose such as the use of restriction enzymes 




Among the enzymes used in molecular biology, exonucleases also have a 
prospect for generating different lengths of DNA for epitope mapping, especially 
exonuclease III. Exonuclease III is an exonuclease which can specifically digest DNA 
in a 3' to 5' direction from 5' protruding or blunt ends. A 3' protruding end is resistant 
to digestion by this enzyme. The rate of digestion can be controlled by adjusting the 
reaction temperature between 4°C (25 bp/min) to 45°C (600 bp/min). This allows the 
progressive deletion of a DNA fragment by removing small aliquots at time intervals 
from a reaction. The single strand overhang of the digested DNA is blunt-ended after 
treatment with Si nuclease and Kienow fragment of DNA polymerasel. 
In this chapter, the inhibitory monoclonal antibody epitopes were mapped 
using progressively deleted recombinant proteins generated by exonuclease III 
digestion of a rap-] gene insert in a recombinant plamid. 
4.2. Results. 
4.2.1. ExonucleaselH digestion. 
The plasmid, PMSEB, from an expression clone which expresses the 
epitopes of all inhibitory monoclonal antibodies (see Chapter 3) is subjected to the 
exonuclease ITT digestion. The strategy is outlined in Fig. 4.1. To generate 
progressively deleted recombinant plasmid, the PMSEB  was purified by the use of 
PEG-preparation method (see method 2.2.2.2.). The plasmid was digested with the 
BamHJ restriction enzyme and precipitated with ethanol (see method 2.2.2.4. and 
2.2.2.2.). The plasmid was then digested with exonuclease III (see method 2.2.2.13) at 
25°C. The nested deletion plasmids were blunt-ended by Si nuclease and Kienow 
treatment. They were circularized with T4 DNA ligase and transformed into the E. coil 
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Figure. 4.1 Schematic diagram shows the strategy of exonuclease ifi digestion in this 
study. The plasmid pEB was cut at the C-terminus of the inserted rap-] gene fragment 
with BamHI. The linearized plaEmid was then digested with exonuclease ifi. The 
stepwise deletions of the inserted fragment were collected at time intervals during the 
digestion. The plasmids were circularized with T4 DNA ligase after the Si nuclease 
and Kienow DNA polymerase treatment. The deleted plasmids were transformed into 
E. coli N1M522 and cultured on agar supplemented with ampicillin. 
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NM522. One hundred colonies from each time point of the first five time point for 
appropriate constructs were handed-picked and screened. 
4.2.2. Screening of expressed clones. 
The screening strategies were based on the colony hybridization (method 
2.2.2.12.) and antibody colony screening by mAb 2.13 (see method 2.3.2.2). As the 
results of the previous chapter showed that the epitopes of the inhibitory monoclonal 
antibodies studied were located between the HindIll and SspI site, three 
oligonucleotides were used as probes, namely 999A, 284B and 205B (Fig. 4.2.). The 
999A oligonucleotide contains a part of the rap-i gene sequence between the cleavage 
site and the HindHI restriction site. The 284B sequence is located between the 
cleavage site and the SspI restriction site and the oligonucleotide 205B has a 
nucleotide sequence identical to the rap-1 gene just downstream from the SspI 
restriction site. Clones which contain the 999A and 284B sequences but gave negative 
signals to the 205B oligonucleotide were selected. The positive clone distribution at 
different time points were shown in Table 4.1. The gradually decrease of positive 
colonies, as the digestion times were extended, suggested that the exonucleaselll 
progressively digested the rap-1 gene fragment. 
To screen for fusion protein expressed by bacteria clones, the selected 
colonies were screened with mAb 2.13. Selected colonies were purified and handed-
picked onto grid-nitrocellulose membrane which were placed on the L-broth agar. 
After induction by placing the nitrocellulose on LB agar containing IPTG, the cells 
were lysed. Expression proteins on the nitrocellulose were detected using the mAb 
.2.13 and alkaline phosphatase conjugated second antibody. After incubation with 
alkaline phosphatase substrate, the expressed protein recognized by the mAb was seen 
as a colony-shaped dark-purple mark on the grid-nitrocellulose (Fig. 4.3.). Antibody 
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Figure. 4.2. Schematic diagrams shows a) the location of all nucleotide probes used in 
this study compared with the Hindu, SspI and BamHI restriction sites on the rap-1 
gene. The cleavage site of the RAP-1 protein is also shown as a tailed arrow. The 
digestion of the rap-] gene by exonucleaseffi was result to progressively deletion as 
shown in b). 
Time points 999A 284B 205B 
1 54 23 3 
2 54 14 2 
3 42 2 1 
4 36 0 0 
5 29 0 0 
Table. 4.1. Table shows the positive clones selected from 100 colonies by 
oligonucleotide probes at each time point of exonuclease m digestion. All the 205B-
positive clones gave positive result when probed with 284B and 999A probes. The 








Figure 4.3. Exonuclease III deleted clones were screened with mAb 2.13 for 
recombinant proteins which contain mAb 2.13 epitope. This picture shows a 
transformant (white arrow) which give a positive result in antibody colony screening. 
The MES clone, described in Chapter 3, also included on the membrane as a positive 
control (arrow heads). 
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colony screening results showed that only a small number 28413-positive clones, 5 
clones from the first time point and 1 clone from the second time point (Table 4.2A), 
expressed recombinant proteins which are recognized by the mAb 2.13. The rest of the 
284B-positive clones gave negative results. The results suggested that the epitope of 
mAb 2.13 is located downstream of the 284B oligonucleotide sequence and the 
epitopes were identified by sequences comparison of the rap-1 gene fragment in these 
clones. 
4.2.3. Epitope mapping of the inhibitory monoclonal antibodies. 
To define the epitope of the mAb 2.13, three mAb 2.13-positive clones and 
seven mAb 2.13-negative clones were sequenced by double strand sequencing method 
using dideoxy-termination technique. The C-terminal amino acid sequence of the rap-1 
inserted fragments were compared with their reactivity to mAb 2.13 and the results are 
shown in Table 4.213. The comparison of the amino acid sequence revealed that the 
epitope of mAb 2.13 is diminished in clone 17 of which the ELYPT121 peptide is 
deleted from the recombinant protein. 
In order to confirm the eptiope mapping results of mAb 2.13 and to 
characterize the epitope of other inhibitory monoclonal antibodies, fusion proteins 
from exonucleaselll generated constructs were tested with rabbit anti-RAP-1 
polyclonal sera and other monoclonal antibodies. The total extracts from seven clones, 
namely 3, 5, 6, 17, 31, 10 and 8 all of which carried different length of rap-1 gene 
were subjected to western blot analysis (Fig. 4.4.). All recombinant proteins from the 
exonuclease ifi deletion clones are recognized by the rabbit anti-RAP-1 polyclonal 
serum in the western blot analysis (Fig. 4.4A.). The analysis also showed that all of the 
inhibitory monoclonal antibodies fail to recognize the fusion protein from clone 17 but 
not in clone 6 (Fig. 4.4B. and 4.5.). The summary of the western blot analysis is 
shown in Fig. 4.6. 
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Time point Clones positive with Clones negative with 
mAb 2.13 mAb 2.13 
1 1,2,3,4,5 7-21 
2 6 22-32 
3 - 33 
RAP-1 
"- 
- -GADEEAPPAPKNTLTPLEELYPTNVNLFNYKYSLNNMEE- - 
Clones C-terminus sequences mAb2.13 
3 - -GADEEAPPAPKNTLTPLEELYPTNVNLFNYKYS + 
5 --GADEEAPPAP}CNTLTPLEELYPTNVNLFNYKY + 
6 --GADEEAPPAPKNTLTPLEELYPT + 
17 --GADEEAPPAPKNTLTPLE - 
9,31 --GADEEAPPAPKNTLT - 
10 --CADEEAPPAP}CNTL - 
8, 19, 25 --GADEEAPPAPKN - 
Table. 4.2. Thirty-three clones were obtained as a result of deletion in the HindIll-
SspI region of the rap-] gene insert which gave a positive signal to 999A and 284B 
but not to 205B. About 18% of these clones gave a positive signal while the rest gave 
a negative signal when probed with the mAb 2.13 (A). Ten clones were sequenced at 
the 3' terminus of the rap-1 insert. The C-terminus amino acids encoded by each 
clones and their reactivity against mAb 2.13 are compared in table B. The relevant 
sequence of the rap-i gene is shown on the top of the table. The cleavage site of the 












Figure. 4.4. Western blot analysis of the total cell extracts from the exonuclease III 
nested deletion clones were probed with anti- 3-galactosidase rabbit polyclonal 









Figure. 4.5. This figure shows western blot analysis of the nested deletion clones, 3, 5, 
6, 17, 31, 10 and 8. All of the inhibitory monoclonal antibodies gave the same result. 
These monoclonal antibodies only recognize the fusion protein from clones, 3, 5 and 6. 
This membrane was probed with mAb 11.4. 
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RAP-1 DEEAPPAPKNTLTPLEELYPTNVNLFNYKYSLNNM--  
EBX3 DEEAPPAPKNTLTPLEELYPTNVNLFNYKYS + + 
ESs DEEAPPAPKNTLTPLEELYPTNVNLFNYK + + 
EBX6 --DEEAPPAPKNTLTPLEELYPT + + 
EBX17 --DEEAPPAPKNTLTPLE + - 
EBX31 --DEEAPPAPKNTLT + - 
EBXIO --DEEAPPAPKNTL + - 
EBX8 --DEEAPPAPKN + - 
minimum size of 
epitope 
LTPLEE 
Figure. 4.6. Epitope mapping of RAP-i protein by using ExonucleaseIll to produce different length of beta-galactosidase fusion protein. 
[RpAb - rabbit polyclonal antibody against purified RAP- 1; mAb - monoclonal antibody 2.13, 2.15, 2.29, 7.12, 8.1, 11.41 
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4.3. Discussion. 
The exonuclease digestion of the rap-1 gene inserted fragment in PMSEB 
gave definitive results. The rate of the exonuclease III digestion was similar to the 
predicted rate at 25°C (90 base pairs/mm.). This was confirmed by the absence of the 
28413-positive clone after third time point (3 mins after the beginning of the digestion 
reaction). Because the 284B probe sequence is 281 base pairs apart from the BamHI 
restriction site, the calculation suggested that the overall rate of digestion reaction was 
approximate 94 base pairs/mm. 
Detection of the expressed proteins from the 999A- and 284B-positive 
clones suggested that ELYPT121 are a part of the epitopes of all inhibitory 
monoclonal antibodies used in this study. This confirms the results in the previous 
chapter which located the epitopes in this part of the RAP-1 protein. It also suggested 
that the inhibitory epitopes of RAP-i protein recognized by these monoclonal 
antibodies are close to each other. On the other hand, the possibility that these 
inhibitory monoclonal antibodies recognized the same epitope cannot be rule out. The 
presence of the inhibitory monoclonal antibodies against this RAP-1 region in different 
mice suggested that this region of the RAP-1 protein is highly immunogenic in mice. 
It is of interest that this epitope-containing region is adjacent to the cleavage 
site of the RAP-1 protein between A190 and D191  (Ridley et al, 1991). It is possible 
that the inhibition effect of the monoclonal antibodies could be result from the 
interference of the proteolytic cleavage which may be an important aspect of RAP-1 
protein function. 
The results from this chapter showed that exonuclease III can be used for 
epitope mapping purpose by using recombinant DNA technology. The striking results 
of the epitope mapping point out that the epitopes of all monoclonal antibodies are 
located in a small region on the RAP-1 protein. This raised the hope that this highly 
immunogenic region may be used as a malaria vaccine component However, to further 
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characterize the epitopes of all inhibitory monoclonal antibodies, the Geysen method 
was applied (Geysen et cii, 1987). In the next chapter, two series of overlapped 
synthesized peptides were generated and used for the epitope mapping. 
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Chapter 5 
Further characterization of inhibitory epitopes of RAP-1 protein using 
overlapping synthesized peptides. 
5.1. Introduction. 
5.1.1. Principle of peptide synthesis. 
In order to chemically synthesize a peptide in vitro, there are several factors 
to be considered. Firstly, the peptide bond forming reaction is not autonomously 
driven. Secondly, in some amino acids, chemically active side chains may take part in 
reactions and produce undesired by-products. Thirdly, the synthesis of a synthetic 
peptide must be specifically controlled to assure the amino acid sequence required. 
The peptide bond is a bond which is formed between two amino acid 
residues. The carboxylic acid group of one amino acid and amino group of the other 
amino acid combine to form an amide bond (peptide bond) with the elimination of a 
water molecule. The peptide bond forming reaction is described in Fig. 5.1. It can be 
autonomously driven by replacement of the hydroxyl group of the carboxylic acid 
group of amino acid with an electron-withdrawing group such as pentafluorophenyl 
group and 3,4.dihydro-4-oxo-benzotriazine-3-oxy group. A negative inductive effect, 
created from the electron-withdrawing group, results in a higher electrophilicity of the 
carbon atom at the carbonyl group. This enhances the possibility of reaction between 
the carbon atom of the carbonyl group and the nitrogen atom of the amino group of 
another amino acid residue which has a free-pair of electrons and is hence very 
nucleophilic. 
Because many amino acid residues contain reactive side chains which may 
participate in the peptide synthesis reaction and generate unwanted by-products, these 
side chain groups have to be protected by specially designed protecting groups. The 
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N2H- &- COOH + N2117 CH- COOH 
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N2H- CH- c 
+ 1120 
COOH 
Figure 5.1. Diagram shows the peptide bond formation between two amino acids. A a-
amino group of one amino acid reacts with the carboxylic group of another amino acid. 
The formula show in parenthesis is intermediate structure during peptide bond 
formation. After the reaction is complete, one molecule of water is obtained. 
120 
necessity and the strategy employed for side chain protection largely depends on the 
synthesis conditions. However, there are general criteria for the properties of 
protecting groups used; (i) they should suppress the intrinsic reactivity of the amino 
acid side chains (ii) the protecting groups must not interfere and take part in the 
synthesis reaction (iii) they are completely stable during peptide synthesis and the 
deblocking reaction in which the cc-amino group of the amino acid is deprotected (see 
below) because side chain protecting groups are only removed after the end of 
synthesis process. (iv) they can be removed under a mild condition which has no effect 
on synthesized peptide. 
The sequence of an in vitro synthesized peptide is controlled by allowing 
only one peptide bond formation between solubilized amino acids and extended 
synthesized peptide (Fig. 5.2.). The amino terminus of a solubilized amino acid is 
modified with a blocking group. After a single amino acid is added to the N-terminus 
of the synthesized peptide, the peptide bond formation to other amino acid is 
inhibited by the blocking group at the N-terminus of the newly incoperated amino acid. 
Another amino acid may be added to the peptide only when the blocking group is 
removed. Similar criteria to the protecting groups for choosing the appropriate 
blocking groups may also be applied. 
5.1.2. Pepscan system. 
In this experiment, the epitopes of all monoclonal antibodies are finely 
mapped using series of overlapping peptides. The peptide synthesis technique used in 
this study is based on solid-phase peptide synthesis (Atherton and Sheppard, 1989). 
In the conventional solid-phase peptide synthesis, the peptides are synthesized one 
amino acid at a time by attachment of the C-terminus end residue to an insoluble 
polymer (a resin) as shown in Fig. 5.3. After a complete process of synthesis, the 
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Figure 5.2. Diagram shows the use of a blocking group to limit peptide bond 
formation. The a-amino group of amino acid bound solid phase (black circle) can form 
a peptide bond with the activated amino acid in the reaction solution but further 
reaction is prevented by the blocking group (black thick line) at the N-terminal of 







Figure. 5.3. Diagram shows the peptide synthesis used by Pepscan system based on 
solid-phase peptide synthesis. 1) The modified amino acid at the C-terminus of the 
peptide is added to a specially-prepared polyethylene pin. The N-terminus of the added 
amino acid is blocked by the Fmoc group (see text), so only one amino acid is added to 
the pin. Side chain groups of some amino acids are also modified by the protecting 
groups to ensure that only the peptide bond is formed in the reaction between amino 
acids. 2) The excess amino acids are washed off before the Fmoc group is removed at 
the alkaline pH. 3) The next modified amino acid is added to the pin. 4) After repeating 
step 1-3 several times the desired peptides were obtained bound to the polyethylene 
pin. The positive charge at the N-terminus of the peptide-is removed by acetylation. All 
protecting groups are also removed by treatment with acid. 
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resin. The synthesis cycle will be repeated until the peptides contain all the amino 
acids required. The peptide is separated from the resin only after the completion of 
peptide synthesis. 
Recently, (3eysen and his colleagues modified the solid-phase peptide 
synthesis for the epitope analysis purposes (Geysen a al, 1987). A peptide 
synthesis kit is commercially available (Pepscan, see materials 2.1.5). Although a 
peptide is synthesized from the C-terminus residue, like normal solid-phase peptide 
synthesis, a polyethylene rod, instead of a resin, acted as a solid supporter as shown 
in Fig. 5.3. 
In the Pepscan system, active ester forms (pentafluorophenyl ester and 
3, 4-dihydro-4-oxo-benzotriazine-3-oxy ester) of amino acids are used because they 
are stable, easy to prepare and their structures cannot generate significant side 
reactions. The rate of peptide bond formation of these active esters is easily increased 
in the presence of hydroxybenzotriazole, a catalyst. The peptide synthesis reaction is 
set up in dimethylformamide solvent. 
Several protecting groups are used for the inhibition of side-chain reaction 
because the amino acid side-chains of different amino acids have different chemical 
reactivities. All the protecting groups are acid-labile, i.e. they can be removed under 
the acid condition. Some amino acid residues contain side-chains which are considered 
as non-reactive in the synthesis conditions used in this system, so side-chain 
protection is not needed. These amino acids are A, F, G, I, L, M, N, P, Q, W and V. 
Some amino acids use t-butyl group as a protecting group, for example 5, T, Y. 
Because the S-t-butyl derivative of the cysteine is very stable at the acid condition, a 
triphenylmethyl group is introduced as a protecting group for this amino acid. The 
carboxy groups of the D and E residues are also protected by a similar group, the 
t-butoxy group. The amino group at the lysine side-chain and the imidazole ring of 
histidine are protected by another protecting group, t-butoxycarbonyl. The guanidino 
group of arginine is highly nucleophilic and can not be adequately suppressed by the 
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t-butoxycarbonyl group, thus, a 4-methoxy-2, 3, 6-trimethylbenzene suiphonyl group 
is used. 
The 9-Flurenylmethoxycarbonyl (Fmoc) group is used to block the a-amino 
group of all amino acids used in the Pepscan system. The advantage of the Fmoc group 
against other blocking groups is that it can be readily removed by secondary bases 
(piperidine) in dimethylformamide without any effects on the acid labile protecting 
groups (as described above) and the fully synthesized peptide. 
The peptide synthesis and epitope mapping procedure are simplified by 
assembly of the ninety-six polyethylene rods into a polyethylene holder in the 
microtiter plate format. Each polyethylene rod represents as a solid support in one 
peptide synthesis reaction. This means that ninety-six different peptides can be 
synthesized at once. For epitope analysis, peptides are synthesized over a region of 
interested protein with one amino acid shift from N- toward C-terminus as shown in 
Fig. 5.4. The series of overlapped peptides are then subjected to an ELISA technique 
using microtiter plate and the reactive peptides were determined. The advantage of this 
technique is that the polyethylene rods can be reused after the bound monoclonal 
antibody is washed off by sonication in the presence of SDS and mercaptoethanol. 
Many researchers have been reported the success of epitope mapping by 
Pepscan system (Geysen et a!, 1984, Papsidero et al, 1989, Epping et al, 1988, Hill 
et a!, 1989, Virji and Heckels, 1989, Ramasamy and Geysen, 1990, Ewing et a!, 1990, 
Radford et a!, 1990 and Napier and Venis, 1992). Most of these experiments based on 
synthesized peptides about 6-8 amino acids long. This chapter described the attempt 
to map the epitopes of inhibitory monoclonal antibodies against RAP-1 protein by 
Pepscan system using overlapping hexapeptides and decapeptides. 
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Figure. 5.4. Digram shows the epitope detection used in a Pepscan system for peptides 
covered from residues Al to All. The epitope mapping is simplified by the synthesis 
of overlapping peptides on the pins assembled in the microtiter plate format. The pins 
are incubated with an antiserum in the presence of BSA (1) and the non-specific 
binding antibodies are washed off by detergent mixture (2). The peptides containing 
the epitope sequence are detected by exposing the pin to the horseradish-peroxidase 
conjugated second antibody. Positive signals can be read by the microtiter plate reader 
at 0D410 after azino-di-3-ethyl-benzthiazodinsulphonate is added (3) 
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5.2. Results. 
5.2.1. Peptides synthesis. 
Two sets of overlapping peptides were synthesized, a hexapeptide set and a 
decapeptide set. Their sequences cover the epitope of inhibitory monoclonal 
antibodies identified by exonuclease III experiment (see Chapter 4). The hexapeptide 
set represents amino acid V102 to amino acid S294 of the RAM protein as shown in 
Fig. 5.5. Each peptide in the set has five amino acid residues identical to the adjacent 
peptide so that each of the peptide sequences shifts one amino acid residue along the 
RAP-1 protein sequence. Another set contains 10 amino acids long synthesized 
peptides each of which overlap 9 amino acids to adjacent peptide. The decapeptide set 
covers the RAP-1 protein from A190 to S221 (Fig.5.5). All the peptides in this set 
were synthesized as duplication to ensure the fidelity of the results. 
The peptide synthesis procedure was carried out as suggested by the 
manufacture manual (see method 2.3.3.). The dimethylformamide (DMF) used in this 
study is specially purified for peptide synthesis purposes so no pretreatment of the 
DMF was required. The peptide bond forming reaction was performed in a lid-black 
plastic box to protect from light (DMF can easily decompose in the presence of light) 
and evaporation. The box was incubated at 30 °C for at least 18 hours to increase the 
coupling reaction rate. 
5.2.2. Epitope mapping of the inhibitory monoclonal antibodies. 
The hexapeptide and decapeptide set were incubated with the inhibitory 
monoclonal antibodies and the epitopes were determined by horseradish peroxidase 
conjugated second antibody. No binding of the inhibitory monoclonal antibodies could 
be detected among synthesized hexapeptides (data not shown). 
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Figure. 5.5. Diagram shows amino acid sequences of the RAP-1 protein which were 
synthesized as the hexapeptides and decapeptides. The diagram of the whole RAP-1 
protein is given for reference. 
All the monoclonal antibodies, except mAE 11.4, bind to a decapeptide, 
TLTPLEELYP210 and LTPLEELYPT211 as shown in Fig. 5.6., 5.7. and 5.8. The 
mAb 2.13, 7.12, 2.29 gave higher signal with the peptide TLTPLEELYP210 than the 
peptide LTPLEELYPT211 while the signal given by the mAb 2.15 showed an 
opposite nature. Although the mAb 8.1 gave similar level of the signal at the 
TLTPLEELYP210 and LTPLEELYPT211 peptide, it also binds strongly to the 
peptide NTLTPLEELY209 (Fig. 5.8.). The mAb 11.4 does not react with either 
synthesized hexa- and decapeptides (Fig. 5.8.). 
5.3. Discussion. 
5.3.1. Epitope mapping results. 
The failure of the inhibitory monoclonal antibodies to bind to synthesized 
hexapeptides in the first experiment suggested that the epitopes of these monoclonal 
antibodies are bigger than 6 amino acid residues. Indeed, the results from the binding 
of synthesized decapeptides confirmed this conclusion. - The inhibitory monoclonal 
antibodies, 2.13, 2.15, 2.29, 7.12 and 8.1 bound to the TLTPLEELYP210 and 
LTPLEELYPT21 1 decapeptides near to the cleavage site of the RAP-1 protein. These 
confirmed the results of the epitope mapping by exonuclease III digestion (see 
Chapter 4). 
The mAb 11.4 has no detectable reactivity against both synthesized hexa-
and decapeptides. There are two possibilities which may explain this finding. First, the 
epitope of this monoclonal antibody may be bigger than 10 amino acid residues so that 
the mAb 11.4 can not bind to the synthesize peptides smaller than its epitope size: 
Second, the epitope of may be composed of a certain secondary structure as the result 
of the protein folding which depends only on amino acid sequence in this area of the 
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Figure. 5.6. Graph shows the binding of the niAb 2.13 (A) and 2.15 (B) to a series of 
the decapeptides. The sequence of the peptides which gave the highest signals also 
shown in each graph. 
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Figure. 5.7. Graph shows the binding of the mAb 2.29 (A) and 7.12 (B) to a series of 
the decapeptides. The sequence of the peptides which gave the highest signals also 












A DEE APP A P K NT L T FLEE L T PT N V N LY NT KY S 
amino acids of RAP—i protein 
 
2.00 






A D B B A P P A P K N T L T P L B B L Y F T N V N L P N 1,1 T S 
amino acids of RA-P-1 protein 
Figure. 5.8. Graph shows the binding of the mAb 8.1 (A) and 11.4 (B) to a series of 
the decapeptides. The sequence of the peptides which gave the highest signals also 
shown in each graph. 
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RAP-1 protein. This type of epitope may be also contributed, in part, by amino acid 
sequence in the related region. 
Although most of the monoclonal antibodies bind to the peptides in the 
same region, their binding to the pin-bound peptides gave slightly different patterns of 
the binding signals. The mAb 2.15 preferably binds to LTPLEELYPT211 rather than 
TLTPLEELYP210 while other monoclonal antibodies gave higher signal binding at 
pin-bound TLTPLEELYP2 10 
The epitope identified bymAb 2.13, 2.15, 2.29, and 7.12 is considered to be 
the biggest reported epitope identified by Pepscan system so far. It is possible that 
not all of the amino acid residues in the identified epitope are bound by the monoclonal 
antibodies and the binding affinity with the RAP-1 native form is enhanced by other 
amino acid residues which come close together by the protein folding. 
The systematic replacement of an amino acid at each position in eptiope 
studies, replacement net analysis, suggested that only some amino acids in the 
epitopes identified by the Pepscan system are crucial for antibody binding and a 
change in these amino acid residues results in the destruction of the antibody binding 
site (Geysen et al, 1984, Geysen et a!, 1985 and Radford et al, 1990). One of these 
experiments also showed that the crucial amino acids for antibody binding are the 
overlapped amino acid residues of the peptides bound to the antibody studied 
(Radford et a!, 1990). These finding implies that the amino acids which play an 
important part in the mAb 2.13, 2.15, 2.29, and 7.12 binding are located in 
nonapeptide LTPLEELYP210 and octapeptide LTPLEELY209 for the mAb 8.1. One 
characteristic of the LTPLEELYP210 epitope is the near-symmetrical amino acid 
sequence at the N and C terminus of the peptide and in the middle of the identified 
epitope. 
Results from this experiment proved that the recombinant proteins 
generated by exonuclease III digestion of the RAP-1 can correctly map the epitopes of 
monoclonal antibodies. A major advantage is that the exonuclease Ill digestion method 
133 
also revealed an epitope of mAb 11.4 which can not be detected in the Pepscan system. 
However, the Pepscan system was significantly able to ensure the amino acid sequence 
of the epitopes. 
5.3.2. Further works in Chapter 6 and 7. 
The reactivity of these inhibitory monoclonal antibodies from 3 different 
mice against the same epitope shows that this inhibitory epitope may be a highly 
immunogenic region on RAM protein in mice when immunized with whole parasite 
(native form of the RAP-1 protein). However, this phenomenon may not occur in 
human which has a similar but not identical immune system to mouse. Another point 
of interest is whether the immunogenicity of a RAM recombinant protein is identical 
to that of the native form. Both of these points will be studied and discussed in 
Chapter 6. 
The rap-] gene was considered as a conserved gene among variety of 
isolates based on the monoclonal antibodies used in this study (Clark et al, 1987). It is 
now clear that these monoclonal antibodies are directed against the same region of the 
RAP-1 protein. This suggests that the conservation of the rap-1 gene needs to be 




Jinmunogenicity studies of the RAM protein in different animals and epitope 
mapping of monoclonal antibodies against a bacterial expression protein. 
6.1. Introduction. 
6.1.1. A problem of a malaria vaccine. 
An important problem related to the malaria vaccine design is the necessity 
to raise an immune response to a protein target which can protect human from malaria 
infection. Unfortunately, several attempts of human immunization experiments using 
short peptides, or irradiated parasites led to unsuccessful results as discussed in 
Chapter 1. This may either be because the protein target cannot eilicit the protective 
immune response or the 'inhibitory epitopes' fail to be recognized by the human 
immune system. 
The native-form of the RAP-1 protein can stimulate mice to produce 
antibodies which can inhibit parasite growth in vitro (see Chapter 3). The results from 
previous chapters located the epitopes of all the inhibitory monoclonal antibodies in 
the same region. This suggested that the binding of monoclonal antibodies to this 
'inhibitory epitope' leads to the interference of RAM protein function and/or its 
structure and so, inhibits parasite growth in vitro. Because several monoclonal 
antibodies from mice raised by the native form of the RAM protein are directly 
against these 'inhibitory epitopes', it seem that this region of the RAM protein is 
highly immunogenic in mice. 
However, it can not be implied that this 'inhibitory epitopes' is also able to 
elicit protective immune responses in other animals, especially humans. Though the 
antigenicity is an non-intrinsic property of a protein, it still depends largely on the 
host immune system to recognize a particular epitopes. Studies of the antigenicity of 
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several proteins in different hosts suggest that the antigenicity of a given protein in a 
host is influence by structural differences between the protein and the host protein as 
well as the hosts immunological regulatory mechanisms (Benjamin et al, 1984). 
Recently, it has been shown that the denatured form of the RAP-1 protein can elicit a 
protective immune response in Saimiri monkey and that the RAP-1 protein was 
recognized by the Nigerian human immune sera pool (Ridley et al, 1991). None of the 
epitope binding sites of these sera have been identified. It would be of interest to know 
whether the 'inhibitory epitope' defined in this study are also recognized by human 
immune response. 
6.1.2. Monoclonal antibodies against a RAP-1 expression protein. 
During the course of this study, another series of monoclonal antibodies 
were raised against the expressed RAP-1 protein and were available for epitope 
mapping. The expressed RAP-1 protein came from a bacterial expression system 
covering amino acid 23 to 711 of the RAP-1 protein. Thirteen monoclonal antibodies 
were obtained (see Table 6.1.). However, only eleven of these monoclonal antibodies 
specifically recognize the RAP-1 protein on western blot of the total parasite extracts. 
No data on the inhibitory effect of these monoclonal antibodies has yet been obtained. 
Because recombinant RAP-1 protein has a prospect for use as a malaria 
vaccine, it is necessary to investigate the ability to generate a protective immunity 
with the recombinant RAP-I protein. The epitope of the monoclonal antibodies 
generated against the recombinant RAP-1 protein must therefore be determined and 
compared to the 'inhibitory epitope' recognized by monoclonal antibodies raised 
against the native protein. If the recombinant RAP-1 protein can generate antibodies 




(cell culture supernatants) 
Reactivity against the total parasite 
extracts 
mAb 1.7 80/65 
mAb 1.8 80/65 
mAb 1.14 80/65 
mAb 1.15 80/65 
mAb 1.22 recognizes only the RAP-i precursor 
mAb 1.25 80/65 
mAb 2.5 80/65 
mAb 2.16 not specific to the RAP-1 protein 
mAb 2.21 80/65 
mAb 2.25 80/65 
mAb 4.9 80/65 
mAb 5.2 80/65 
mAb 8.2 negative result 
Table 6.1. The list shows monoclonal antibodies generated from Hoffman-La 
Roche. The mAb 1.22 was excluded from this study because its epitope is 
located at the N-terminus of the RAP-1 protein. The mAb 2.16 and 8.2 was also 
excluded. 
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6.1.3. Characterization of the RAP-1 protein immunogenicity. 
This chapter is divided into two parts. The first part describes the attempt 
to establish the immunogenicity of the RAP-1 protein in different animals, especially 
human. Some epitopes recognized by Nigerian human immune sera pool and rabbit 
antisera raised against the native form of the RAM protein were identified and 
compared. The second part is devoted to the epitope mapping of the monoclonal 
antibodies raised against the bacterial expressed RAM protein in order to compare 
the antigenicity of native and non-native RAP-i protein. 
6.2. Results. 
6.2.1. Comparison of some epitopes recognized by immune human sera and 
rabbit polyclonal antibodies. 
To locate some epitopes recognized by Nigerian immune human sera pool 
and rabbit polyclonal antibodies, both sera were probed against fusion proteins 
encoded by plasmid constructs generated by the subcioning of the restriction enzymes 
digested rap-] gene fragments (see Chapter 3). The results showed that the Nigerian 
immune sera pool recognizes all fusion proteins while the rabbit serum fails to 
recognize the fusion protein from bacteria clone UREH  (Fig. 6.1.). The results 
suggested that the human and rabbit immune system react differently to the RAM 
protein. In both cases, there may be more than one epitope located on different 
fragments of the fusion proteins. However, the possibility of cross reaction between 
those RAP-1 protein fragments can not be ruled out. 
Both sera were also tested with the overlapped synthesized hexapeptides 
(amino acid 102-294) and decapeptide (amino acid 190-221). The human immune sera 
pool recognizes decapeptide APPAPKNTLT203 with relatively high background. The 
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Figure. 6.1. Western blot analysis of the Nigerian immune sera pool (A) and rabbit 
serum (B) with the recombinant RAM protein from bacteria clones generated by 
restriction enzymes. track 1.) MS, 2) MSp, 3) UREH, 4) MSE s , 5) MSEB, 6) 
MSES. 
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rabbit serum gave two peaks of the signal with the highest peaks ' at 
EAPPAPKNTL202 and TPLEELYPTN212 (Fig. 6.2.) The synthesized hexapeptides 
gave no strong positive signal.by  both sera (data not shown). This suggested that the 
region containing the 'inhibitory epitope' can stimulate an immune response in both 
human and rabbit. However, the exact location of epitopes recognized by both sera do 
differ. 
6.2.2. Epitope mapping using fusion proteins from different fragments of rap-I 
gene. 
The monoclonal antibodies derived from 4 different mice (see Table 6.1.) 
were tested against fusion proteins from different fragments of the rap-i gene as 
described in Chapter 3. The fragments which contain the epitopes of these monoclonal 
antibodies were determined by western blot as previously described (see Chapter 3). 
The results showed that nine monoclonal antibodies from two mice, mAb 1.7, 1.8, 
1.14, 1.15, 1.25, 2.5, 2.16, 2.21 and 2.25 recognized fusion proteins from all 
constructs except the fusion protein from the clone JJIREH (Fig. 6.3.). This suggests 
that these monoclonal antibodies recognize epitopes encoded by the HindIIT-SspI 
fragment of the rap-] gene. The other two monoclonal antibodies from two other 
mice, mAb 4.9 and mAb 5.2 recognized fusion protein from all constructs except 
UREH and MSE5 which suggested that the epitopes of these monoclonal antibodies 
located in SspI-BamHI fragment (Fig. 6.4.). The results are summarized in Table 6.2. 
6.2.3. Epitope mapping of monoclonal antibodies by Pepscan. 
All epitopes of the monoclonal antibodies were specifically mapped using 
hexa- and decapeptides which had been previously synthesized (see Chapter 5). Only 
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Figure. 6.2. Graphs show epitope scanning panels of Nigerian human immune sera 
pool (A) and rabbit serum (B) using decaapepdes at dilution 1:100 and 1:1000 










Figure 6.3. The western blot of total cell extracts from restriction enzymes generated 
clones was probed with monoclonal antibodies; track 1.) MS, 2) MSHB, 3) UREH, 4) 
MSEs , 5) MSEB, 6) MSES. All of the monoclonal antibodies tested gave the same 













Figure 6.4. Western blot analysis of mAb 4.9 (A) and 5.2 (B) with total cell extracts 
from restriction enzymes generated clones; track 1.) MS1S, 2) MSHB, 3) UREH, 




mAb MSES MSEB MSEç MS}{B EH 
1.7 + + + + - 
1.8 + ± + + - 
1.14 + + + + - 
1.15 + + + + - 
1.25 + + + + - 
2.5 + ± + + - 
2.16 + + + + - 
2.21 + + + + - 
2.25 + + + + - 
4.9 + + - + - 
5.2 + + - + - 
Table 6.2. The summary of the results of epitope mapping using western blot analysis 
of fusion protein from different plasmid constructs generated by restriction enzymes. 
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used in this experiment because all nine epitopes had been potentially mapped to this 
region of the RAP-1 protein. The synthesized decapeptides include amino acid 190 to 
221. Two monoclonal antibodies, mAb 4.9 and mAb 5.2, which gave different signal 
pattern on the western blot from other monoclonal antibodies were probed only to the 
hexapeptides block since their epitopes lay outside the region covered by the 
decapeptides (see above). 
The results indicated that these monoclonal antibodies can be divided into 
three different groups according to their epitopes (Fig. 6.5.). The first group of 
monoclonal antibodies recognize similar epitopes on hexapeptide EEFEYD248 and 
gave a negative result on synthesized decapeptides. These monoclonal antibodies are 
mAb 1.7, 1.8, 1.25, 2.21 and 2.25. The second group, mAb 1.14 and 1. 15, recognized 
only the decapeptides NTLTPLEELY209. The third group, mAb 5.2, reacts with 
hexapeptide FLENQV286. No reactivity against hexa- or decapeptides was observed 
with mAb 2.5, 2.16 and 4.9. This may either because their epitopes locate outside the 
synthesized peptide region or their epitopes are bigger than 6-amino acid in length. The 
summary of this study is shown in Fig 6.6. 
6.3. Discussion. 
6.3.1. Immunogenicity of the RAP-1 protein in different animals. 
The studies of rabbit and human sera suggested that the immune responses 
in rabbit and human to the RAP-1 protein are distinguishable. However, the region 
near the inhibitory epitope is recognized by both rabbit and human sera. The 
decapeptide APPAPKNTLT203 recognized by the human sera pool was also 
overlapped with one of the rabbit sera epitopes EAPPAPKNTL202 and with the 
inhibitory epitopes ThTPLEELYP210. This results suggest that this region is a 
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Figure. 6.5. Graphs show epitope scanning panels of three groups of monoclonal 
antibodies (only one graph from each group is presented here). The amino acid 
sequences of high peaks were shown. A) mAb 1.7, 1.8, 1.25, 2.21 and 2.25 group, B) 
mAb 1.14 and 1.15 group, C) mAb 5.2 
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Figure 6.6. The summary diagram demonstrates the epitopes recognized by the monoclonal antibodies which were raised against the recombinant 
RAP:1 protein from bacterial expressing system. 
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particular region can occur in some animals including human. 
6.3.2. Immunogenicity comparison between native and non-native form of the 
RAP-1 protein. 
The epitope mapping of monoclonal antibodies indicated that the expressed 
protein (non-native forth) of the RAP-1 protein demonstrates similar immunogenicity 
to the native form. However, a few epitopes from different region of the protein were 
identified compared to a single epitope recognized by inhibitory monoclonal 
antibodies. The significance of this study is that the recombinant protein was able to 
elicit an immune response against the 'inhibitory epitope' (TLTPLEELYP210). The 
results also suggested that the EEFEYD248 peptide may be highly immunogenic on 
the expressed RAP-1 protein molecule because most of the monoclonal antibodies 
recognized this epitope. The contradiction of the epitope mapping results between 
western blot of the fusion proteins and Pepscan may be caused by the cross-reaction 
among different fragments of the RAP-1 protein. 
These studies contribute several important point toward the development 
of the RAP-1 protein as a malaria vaccine. They revealed that a specific region which 
contains 'inhibitory epitope' is recognized by rabbit, human as well as mice. Moreover, 
there is an evidence that the non-native form of the RA-P-1 protein can generate 
immune response against the same region recognized by inhibitory monoclonal 
antibodies raised against the native form of the protein. This suggests that it may be 
possible to stimulate human immune responses against the inhibitory epitope region 
by using recombinant protein or a short synthetic peptide. 
The next chapter of this thesis will described the study of rap-1 gene 
diversity in different isolates and clones of P. falciparum. This information is required 
for establishment the importance of the RAP-i protein as a malaria vaccine candidate. 
Chapter 7 
Sequence analysis of the rap-] gene in different isolates and clones 
of P. falciparurn from different sources. 
7.1. Introduction. 
7.1.1. The need for sequence analysis of the rap-1 gene. 
Ideally, a good vaccine candidate must able to stimulate a protective immune 
response against the majority, if not all, P. falciparum isolates. However, many of the 
P. falciparum genes display significant genetic polymorphisms, as was discussed in 
Chapter 1. Although the data from previous conservation studies of the RAP-1 
protein using the group of monoclonal antibodies used in this study suggested that this 
protein is conserved among different isolates (Clark et al, 1987), the conservation of 
the rap-] gene is still in question, since these monoclonal antibodies appear to 
recognize a small amino acid sequence in the RAP-i protein molecule (see Chapter 5). 
In this chapter, the degree of polymorphism exhibited by the rap-1 gene was 
investigated in more detail. Several isolates of P. falciparum from a variety of 
geographical sources were selected. The rap-1 alleles from these isolates were cloned, 
using the polymerase chain reaction (PCR) technique, and their sequences were 
compared. 
7.1.2. Polymerase chain reaction (PCR) technique. 
PCR is a technique in which a specific DNA fragment can be biochemically 
synthesized and amplified in vitro from purified genomic DNA or a cell lysate (Erlich, 
1989). The PCR technique was originally made practicable by the discovery of a 
thermostable DNA polymerase isolated from a thermophi]ic microorganism, 
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The rmus aquaticus, namely Taq DNA polymerase (Gelfand, 1989). Taq DNA 
polymerase has an optimum activity at 75-80°C, depending on the nature of the DNA 
template and it is relatively stable at temperatures as high as 94-95°C. The principle of 
PCR reaction involves three main steps: (i) heat-denaturation of DNA, (ii) annealing of 
oligonucleotide primers and (iii) primers extension or polymerization step as shown in 
Fig. 7.1.. In the first step, the DNA template is heated up to about 90 °C in order to 
separate double stranded DNA into single strand DNA. The temperature is then 
decreased. This allows the annealing of two oligonucleotides primers, each of which 
complements a flanking region on the opposite strands of a specified DNA fragment. 
The polymerization step is carried out after the temperature is raised to the optimum 
temperature, about 70°C. In this step, the Taq DNA polymerase synthesizes DNA 
from hybridized primers in the 5' to 3' direction. The two newly synthesized DNA 
fragment then act as a template in the another cycle of reactions. The target DNA 
fragment copies will be doubled in every cycle of the subsequent PCR reaction. 
Microgram quantities of a specified DNA fragment can be obtained after the PCR 
reactions are repeated many times. 
Practically, these steps are easily manipulated in a single microcentrifuge 
tube and only a once and for all' preparation is needed for the multiple amplification 
cycles. The thermostable DNA polymerases diminish the need of adding fresh enzyme 
for each cycle and also increase the specificity and reaction yield as a result of the 
ability to use more stringent conditions (higher temperature) in the reaction. 
Thermo-cycling devices with their sophisticated software enable researchers to 
efficiently control the temperature and also the rate and time of temperature changes. 
The PCR technique may also serve as a special tool for subcloning purposes. 
A subcloning procedure may be complicated by the need for a restriction site on a 
DNA fragment of interest. Using PCR, any restriction sites can be incorporated into 
both ends of the newly synthesized DNA fragments. This can be achieved because 








4, polymerase and dNTP 
Next cycle 
Figure 7.1. Simplified diagram showing the principle of the PCR 
technique. The double stranded DNA template is heat-denatured 
(typically at 90-95°C) into single strand DNAs. The temperature is 
then lowered to 40-60°C to allow the annealing of the primers. The 
primers are extended by the thermostable DNA polymerase at the 
optimum temperature about 70°C. The result is two identical double 
strand DNAs which can act as templates in the next cycle of PCR 
reaction. 
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5' end can still hybridize successfully to the DNA template and prime the reaction. By 
altering the primer sequence or adding restriction site sequences at the 5' end of the 
primer, the PCR products generated will also contain these restriction sites. Thus they 
can be digested and subcloned into a suitable restriction site in the plasmid vector. 
7.1.3. PCR technical problems. 
Like many methods, the PCR technique has its own problems. The reaction 
kinetics between a specific template and a set of primers differ depending on the 
primers used. The specificity of the PCR reaction may depend on many factors, for 
example concentration of the template DNA, Mg concentration, enzyme 
concentration, primer concentration, temperature, rate and time of temperature 
changes, contaminated substances in the reaction and pH (Saiki, 1989 and Gelfand, 
1989). The reaction conditions need to be evaluated before the PCR reactions are 
performed and optimization is often an empirical process. The fidelity of the PCR 
product may also vary in different reaction conditions. This is because the DNA 
polymerases, e.g. Taq DNA polymerase, used in the PCR protocol lack proof-reading 
activity, and some nucleotides may be misincorporated into the newly synthesized 
DNA. This problem is often minimized by optimizing the factors already mentioned 
above and lowering the number of cycles used. Recently, this problem has been 
minimized by the introduction of thermostable DNA polymerases which have 
'proof-reading' activity. 
Several P. falciparum genes have been analyzed by PCR techniques, for 
example, DHFR-TS (Thaithong et al, 1992), MSA-1 (Jongwutiwes et al, 1992), 
RAP-2 (Saul et al, 1992) and AMA-1 (Thomas .et al, 1990). In fact, the rap-] gene 
from Honduras JICDC isolate was also subcloned by this technique and its sequence 
determined (Howard, 1992). The conservation of the rap-1 gene is also further 
investigated by the PCR technique in this chapter. 
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7.2. Results. 
7.23. Polymerase chain reaction (PCR) and Southern blot analysis. 
In this 	study, the rap-] 	genes 	of nine culture-adapted 
Plasmodiumfalciparum clones or isolates were amplified from genomic DNA by the 
PCR technique (see Method 2.2.2. 14.). The clones or isolates are 3D7, HB3, GF881, 
1(29, MAD20, NF54, T9/94, T9/96 and 1(1. Details about all clones and isolates are 
described in Table 7.1. Because the sequence of the primers used in this experiment 
were derived from the rap-i gene of the Kl allele (Ridley et al, 1990a), the Ki isolate 
was included as a positive control. 
Two oligonucleotides, 142H and 143H, were used as primers in the PCR 
reactions. The sequence of both primers are shown in Fig. 7.2. and the flanking regions 
of the rap-1 gene from Ki isolate is compared. PstI and XbaI restriction sites were 
added to the 5' end of 142H and 143H primers respectively for future manipulation. 
The PCR product from each isolate, including the Ki isolate, gave a single 
band by agarose gel electrophoresis as illustrated in Fig. 7.3. (lane 1-9). The size of all 
the PCR products was about 2.4 kb, the same size as that two reported rap-] alleles of 
which the sequence are known (Ridley et al, 1990a and Howard, 1992). This 
suggested that there is no notable insertion and deletion in the rap-1 gene from any of 
the clones and isolates used in this study. No non-specific product was detected. 
To verify the identity and homology of the rap-1 gene, the PCR products of 
all isolates were transferred onto a Hybond-N membrane by Southern blotting and 
probed with the radiolabelled EcoRI-SalI fragment which had been purified from the 
recombinant clone, PMSES (as described in Chapter 3.). The probe is a part of rap.-1 
gene from the Ki isolate which covers the nucleotides 182 to 1824. The transferred 
membrane was washed under high stringency conditions. The result is shown in 
Fig. 7.4.. The PCR products from all isolates and clones tested were hybridized to the 
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Isolates or Name Origins 
Clones  
Remarks 
Isolates 0F881 Gambia 
Ki Thailand from Kanchanaburi province. 
K29 Thailand from Kanchanaburi province. 
MAD20 Papua 
NF54 Netherlands  
Clones 3D7 Netherlands derived from NF54 isolate. 
HB3 Honduras derived from Honduras I isolate. 
T9194 Thailand derived from T9 isolate (Tak province).  
719196 Thailand I derived from T9 isolate (Talc province).. 
Table 7.1. Details of all isolates and clones used in this study. 










Figure 7.2. The sequence of primers used in the PCR experiment (in bold letters) 
shown in comparison with the sense strand of the rap-1 gene sequence from Ki isolate 
(in normal letter). The restriction enzyme sites PstI and XbaI, which were 
incorporated into the primer sequence are also shown (underlined). The RAP-1 coding 
region, starting with the initiating methionine (142H) and ending with the stop codon 
(143H) is shown as broken line. The numbers below, -9 and 2359, indicate positions of 









1 2 	3 	4 	5 	6 7 	8 	9 10 11 12 
Figure 7.3. PCR products of different strains of Plasmodium faiciparum are subjected to 
agarose gel elecrophoresis (lane 1-9) and stained with ethidium bromide. 1.) T9/96, 2.) 
T9/94, 3.) NF54, 4.) MAD20, 5.) K29, 6.) Ki, 7.) HB3, 8.) GF881, 9.) 3D7. Positive and 
negative control for hybridization analysis also included (lane 10 and 11 respectively). 10.) 
EcoRI -Sail fragment from PMSES, 11.) pMS1S vector without insert. Lambda markers cut 
with HindIII are shown in lane 12. 
1 	2 	3 	4 	5 	6 	7 	8 	9 	10 	11 	12 
_ 	 - 
Figure 7.4. Southern blot analysis. The DNA fragments shown in Fig. 7.3. were transfered 
onto a nylon membrane. Hybridization was carried out at 40°C as described (see Method 
2.2.2.12.) and the blot was wash at high stringency condition, 0.1 times SSC, 1%SDS at 65° 
C for 15 mins twice. 1.) T9/96, 2.) T9/94, 3.) NF54, 4.) MAD20, 5.) K29, 6.) K!, 7.) HB3, 
8.) GF881, 9.) 3D7, 10.) EcoRI- Sail fragment from pME4, 11.) pMS1S, 12.) Lamda 
markers cut with Hindlil. 
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probe, indicating a high level of homology between the Ki allele and the PCR products 
of all isolates and clones. However, this cannot rule out the presence of minor variation 
or blocks of variation sequence within conserved regions. To confirm the degree of 
conservation of the rap-i gene, the whole gene from different clones and isolates need 
to be sequenced and compared. 
7.2.2. Subcloning of PCR products and sequence analysis. 
As mentioned before, the thermostable DNA polymerase may 
misincorporate some nucleotides during PCR reaction. To ensure that the changes 
found are a result of differences in the P. falciparurn genomic sequence, two 
independent PCR reactions were performed for each isolate and clone and their PCR 
products were separately subcloned into PstI and SmuT sites of the pMS1S vector and 
transformed into Escherichia coil strain NM522 as illustrated in Fig. 7.5.. Therefore, 
the differences in DNA sequence between different isolates and clones could be easily 
confirmed by sequencing the products from the second PCR reaction. 
Recombinant plasmids containing PCR generated DNA fragments from 
3137, HB3, GF881, K29 and T9/96 were obtained. Not all of the PCR products were 
able to subclone into the plasmid vector. The subcloning of PCR products from 
duplication PCR reactions of 3137, K29 and 0881 were easily achieved. However, in 
the case of HB3 and T9/96, only one PCR product from each clone was successfully 
subcloned. Confirmation sequencing of the duplicate recombinant plasmids (kindly 
performed by R. Moon and A. Edgar) demonstrated that there is no misincorporation 
of nucleotide by thermostable DNA polymerase under the conditions used. This 
suggested that the HB3 and T9196 allele sequences were generated by a high fidelity 
condition and can be represented as the genomic DNA sequences. 
The PCR product fragments in the recombinant plasmids were sequenced by 








Figure. 7.5. The strategies for subcloning the rap-1 gene is as described in the 
text (see Results). To confirm the changes in the genomic DNA, two PCR 
reactions were performed (1) with each isolates and clones. The PCR products 
were digested with PstI (2) and individually subcloned into the pMS1S vector 
digested with PstI and SmaI (3). After the ligation, the recombinant plasmids 
were obtained (4). The recombinant plasmids were then separately 
transformed, screened and sequenced. 
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oligonucleotides derived from the Ki allele sequence. The results are shown in 
Fig. 7.6. From all the sequence data available, only 21 divergent nucleotides from the 
Ki allele are found. Five of these are silent and result in no amino acid changes 
(position 264, 1005, 1653, 1926 and 2286). The other sixteen position, however, 
result in amino acid changes (position 187, 197, 425, 446, 802, 859, 880, 982, 990, 
1019, 1108, 1204, 1351, 1427, 2155 and 2198). No deletion or addition of nucleotide 
was found. All of these nucleotide changes occur preferably at the first, second and 
third base of a codon, respectively. 
The pattern of nucleotide variations in rap-i gene show some similarity 
among different isolates of P. falciparum. Seven variations are found more than once. 
Nucleotide change at position 1019 is found in all strains studied and is also present in 
the Honduras IICDC clone (Howard, 1992). The nucleotide changes at 187th , 425th , 
802th , 990th 1180th and 1351th  also found at least twice. This suggested that the 
nucleotide changes in these positions do not occur randomly. Among the alleles 
studied, it seems that only one of two nucleotides will occupy a given position. This 
implies that any given position one of two amino acids will be found. The only 
exception is the nucleotide at position 990 where three types of codon changes were 
found. However, it still shows dimorphic variation at the amino acid level. The amino 
acid variations in the different rap-1 alleles are shown in Fig. 7.7.. 
There are several features should be noted (i) all proline and cysteine 
residues in the Ki allele are conserved in all isolates studied. (ii) No amino acid change 
is found in the KSSSPS motifs and its related repeats. (iii) The identified 
immunodominant epitepes of the monoclonal antibodies studied in this thesis and the 
sequence surrounding the adjacent cleavage site are also conserved. (iv) There is no 
amino acid change in the putative signal peptide sequence at the N-terminus. 
Most variations are found to occur in the middle and toward the N terminus 
of the gene as shown in Fig. 7.8. The majority of non-silent nucleotide variations 
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187 197 264 425 446 802 859 880 982 990 1005 1019 1108 1204 1351 1427 1653 1926 2155 2198 2286 
Ki 	. . GAA. .AGT. .ACA. .TTA. .AGT. .CAA. .AAA. .TCC. .CTT. .GAC. .GTA. .GCA. .ATA. .AAC. .CAT. .GAA. .GAA. .CCA. .CTT. .AAT. .TTA. •a 
E 	S 	T 	L 	S 	Q 	K 	S 	L 	D 	V 	A 	I 	N 	H 	E 	E 	P 	L. 	N 	L. 
No of base changes 
No of amino acid changes) 
K29....... AAT ............ ATT ................................ GTA ................................ ATT ............ 
S S S 	 S 
3D7 	..AAA ....... ACT ............ GAA. .GAA ....... TTT. .GAG. .GTG. .GTA. .GTA ....... CAT ....... GAG ...................... • * . 	. . 	S 	* S 	• • 	* 
GF881 ........................... cia ................. GAG ....... OTA. .GTA ....... CAT ............ CCT ....... ATT. .TTG.. 
S S S 	S 	 • 	 * 	S 	* 
T9/96 	................. TCA ....... Cia ................. cia ....... GTA ................. GGA ........................... . 	I . S 	 S 
HB3 	..AAA ............ TCA .......Cia ....... CCC ....... GAA ....... CTA ....... CAC ..................................... 7(7) C • . 	 I S 	 S S 	 S 
CDC 	..AAA ............ TCA ....... Cia ................. cia ....... CTA ............................................... • . 	. S S 
Figure 7.6. Schematic diagram shows nucleotide changes among different strains of P. falciparum from different geographic sources. The numbers on 
the top represent the mutation position. Most of the base changes result in amino acid changes (.) but some of them are silent mutation (*). 
from Ridley et al, 1990a. 
sequences were generated from PCR products and were confirmed by sequencing two independent PCR reactions. 
only one PCR product was sequenced. 
from Howard, 1992. 	 159 
63 	66 142 149 268 287 294 328 330 340 370 402 451 476 719 733 
K! 	. . . . E.. . 	. . .L. . . .S. . . .Q. .. .K. . . .S. . . .L. .. .D .... . .... I .... N... .H.. . .E. . . .L. . . .N.... 	a 
K29......... N .........i .............................v ........................i ......... b 
3D7. . . .ic ................... E .... E ......... F .... E. . . .V. .. .V ......... ID ................... b 
0F881................. ....... E ................... E .... V.. . .V ......... D .............. I.... 	b 
T9196.............. s ......... E ................... E .... V ................... G .............. 
HB3 . . . .i< ......... S ......... E ......... P ......... P2... .11 ......... ID ........................ 
CDC . . . .i< ......... S ......... P2 ................... P2... .11 .................................. d 
Figure 7.7. Schematic diagram shows amino acids changes of RAP-i protein among different strains of P. falciparum from 
different geographic sources. The numbers on the top represent the amino acid numbers. The silence mutations (compared 
to the Ki sequence) are excluded. 
from Ridley a a!, 1990a. 
sequences were generated from PCR products and were confirmed by sequencing two independent PCR reactions. 
only one PCR product was sequenced. 
from Howard, 1992. 
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Figure 7.8. Schematic diagram shows amino acid variation in different strains in comparison with the structural diagram of RAP-1 protein in 
the Ki isolate. 
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cluster in the middle of the rap-1 gene. The nucleotide variations at the C terminus are 
mostly silent or result in conserved amino acid changes. 
The isolate, which is the most diverse from the Ki isolate is 3D7. K29 has 
the closest sequence to the Ki isolate. Silent nucleotide variations are found only in 
the isolates which are the most diverse from the K1 isolate, namely 3D7 and GF881 
(Fig. 7.6). The alignment of variation points between different isolates show some 
similarity in the T9/96 and Honduras JJCDC clone (Fig. 7.6). 
7.3. Discussion. 
The accumulative data presented here demonstrates that the rap-1 gene 
exists in all studied isolates and confirms  that the rap-i gene is highly conserved 
- among different isolates and clones regardless of their origins (see below). Some 
antigens and isoenzymes of these isolates and clones have previously been 
characterized and demonstrated variation in several phenotypes, for example reactivity 
against monoclonal antibodies (McBride et al, 1982, McBride et al, 1985 and 
Walliker et al, 1987), differences in protein mobility on 2-dimensional gel 
electrophoresis (Fenton, 1987) or differences in the forms of adenosine deaminase 
isoenzyme (Walliker et al, 1987 and Thaithong et al, 1984). 
The conservation of the RAP-1 protein and other rhoptry antigens such as 
RAP-2 (Saul .et al, 1992), RhopH3 (Brown and Coppel, 1991) and the 
apical-associated protein AMA-1 or PF83 (Thomas et al, 1990) supports the idea that 
rhoptry proteins may play an important role in the parasite. 
From the sequence analysis, the data suggested that between 99.5 to 99.8% 
of nucleotide sequences or approximately 99 to 99.5% of protein sequences of rap-i 
allele are conserved when compared with the Kl allele (Fig. 7.6. and Fig. 7.7.). 
Another protein which possibly associates with rhoptries, AMA-1/PF83, shows 
approximately 4% variation in both the amino acid and DNA level (Thomas et al, 
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1990). This protein not only has a cluster of amino acid changes at the middle of the 
gene and toward the N-terminus but also shows the highest frequency of amino acid 
variation in the middle region of the gene, similar to rap-I. Analysis of another rhoptry 
protein which associates with the RAP-i protein, namely RAP-2, showed that about 
99.7% of amino acid residues are conserved (Saul et al, 1992). 
Because the fact that the use of Ki allele as a reference in the comparison 
may distort the overall image of rap-1 gene variations, a consensus sequence of the 
rap-1 gene was deduced and compared with other rap-1 alleles. The result is shown in 
Fig. 79.. The rap-] gene appears more conserved when it is compared with consensus 
sequence with between 99.4 to 99.7% of the nucleotide sequence conserved. 
Most of the positions where amino acid variations are observed, the 
consensus amino acid residues, 14 of 16, have preferences toward the higher frequency 
amino acids (of nonrepetitve coding regions) found in Plasmodium falciparum as 
observed by Saul and Battistutta (Saul and Battistutta, 1988). The same result was also 
observed at the nucleotide level. Fifteen of twenty-one codon change positions have 
consensus codons which are found at a higher frequency than their variants. 
It is known that proline and cysteine residues are important for the 
structural determination of a protein. Proline is known to interrupt the helical structure 
while two cysteine residues are able to form a disulfide bond in a protein molecule. 
These amino acid residues are well conserved among different rap-] alleles. Only one 
nucleotide change occurs at a proline codon at the 642nd amino acid but there is no 
change at the amino acid level. This suggests that these amino acids may be 
particularly important for the overall structure and function of the RAP-1 protein as 
suggested by Ridley and his collaborates (Ridley et al, 1991). 
No correlation between diversity of RAP-1 gene and geographical origin 
can be drawn as the sample size is too small. However, the different alleles can be 
divided into three broad groups, Kl group (Kl and K29), 3D7 group (3D7 and 
GF881), CDC group (CDC, HB3 and T9/96). This classification based on the 
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63 	66 142 149 268 287 294 328 330 340 370 402 451 476 719 733 
Consensus 	. . . . E. . . . s. . . . L.. . . s. . . .. . . . K... .s. .. .L. . . .E. . - .V.. ..I... .N. . - -H.. - .E... .L. - . .N. 
K! 	........................Q ................... D .... A ..................................a 
K29 N ......... I .... Q ................... D ............................. I ......... b 
3D7 . . - .K ........................ E ......... F .............. V ......... ID ................... b 
GF881 ...................................................... . ......... D .............. I.... 	b 
T9/96 	..............s ........................ .. ............................ c .............. 
HB3 . . . .1< .........s ...................p ........................ D ........................ 
CDC . . - .ic ......... S ................................. ..................................... 	d 
Figure 7.9. Schematic diagram shows amino acids changes of RAP-i protein among different strains of P. falciparum from different 
geographic sources compared with consensus sequence. The numbers on the top represent the amino acid numbers. The silence 
mutations (compared to the consensus sequence) are excluded. 
from Ridley et al, 1990a. 
sequences were generated from PCR products and were confirmed by sequencing two independent PCR reactions. 
only one PCR product was sequenced. 
from Howard, 1992. 
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similarity of the amino acid variations, comparison with the consensus sequence 
(Fig. 7.9.). It must be noted that the T9/96 clone which was originally isolated from 
another province in Thailand has no amino acid change in common with Kl and K29 
alleles. On the other hand, the sequence of rap-1 alleles from Thailand isolate and 
clones, Ki, K29 and T9/96, are similar to each other compared with those from 
different origins, 3D7 and GF881 (Fig. 7.7.). The low level of sequence diversity 
among CDC, HB3, and Ki alleles which originated from different geographical 
sources was also observed (Fig. 7.7.). This partly suggested that the amino acid 
changes in closely related alleles may similar to each other but this has to he confirmed 
by further study of rap-1 alleles. 
The sequence data received from the HB3 and Honduras IICDC clone both 
of which are derived from Hi from Honduras (Walliker eta!, 1987 and Howard, 1992) 
are similar, but not identical, to each other. There are two unique nucleotide changes at 
position 880 and 1024 which only occurred in the HB3 clone (Fig. 7.6.). This may be 
because there are multiple populations in the Hi isolate which is a common occurrence 
in field isolates (Thaithong et al, 1984). Alternatively, mutations could have been 
generated during prolonged culture. 
In short, the results in this chapter indicate that the rap-] alleles in different 
isolates and clones studied are highly conserved, but limited variations are observed. 
The proline and cysteine residues, in particular, are conserved. All the major epitopes 
of monoclonal antibodies tested and the proteolytic cleavage site region are also highly 
conserved. Together with the inhibitory effect of 2.13-group monoclonal antibodies, it 
leads to the conclusion that the immunodominant region near the cleavage site, 






The eptiope mapping studies of the inhibitory monoclonal antibodies reveal 
information about the possible structure-function relationships of the RAP-1 protein 
and the immunogenicity. Because all the inhibitory monoclonal antibodies recognized a 
linear epitope, TLTPLEELYP210, near to the cleavage site (Between A190  and 
D191), it suggests that the cleavage of the RAP-1 protein may be important for its 
functions, e.g. for activation. Activity regulation of protein function by means of 
proteolytic cleavage was also found in other proteins, for example human cathepsin S. 
a lysosomal cysteine protease (Wiederanders et at, 1992) and several aspartic protease 
(Blair and Semler, 1991) etc. 
Pulse-chase labelling studies previously showed that the RAP-1 protein is 
synthesized at mid-trophozoite stage and processed into 65 kDa protein at the time of 
schizont rupture (Clark et al, 1987). Other studies carried out in Dr. J. McBride's 
laboratory demonstrated that the 65 kDa protein is only associated with parasitised 
erythrocytes and not with merozoites (Harnyuttanakorn et at, 1992). These lead to the 
conclusion that the 65 kDa form of the RAP-1 protein may play an important role in 
the releasing of malaria parasites from the red blood cells and the cleavage of the 
RAP-1 to the 65 kDa form may be a crucial step to the protein functon. The 
amphiphilic sequences on the RAP-1 protein may allow for membrane interaction 
leading to disruption of the erythrocyte membrane (Ridley et al, 1990a). 
The immunodominant of the epitope TLTPLEELYP210 in mice immunized 
with the native form of the RAP-1 protein is striking. Information about the RAP-1 
protein isnmunogenicity in different animals is obtained from the comparison of the 
rabbit polyclonal sera and the human sera. Although an antigenicity of a protein is not 
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an intrinsic property of the protein and depends largely on immunized animals, the 
inhibitory epitope' region on the RAP-1 protein is recognized by both rabbit and 
human immune sera pool which had arisen from exposure to the native form of the 
RAP-1 protein. This result suggests the possibility of using the RAP-1 protein to 
stimulate an immune response to the inhibitory epitope' in order to achieve protective 
immunity in humans. 
Different forms of the RAP-1 protein, native and non-native forms, show 
similar but not identical immunogenicity in mice. While all inhibitory monoclonal 
antibodies, obtained from immunization with native form of the RAP-1 protein, 
recognized the 'inhibitory epitope', the expressed RAP-1 protein (non-native form) 
elicits immune response against 3 different epitopes. Most of these monoclonal 
antibodies recognized the EEFEYD248 peptide which suggests that this epitope may 
be highly immunodorminant in the non-native form. However, two of these 
monoclonal antibodies also recognized the NTLTPLEELY209 peptide. This suggests 
that the 'inhibitory epitope' is immunogenic in both native and non-native forms. The 
use of expressed protein which represents only a part of the RAP-1 protein in 
immunization also suggests that it is possible to design the malaria vaccine based on 
the RAP-1 protein as a small expressed protein or a synthetic peptide containing the 
'inhibitory epitope'. 
The sequence analysis of the rap-] gene in different isolates and clones 
points out that the rap-i gene is a highly conserved gene. The 'inhibitory epitope' 
region and other identified epitopes are also conserved. No amino acid change is found 
at the cleavage site. This supports the hypothesis that a specific cleavage mechanism 
operates during the processing of the RAP-1 protein. The conservation of this protein 
strengthens its potential as a malaria vaccine and a target gene for P. falciparum 
screening in the field. 
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8.2. Future study. 
Several topics arising from this study on the RAP-1 protein and the 
inhibitors' monoclonal antibodies need to be studied in more detail. In particular the 
mechanisms by which the inhibitory monoclonal antibodies work needs to be 
confirmed. The inhibitory effects of monoclonal antibodies from Hoffman La Roche 
should also be established to assess if proximity of an epitope to the cleavage site 
results in monoclonal antibody inhibition. The expressed RAP-1 protein or a synthetic 
peptide containing the 'inhibitory epitope' should be used for vaccination trial in 
monkeys to study their immunogenicity and protective capabilities. Also, the immune 
response against this protein should be studied in the field to reveal the response to the 
RAP-i protein in immune individuals. 
"Sr. 
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Inhibitory monoclonal antibodies recognise epitopes adjacent to a 
proteolytic cleavage site on the RAM protein of Plasmodiumfalciparwu 
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The low-molecular-weight rhoptry-associatcd protein (RAP) complex of Plasniadiuni falciparum consists of at least two 
gene products. RAP-1 and RAP-2, and has the ability to immunise Saimiri monkeys against experimental P. /ilei'ariun 
infection. Several monoclonal antibodies specifically recognise this complex and in this study we show that purified 
immunoglobulin derived from these monoclonals is capable of inhibiting parasite growth in vitro. It has previously been 
shown that RAP-1 initially appears as an 80-kDa protein (p80) in early schizogony and is processed to a 65-kDa protein (p65) 
in late schizogony. Several of the inhibitory monoclonals recognise both the 80- and 65-kDa proteins by Western blot analysis 
suggesting that they recognise linear cpitopcs on RAP-I. We have mapped these epitopes by testing the reactivity of the 
monoclonals against fragments of the rap-I gene expressed as fl-galactosidase fusion proteins and subsequently against 
synthetic peptides. All of the epitopes map to a region 10-20 amino acids C-terminal to the proteolytic cleavage site for the 
processing of p80 to p65 at amino acid 190. We also show that the 65-kDa protein is not present in purified merozoites, 
suggesting that its generation is associated with mcrozoitc release rather than erythrocyte invasion. These results are discussed 
with respect to possible inhibitory mechanisms for the monoclonals. 
Key words: Malaria; Plasmnodium fakiparumn; Rhoptry; Inhibitory monoclonal antibody; RAP-I; Epitope mapping 
Introduction 
Merozoite release from P. fizlciparum in-
fected red blood cells and their subsequent 
invasion into fresh red blood cells is a 
complicated process believed to involve the 
co-ordinated action of many proteins. Several 
groups of parasite antigens have been impli-
cated in this process and have been identified 
as vaccine candidates, including proteins of the 
Correspondence address: Robert C. Ridley, Department 
I'RPI, F. IIoflman-La Roche, CH-4002 Basel, Switzerland. 
Tel.: 61-688-I11: Fax: 61-691-9391. 
,1/,Irrru,tu,pi.c: mAb. monoclonal antibody: I PTG, isopropyl-
/t-t h iouu lactopyra noside: S DS. sodium dodecyl sulphate: 
PAGE. polyacrylarnide gel electrophoresis: LB. Luria broth. 
merozoite surface [1,2], the parasitophorous 
vacuole [3], parasitophorous vacuole mem-
brane [4], dense granules [5,6] and the rhoptry 
organelles [2,7]. The function of most of these 
antigens is poorly understood, though se-
quence homologies have indicated that the 
parasitophorous vacuolar protein SERA is a 
cysteine protease [8] and biochemical evidence 
has shown that another antigen of uncertain 
location [9] contains a phospholipase C 
activated serine protease [10]. In the absence 
of a defined function for a given antigen one 
may still determine regions of Functional 
significance on a protein by defining epitopes 
recognised by monoclonal antibodies which 
inhibit parasite growth. This approach has 
recently focused attention on the C-terminal 
region of the merozoite surface protein MSP-1 
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Fig. 1. Recombinant rap-1 
gene expression constructs used for preliminary mapping olcpitopcs. The restriction cnzyme sites 
used to generate appropriate DNA fragments are given relative to their position within the coding region of the rap-1 gene. 
These fragments were ligated into the polylinker cloning site of a pMS expression vector [28] and expressed as fl-galactosidase 
fusion proteins. The region encoding the proteolytic cleavage site is arrowed. 
IPTG. The fragments subcloned into the pMS 
plasmid were termed iacZ constructs (Zcl-Zc5) 
and are shown in Fig. 1. Their positions 
relative to the rap-] gene are presented. It 
should be noted that the EcoRl site indicated 
in the figure, by which many of the fragments 
were ligated into the pMS vector, is not present 
in the rap-] gene itself, but comes from an 
EcoRI linker present in the ).gti I expression 
clone, Arapi.l, which was isolated in the initial 
cloning of the gene [12]. In cases where there 
was no compatible site in the vector for 
subcioning, fragments were end-filled using 
Klenow and blunt-end ligated into pMS. All 
constructs were confirmed by DNA sequencing 
[29]. 
Further derivatives of a clone containing the 
EcoRI-BamHI fragment (Fig. 1, construct Zc4) 
were obtained as a set of 'nested deletions'. The 
construct was linearised with BamHI and 
subjected to exonuclease III digestion using 
the Erase-a-Base kit (Promega Biotech). 
Products which had deletions from the 
BamHI site to the vicinity of the rap-] gene 
encoding amino acid residues 190-230 were 
selected. The ragged ends were filled by Si 
nuclease and Klenow according to the manu-
facturers instructions and then ligated to 
generate a functional plasmid expressing 
truncated forms of the rap-I gene. All vectors 
were transformed into E. cvii strain NM522 
[30] For expression. 
Epitope expression by recombinants. Bacteria 
containing recombinant plasmids were grown 
to mid-log phase and IacZ gene expression 
induced by addition of IPTG to 1 mM. After 2 
h, cells were harvested, resuspended in water 
and I vol. of 2 x Laemmli loading buffer 
added [31]. Samples were subjected to SDS-
PAGE, blotted to a Hybond-C membrane 
(Amersham) and probed for reactivity with a 
variety of antibodies using an alkaline phos-
phatase conjugated second antibody system 
(Protoblot components; Promega Biotech). 
Peptide epitope mapping. Linear epitopes 
were accurately mapped by testing the reactiv-
ity of antibodies to overlapping peptides 
synthesised on a 96-pin plastic support in an 
epitope scanning kit (Cambridge Research 
Biochemicals) using the Geysen technique [32]. 
Results 
Monoclonal antibody inhibition of parasite 
growth. The results of inhibition assays 
carried out using a variety of monoclonal 
antibodies recognising the RAP complex are 
shown in Fig. 2. All RAP mAbs showed a 
marked inhibitory effect over the control 
antibody. The antibody concentrations re-
quired to inhibit parasite growth were compar-
able to those observed previously for other 
18! 
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Fig. 3. Monoclonal antibody reactivities against fusion 
constructs ZcI-Zc5. Bacterial extracts containing protein 
after induction of IacZ expression, either from the original 
pMS expression vector which produces fl-galactosidase 
(lane Z) or the RAP-1 fusion constructs Zcl-Zc5 (lanes cI- 
c5) were separated by SIDS-PAGE, blotted on to nitrocel- 
lulose membranes and probed with antisera. (A) Control 
experiment using rabbit polyclonal sera raised against fi- 
galactosidase. (B) Results obtained using mAb 2.13. 
Identical results were obtained for inAbs 2.15, 2.29, 7.12, 
8.1 and 11.4. 
recognised by mAb 2.13 is encoded by all of 
the constructs except Zc2, suggesting that the 
epitope is encoded within the IIi,idl I l-Sspl 
fragment of the rap-1 gene (Fig. 1). Identical 
results were obtained for all the mAbs tested 
(2.13, 2.15, 2.29, 7.12, 8.1 and 11.4) indicating 
that the respective target epitopes were all 
encoded within this same region. 
Next, exonuclease-derived constructs from 
the expression clone Zc4 (Fig. 1) were made 
and tested in a similar manner. The deleted 
RAP-I sequences covering the region of 
interest for several of these constructs are 
given in Table I, together with the reactivity of 
the fusion proteins with monoclonal antibod-
ies. The proteolytic cleavage site determining 
the p80 -* p65 transition is shown for refer -
ence. Once again the epitopes could not be 
distinguished since all the mAbs reacted 
positively with the same constructs. From 
sequences of these constructs it was deduced 
that the mAbs recognised epitopes which are 
lost with the removal of amino acid residues 
E207 to T211. Thus the epitopes are no further 
than 20 amino acids downstream of the 
proteolytic cleavage site at D 191 . 
The epitopes were finally defined by the 
Geysen epitope mapping technique [32] using 
synthetic peptides covering residues A 190 to 
S222. Overlapping hexapeptides covering this 
region did not react with any of the mAbs (not 
shown). The procedure was therefore repeated 
using overlapping decapeptides. From results 
shown in Fig. 4 we deduced that the mono-
clonals 2.13, 2.15, 2.29 and 7.12 recognised the 
nonapeptide LTPLEELYP while mAb 8.1 
recognised an 8-amino acid epitope within 
this nonapeptide, namely LTPLEELY. The 
mAb 11.4 did not recognise any of the 
decapeptides. It is possible that the antibody 
recognised an epitope larger than 10 amino 
acids or an epitope that is determined by a 
secondary structure which could be present in 
the /3-galactosidase fusion proteins but was 
absent in the peptides. 
To summarise, the monoclonals all recog-
nise an epitope within approximately 10 to 20 
residues C-terminal to the proteolytic cleavage 
site at D 191 giving rise to the p80 - p65 
transition. Even mAb 11 .4, whose epitope has 
not been definitively determined must recog-
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Fig. 4. Peptide mapping of monoclonal antibody epitopes. Decapeptides overlapping by one residue and covering the RAP-I protein from residues 190-221 were 	— 
prepared by the Geysen technique [32] and tested for antibody reactivity by ELISA. The sequences of peptides recognised by the antibodies are indicated. kj 
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merozoite release is not new. An electron 
microscopy study has shown rhoptries releas-
ing material inside infected erythrocytes and, 
in some cases, merozoites within mature 
schizonts were observed with one full' rhop-
try and one 'empty' rhoptry. It should be noted 
that only a fraction of the 80-kDa RAP-1 is 
ever processed to the 65-kDa product in 
schizonts. Much of the 80-kDa RAP-I is 
carried to the newly invaded ring stages where 
the 65-kDa fragment is not detectable [14,16]. 
It is tempting to speculate that the 80-kDa 
protein performs a different function to its 65-
kDa fragment. One could postulate that the 
65-kDa form is associated with merozoite 
release while the 80-kDa form in freed 
merozoites contributes subsequently to ery-
throcyte invasion or to the formation of 
parasitophorous vacuole membrane around 
the new ring form [14,19]. Another alternative 
that is not ruled out is that the 80-kDa protein 
is active in both merozoite release and 
erythrocyte invasion and that the 65-kDa 
protein is a residual by-product generated 
after the 80-kDa protein has been released 
from the rhoptries and performed its merozoite 
release function. In this case the processing 
could serve to inactivate the 80-kDa protein 
once its task has been done. In either case the 
function of RAP-1 would be controlled by its 
proteolytic processing. We have previously 
presented evidence that RAP-1 may be cap-
able of autocatalytic cleavage [12]. Self-clea-
vage as a means of regulating protein activity is 
not uncommon and is exhibited by regulatory 
proteins such as the E. co/i S.O.S. response 
protein. Lex A, by several aspartic acid 
proteases and by viral polyproteins (see ref. 
33 for review). Further work on the p80 - p65 
cleavage of RAP-1 should clarify these aspects 
of RAP-1 function. 
Other results from this study deserve 
comment. It is quite surprising that six 
monoclonals derived from four different mice 
all recognise the same region of RAP-1 and 
that Five actually recognise the same linear 
peptide sequence. This suggests that the 
pcptide represents a RAP-1 epitope which is 
immunodominant in vivo. The immunodomi- 
nance of the LTPLEELYP epitope requires 
that we reinterpret previous work showing that 
all of our RAP monoclonals recognised all of 
over 80 isolates of P.falciparuin [14]. Although 
this led us to propose that the RAP antigen 
was highly conserved, we were looking at the 
conservation of essentially only two epitopes, 
one conformational and one linear. We are 
now cloning the rap-1 gene from a variety of P. 
Jalciparuin isolates to check its degree of 
sequence conservation. 
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